EP2188263B1 - Benzimidazole derivatives used as fxr agonists - Google Patents
Benzimidazole derivatives used as fxr agonists Download PDFInfo
- Publication number
- EP2188263B1 EP2188263B1 EP08787302A EP08787302A EP2188263B1 EP 2188263 B1 EP2188263 B1 EP 2188263B1 EP 08787302 A EP08787302 A EP 08787302A EP 08787302 A EP08787302 A EP 08787302A EP 2188263 B1 EP2188263 B1 EP 2188263B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- benzoimidazol
- acetamide
- fluoro
- dicyclohexyl
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Not-in-force
Links
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title abstract description 4
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 202
- 150000003839 salts Chemical class 0.000 claims abstract description 29
- 150000002148 esters Chemical class 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 6
- -1 aryl-lower-alkyl Chemical group 0.000 claims description 37
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 36
- 125000000623 heterocyclic group Chemical group 0.000 claims description 32
- 239000001257 hydrogen Substances 0.000 claims description 30
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 26
- 125000004432 carbon atom Chemical group C* 0.000 claims description 25
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 150000002367 halogens Chemical group 0.000 claims description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 125000006239 protecting group Chemical group 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 9
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 239000005864 Sulphur Substances 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 125000002950 monocyclic group Chemical group 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 108010028554 LDL Cholesterol Proteins 0.000 claims description 7
- 238000008214 LDL Cholesterol Methods 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 210000004185 liver Anatomy 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 150000003626 triacylglycerols Chemical class 0.000 claims description 7
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 6
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 6
- 230000001906 cholesterol absorption Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- PPVSDDFTSPPNHD-UHFFFAOYSA-N n,2-dicyclohexyl-2-[5-fluoro-2-[2-(2-methoxyethoxy)ethoxymethyl]benzimidazol-1-yl]acetamide Chemical compound COCCOCCOCC1=NC2=CC(F)=CC=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 PPVSDDFTSPPNHD-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000011321 prophylaxis Methods 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- MAXDJYGVHNACQO-NDEPHWFRSA-N (2s)-2-[2-[(4-chloro-2-methylphenoxy)methyl]-6-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound CC1=CC(Cl)=CC=C1OCC1=NC2=CC=C(F)C=C2N1[C@H](C(=O)NC1CCCCC1)C1CCCCC1 MAXDJYGVHNACQO-NDEPHWFRSA-N 0.000 claims description 5
- UEPQRTBEJYBKOL-UHFFFAOYSA-N 2-[2-[(2-chlorophenoxy)methyl]-5-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound C=1C=CC=C(Cl)C=1OCC1=NC2=CC(F)=CC=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 UEPQRTBEJYBKOL-UHFFFAOYSA-N 0.000 claims description 5
- MAXDJYGVHNACQO-UHFFFAOYSA-N 2-[2-[(4-chloro-2-methylphenoxy)methyl]-6-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound CC1=CC(Cl)=CC=C1OCC1=NC2=CC=C(F)C=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 MAXDJYGVHNACQO-UHFFFAOYSA-N 0.000 claims description 5
- VAGMTYLRPUWQTK-UHFFFAOYSA-N 2-[2-[1-(4-chloro-2-methylphenoxy)ethyl]-6-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound N=1C2=CC=C(F)C=C2N(C(C2CCCCC2)C(=O)NC2CCCCC2)C=1C(C)OC1=CC=C(Cl)C=C1C VAGMTYLRPUWQTK-UHFFFAOYSA-N 0.000 claims description 5
- HRMRAUPWRSMECG-UHFFFAOYSA-N 2-[6-chloro-5-fluoro-2-[(4-fluorophenyl)sulfanylmethyl]benzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound C1=CC(F)=CC=C1SCC1=NC2=CC(F)=C(Cl)C=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 HRMRAUPWRSMECG-UHFFFAOYSA-N 0.000 claims description 5
- 206010008635 Cholestasis Diseases 0.000 claims description 5
- 108010023302 HDL Cholesterol Proteins 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 201000001883 cholelithiasis Diseases 0.000 claims description 5
- 231100000359 cholestasis Toxicity 0.000 claims description 5
- 230000007870 cholestasis Effects 0.000 claims description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- JYLZBOPWDTVNFO-UHFFFAOYSA-N n,2-dicyclohexyl-2-[2-[(4-ethylphenoxy)methyl]-5,6-difluorobenzimidazol-1-yl]acetamide Chemical compound C1=CC(CC)=CC=C1OCC1=NC2=CC(F)=C(F)C=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 JYLZBOPWDTVNFO-UHFFFAOYSA-N 0.000 claims description 5
- WKRPIWQGLZTGFV-UHFFFAOYSA-N n,2-dicyclohexyl-2-[2-[1-(2,4-dichlorophenoxy)ethyl]-5,6-difluorobenzimidazol-1-yl]acetamide Chemical compound N=1C2=CC(F)=C(F)C=C2N(C(C2CCCCC2)C(=O)NC2CCCCC2)C=1C(C)OC1=CC=C(Cl)C=C1Cl WKRPIWQGLZTGFV-UHFFFAOYSA-N 0.000 claims description 5
- WOOGOEGHMVIQLA-UHFFFAOYSA-N n,2-dicyclohexyl-2-[5,6-difluoro-2-(phenoxymethyl)benzimidazol-1-yl]acetamide Chemical compound C1CCCCC1C(C(=O)NC1CCCCC1)N1C=2C=C(F)C(F)=CC=2N=C1COC1=CC=CC=C1 WOOGOEGHMVIQLA-UHFFFAOYSA-N 0.000 claims description 5
- LWQZMJHUXDMPQS-UHFFFAOYSA-N n,2-dicyclohexyl-2-[5-fluoro-2-(2-phenylethyl)benzimidazol-1-yl]acetamide Chemical compound C=1C=CC=CC=1CCC1=NC2=CC(F)=CC=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 LWQZMJHUXDMPQS-UHFFFAOYSA-N 0.000 claims description 5
- ZJSOVVWNQDOTQI-UHFFFAOYSA-N n,2-dicyclohexyl-2-[5-fluoro-2-(pyridin-2-yloxymethyl)benzimidazol-1-yl]acetamide Chemical compound C=1C=CC=NC=1OCC1=NC2=CC(F)=CC=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 ZJSOVVWNQDOTQI-UHFFFAOYSA-N 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 4
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 4
- 230000003143 atherosclerotic effect Effects 0.000 claims description 4
- 125000002619 bicyclic group Chemical group 0.000 claims description 4
- 230000004761 fibrosis Effects 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- STRAHLZNKGRPTC-UHFFFAOYSA-N n,2-dicyclohexyl-2-[5-fluoro-2-[(4-methoxyphenoxy)methyl]benzimidazol-1-yl]acetamide Chemical compound C1=CC(OC)=CC=C1OCC1=NC2=CC(F)=CC=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 STRAHLZNKGRPTC-UHFFFAOYSA-N 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- MAXDJYGVHNACQO-MUUNZHRXSA-N (2r)-2-[2-[(4-chloro-2-methylphenoxy)methyl]-6-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound CC1=CC(Cl)=CC=C1OCC1=NC2=CC=C(F)C=C2N1[C@@H](C(=O)NC1CCCCC1)C1CCCCC1 MAXDJYGVHNACQO-MUUNZHRXSA-N 0.000 claims description 3
- VAGMTYLRPUWQTK-NGOKVRLYSA-N (2s)-2-[2-[(1r)-1-(4-chloro-2-methylphenoxy)ethyl]-6-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound O([C@H](C)C=1N(C2=CC(F)=CC=C2N=1)[C@@H](C1CCCCC1)C(=O)NC1CCCCC1)C1=CC=C(Cl)C=C1C VAGMTYLRPUWQTK-NGOKVRLYSA-N 0.000 claims description 3
- VAGMTYLRPUWQTK-MMTVBGGISA-N (2s)-2-[2-[(1s)-1-(4-chloro-2-methylphenoxy)ethyl]-6-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound O([C@@H](C)C=1N(C2=CC(F)=CC=C2N=1)[C@@H](C1CCCCC1)C(=O)NC1CCCCC1)C1=CC=C(Cl)C=C1C VAGMTYLRPUWQTK-MMTVBGGISA-N 0.000 claims description 3
- LCVFHMUIBMBVRT-UHFFFAOYSA-N 2-[2-(benzenesulfinylmethyl)-6-chloro-5-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound C1CCCCC1C(C(=O)NC1CCCCC1)N1C=2C=C(Cl)C(F)=CC=2N=C1CS(=O)C1=CC=CC=C1 LCVFHMUIBMBVRT-UHFFFAOYSA-N 0.000 claims description 3
- OJEXSWVPQOGCKB-UHFFFAOYSA-N 2-[2-(butoxymethyl)-5,6-difluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound CCCCOCC1=NC2=CC(F)=C(F)C=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 OJEXSWVPQOGCKB-UHFFFAOYSA-N 0.000 claims description 3
- YGCMJDZFVSOQPC-UHFFFAOYSA-N 2-[2-(butoxymethyl)-6-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound CCCCOCC1=NC2=CC=C(F)C=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 YGCMJDZFVSOQPC-UHFFFAOYSA-N 0.000 claims description 3
- SMOJFXAGLFADGT-UHFFFAOYSA-N 2-[2-[(2-chloro-6-methylphenoxy)methyl]-6-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound CC1=CC=CC(Cl)=C1OCC1=NC2=CC=C(F)C=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 SMOJFXAGLFADGT-UHFFFAOYSA-N 0.000 claims description 3
- PEGVBMFBSZTZKW-UHFFFAOYSA-N 2-[2-[(2-chlorophenoxy)methyl]-5,6-difluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound C1CCCCC1C(C(=O)NC1CCCCC1)N1C=2C=C(F)C(F)=CC=2N=C1COC1=CC=CC=C1Cl PEGVBMFBSZTZKW-UHFFFAOYSA-N 0.000 claims description 3
- KWWOVPPSCHRWFM-UHFFFAOYSA-N 2-[2-[(4-acetylphenoxy)methyl]-6-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound C1=CC(C(=O)C)=CC=C1OCC1=NC2=CC=C(F)C=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 KWWOVPPSCHRWFM-UHFFFAOYSA-N 0.000 claims description 3
- ICRCVQFYXLTZOL-UHFFFAOYSA-N 2-[2-[(4-chloro-2-methylphenoxy)methyl]-5,6-difluorobenzimidazol-1-yl]-n-cyclopentyl-2-(oxan-2-yl)acetamide Chemical compound CC1=CC(Cl)=CC=C1OCC1=NC2=CC(F)=C(F)C=C2N1C(C(=O)NC1CCCC1)C1OCCCC1 ICRCVQFYXLTZOL-UHFFFAOYSA-N 0.000 claims description 3
- ZLKFBXGFAPLRKO-UHFFFAOYSA-N 2-[2-[(4-chloro-2-methylphenoxy)methyl]-5-fluorobenzimidazol-1-yl]-2-cycloheptyl-n-cyclohexylacetamide Chemical compound CC1=CC(Cl)=CC=C1OCC1=NC2=CC(F)=CC=C2N1C(C(=O)NC1CCCCC1)C1CCCCCC1 ZLKFBXGFAPLRKO-UHFFFAOYSA-N 0.000 claims description 3
- OKMMGGDJHMDQJH-UHFFFAOYSA-N 2-[2-[(4-chloro-2-methylphenoxy)methyl]-5-fluorobenzimidazol-1-yl]-2-cycloheptyl-n-cyclopentylacetamide Chemical compound CC1=CC(Cl)=CC=C1OCC1=NC2=CC(F)=CC=C2N1C(C(=O)NC1CCCC1)C1CCCCCC1 OKMMGGDJHMDQJH-UHFFFAOYSA-N 0.000 claims description 3
- XEQDYZBTRBXVBC-UHFFFAOYSA-N 2-[2-[(4-chloro-2-methylphenoxy)methyl]-6-fluorobenzimidazol-1-yl]-2-cycloheptyl-n-cyclohexylacetamide Chemical compound CC1=CC(Cl)=CC=C1OCC1=NC2=CC=C(F)C=C2N1C(C(=O)NC1CCCCC1)C1CCCCCC1 XEQDYZBTRBXVBC-UHFFFAOYSA-N 0.000 claims description 3
- RXMQXIRZDLYKRR-UHFFFAOYSA-N 2-[2-[(4-chloro-2-methylphenoxy)methyl]-6-fluorobenzimidazol-1-yl]-2-cycloheptyl-n-cyclopentylacetamide Chemical compound CC1=CC(Cl)=CC=C1OCC1=NC2=CC=C(F)C=C2N1C(C(=O)NC1CCCC1)C1CCCCCC1 RXMQXIRZDLYKRR-UHFFFAOYSA-N 0.000 claims description 3
- OWBOXBFQZZZWOX-UHFFFAOYSA-N 2-[2-[1-(2-chlorophenoxy)ethyl]-5,6-difluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound N=1C2=CC(F)=C(F)C=C2N(C(C2CCCCC2)C(=O)NC2CCCCC2)C=1C(C)OC1=CC=CC=C1Cl OWBOXBFQZZZWOX-UHFFFAOYSA-N 0.000 claims description 3
- HDCLCQQZWVZLEB-UHFFFAOYSA-N 2-[2-[1-(2-chlorophenoxy)ethyl]-5-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound N=1C2=CC(F)=CC=C2N(C(C2CCCCC2)C(=O)NC2CCCCC2)C=1C(C)OC1=CC=CC=C1Cl HDCLCQQZWVZLEB-UHFFFAOYSA-N 0.000 claims description 3
- PJUKJMAYYFBUQS-UHFFFAOYSA-N 2-[2-[1-(2-chlorophenoxy)ethyl]-6-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound N=1C2=CC=C(F)C=C2N(C(C2CCCCC2)C(=O)NC2CCCCC2)C=1C(C)OC1=CC=CC=C1Cl PJUKJMAYYFBUQS-UHFFFAOYSA-N 0.000 claims description 3
- BVWUHZKGNYYDKM-UHFFFAOYSA-N 2-[2-[1-(3-chlorophenoxy)ethyl]-6-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound N=1C2=CC=C(F)C=C2N(C(C2CCCCC2)C(=O)NC2CCCCC2)C=1C(C)OC1=CC=CC(Cl)=C1 BVWUHZKGNYYDKM-UHFFFAOYSA-N 0.000 claims description 3
- RJZMELGWULHOMD-UHFFFAOYSA-N 2-[2-[2-(1,3-benzodioxol-5-yl)ethyl]-6-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound C12=CC(F)=CC=C2N=C(CCC=2C=C3OCOC3=CC=2)N1C(C(=O)NC1CCCCC1)C1CCCCC1 RJZMELGWULHOMD-UHFFFAOYSA-N 0.000 claims description 3
- KZPUZQNYRCNAJS-UHFFFAOYSA-N 2-[2-[2-(4-chlorophenoxy)propan-2-yl]-6-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound N=1C2=CC=C(F)C=C2N(C(C2CCCCC2)C(=O)NC2CCCCC2)C=1C(C)(C)OC1=CC=C(Cl)C=C1 KZPUZQNYRCNAJS-UHFFFAOYSA-N 0.000 claims description 3
- VOISXGPYGFOKAV-UHFFFAOYSA-N 2-[2-[2-(4-chlorophenyl)ethyl]-6-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound C1CCCCC1C(C(=O)NC1CCCCC1)N1C2=CC(F)=CC=C2N=C1CCC1=CC=C(Cl)C=C1 VOISXGPYGFOKAV-UHFFFAOYSA-N 0.000 claims description 3
- KALMGYVDQWSXHV-UHFFFAOYSA-N 2-[6-chloro-2-[(3,4-dimethoxyphenyl)sulfanylmethyl]-5-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound C1=C(OC)C(OC)=CC=C1SCC1=NC2=CC(F)=C(Cl)C=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 KALMGYVDQWSXHV-UHFFFAOYSA-N 0.000 claims description 3
- SUQPEKCWRMIEJA-UHFFFAOYSA-N 2-[6-chloro-2-[(4-chlorophenoxy)methyl]-5-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound C1CCCCC1C(C(=O)NC1CCCCC1)N1C=2C=C(Cl)C(F)=CC=2N=C1COC1=CC=C(Cl)C=C1 SUQPEKCWRMIEJA-UHFFFAOYSA-N 0.000 claims description 3
- NHGNQJKZSAFHSA-UHFFFAOYSA-N 2-[6-chloro-2-[(8-chloronaphthalen-1-yl)sulfanylmethyl]-5-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound C1=2C=C(Cl)C(F)=CC=2N=C(CSC=2C3=C(Cl)C=CC=C3C=CC=2)N1C(C(=O)NC1CCCCC1)C1CCCCC1 NHGNQJKZSAFHSA-UHFFFAOYSA-N 0.000 claims description 3
- NWKBWRWSSVOBTI-UHFFFAOYSA-N 2-[6-chloro-2-[1-(3-chlorophenoxy)ethyl]-5-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound N=1C2=CC(F)=C(Cl)C=C2N(C(C2CCCCC2)C(=O)NC2CCCCC2)C=1C(C)OC1=CC=CC(Cl)=C1 NWKBWRWSSVOBTI-UHFFFAOYSA-N 0.000 claims description 3
- WPZQOHAIVFOQNJ-UHFFFAOYSA-N 2-[6-chloro-5-fluoro-2-(1-phenoxypropyl)benzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound N=1C2=CC(F)=C(Cl)C=C2N(C(C2CCCCC2)C(=O)NC2CCCCC2)C=1C(CC)OC1=CC=CC=C1 WPZQOHAIVFOQNJ-UHFFFAOYSA-N 0.000 claims description 3
- PDFXAGVGGDXBNP-UHFFFAOYSA-N 2-[6-chloro-5-fluoro-2-[2-(3-propan-2-yloxy-1,2-oxazol-5-yl)ethyl]benzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound O1N=C(OC(C)C)C=C1CCC1=NC2=CC(F)=C(Cl)C=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 PDFXAGVGGDXBNP-UHFFFAOYSA-N 0.000 claims description 3
- IASBTUWRQZQDAB-UHFFFAOYSA-N 2-[6-chloro-5-fluoro-2-[[4-(trifluoromethyl)phenyl]sulfanylmethyl]benzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound C1CCCCC1C(C(=O)NC1CCCCC1)N1C=2C=C(Cl)C(F)=CC=2N=C1CSC1=CC=C(C(F)(F)F)C=C1 IASBTUWRQZQDAB-UHFFFAOYSA-N 0.000 claims description 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 3
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 3
- KDRXDSXHRVLSFB-UHFFFAOYSA-N n,2-dicyclohexyl-2-[2-(ethoxymethyl)-5,6-difluorobenzimidazol-1-yl]acetamide Chemical compound CCOCC1=NC2=CC(F)=C(F)C=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 KDRXDSXHRVLSFB-UHFFFAOYSA-N 0.000 claims description 3
- MBZNEZGKCPXQBZ-UHFFFAOYSA-N n,2-dicyclohexyl-2-[2-(ethoxymethyl)-5-fluorobenzimidazol-1-yl]acetamide Chemical compound CCOCC1=NC2=CC(F)=CC=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 MBZNEZGKCPXQBZ-UHFFFAOYSA-N 0.000 claims description 3
- NQSBAMCZBFHUHJ-UHFFFAOYSA-N n,2-dicyclohexyl-2-[2-[(2,4-dichlorophenoxy)methyl]-6-fluorobenzimidazol-1-yl]acetamide Chemical compound C1CCCCC1C(C(=O)NC1CCCCC1)N1C2=CC(F)=CC=C2N=C1COC1=CC=C(Cl)C=C1Cl NQSBAMCZBFHUHJ-UHFFFAOYSA-N 0.000 claims description 3
- CDZQVNSFMRBFCE-UHFFFAOYSA-N n,2-dicyclohexyl-2-[2-[(2,4-dichlorophenyl)sulfanylmethyl]-6-fluorobenzimidazol-1-yl]acetamide Chemical compound C1CCCCC1C(C(=O)NC1CCCCC1)N1C2=CC(F)=CC=C2N=C1CSC1=CC=C(Cl)C=C1Cl CDZQVNSFMRBFCE-UHFFFAOYSA-N 0.000 claims description 3
- WKGNNMKETPMKHF-UHFFFAOYSA-N n,2-dicyclohexyl-2-[2-[(2,4-dimethylphenoxy)methyl]-5-fluorobenzimidazol-1-yl]acetamide Chemical compound CC1=CC(C)=CC=C1OCC1=NC2=CC(F)=CC=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 WKGNNMKETPMKHF-UHFFFAOYSA-N 0.000 claims description 3
- RDCFVTGHEMYNNZ-UHFFFAOYSA-N n,2-dicyclohexyl-2-[2-[(2,5-dimethylphenoxy)methyl]-6-fluorobenzimidazol-1-yl]acetamide Chemical compound CC1=CC=C(C)C(OCC=2N(C3=CC(F)=CC=C3N=2)C(C2CCCCC2)C(=O)NC2CCCCC2)=C1 RDCFVTGHEMYNNZ-UHFFFAOYSA-N 0.000 claims description 3
- ZZUSDSVKRRMPKF-UHFFFAOYSA-N n,2-dicyclohexyl-2-[2-[(2,6-dichlorophenyl)sulfanylmethyl]-6-fluorobenzimidazol-1-yl]acetamide Chemical compound C1CCCCC1C(C(=O)NC1CCCCC1)N1C2=CC(F)=CC=C2N=C1CSC1=C(Cl)C=CC=C1Cl ZZUSDSVKRRMPKF-UHFFFAOYSA-N 0.000 claims description 3
- UWBSTQFGWDZEPC-UHFFFAOYSA-N n,2-dicyclohexyl-2-[2-[(3,4-dimethylphenoxy)methyl]-5-fluorobenzimidazol-1-yl]acetamide Chemical compound C1=C(C)C(C)=CC=C1OCC1=NC2=CC(F)=CC=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 UWBSTQFGWDZEPC-UHFFFAOYSA-N 0.000 claims description 3
- SIGRJVPSMVTMHT-UHFFFAOYSA-N n,2-dicyclohexyl-2-[2-[(4-ethylphenoxy)methyl]-6-fluorobenzimidazol-1-yl]acetamide Chemical compound C1=CC(CC)=CC=C1OCC1=NC2=CC=C(F)C=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 SIGRJVPSMVTMHT-UHFFFAOYSA-N 0.000 claims description 3
- KUSGBZMKVBYXEA-UHFFFAOYSA-N n,2-dicyclohexyl-2-[2-[1-(2,3-dihydro-1,4-benzodioxin-6-yloxy)ethyl]-5,6-difluorobenzimidazol-1-yl]acetamide Chemical compound C=1C=C2OCCOC2=CC=1OC(C)C1=NC2=CC(F)=C(F)C=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 KUSGBZMKVBYXEA-UHFFFAOYSA-N 0.000 claims description 3
- FGURVTAXIHTQSZ-UHFFFAOYSA-N n,2-dicyclohexyl-2-[2-[1-(2,3-dihydro-1,4-benzodioxin-6-yloxy)ethyl]-5-fluorobenzimidazol-1-yl]acetamide Chemical compound C=1C=C2OCCOC2=CC=1OC(C)C1=NC2=CC(F)=CC=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 FGURVTAXIHTQSZ-UHFFFAOYSA-N 0.000 claims description 3
- IKVOMHVMBPOYCO-UHFFFAOYSA-N n,2-dicyclohexyl-2-[2-[1-(2,3-dihydro-1,4-benzodioxin-6-yloxy)ethyl]-6-fluorobenzimidazol-1-yl]acetamide Chemical compound C=1C=C2OCCOC2=CC=1OC(C)C1=NC2=CC=C(F)C=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 IKVOMHVMBPOYCO-UHFFFAOYSA-N 0.000 claims description 3
- OPXTUCFUNJHGBI-UHFFFAOYSA-N n,2-dicyclohexyl-2-[2-[1-(2,4-dichlorophenoxy)ethyl]-5-fluorobenzimidazol-1-yl]acetamide Chemical compound N=1C2=CC(F)=CC=C2N(C(C2CCCCC2)C(=O)NC2CCCCC2)C=1C(C)OC1=CC=C(Cl)C=C1Cl OPXTUCFUNJHGBI-UHFFFAOYSA-N 0.000 claims description 3
- CNGPVFASXPLPNP-UHFFFAOYSA-N n,2-dicyclohexyl-2-[5,6-difluoro-2-(3-phenylpropyl)benzimidazol-1-yl]acetamide Chemical compound C1CCCCC1C(C(=O)NC1CCCCC1)N1C=2C=C(F)C(F)=CC=2N=C1CCCC1=CC=CC=C1 CNGPVFASXPLPNP-UHFFFAOYSA-N 0.000 claims description 3
- QVMIFPWKIKLGKL-UHFFFAOYSA-N n,2-dicyclohexyl-2-[5,6-difluoro-2-[(2-methylphenoxy)methyl]benzimidazol-1-yl]acetamide Chemical compound CC1=CC=CC=C1OCC1=NC2=CC(F)=C(F)C=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 QVMIFPWKIKLGKL-UHFFFAOYSA-N 0.000 claims description 3
- MQFNSUJJTUVQBY-UHFFFAOYSA-N n,2-dicyclohexyl-2-[5,6-difluoro-2-[(3-methylphenoxy)methyl]benzimidazol-1-yl]acetamide Chemical compound CC1=CC=CC(OCC=2N(C3=CC(F)=C(F)C=C3N=2)C(C2CCCCC2)C(=O)NC2CCCCC2)=C1 MQFNSUJJTUVQBY-UHFFFAOYSA-N 0.000 claims description 3
- NIOBCIBPEDHTDA-UHFFFAOYSA-N n,2-dicyclohexyl-2-[5,6-difluoro-2-[(4-fluorophenoxy)methyl]benzimidazol-1-yl]acetamide Chemical compound C1=CC(F)=CC=C1OCC1=NC2=CC(F)=C(F)C=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 NIOBCIBPEDHTDA-UHFFFAOYSA-N 0.000 claims description 3
- JZPCOFXXXRSHSC-UHFFFAOYSA-N n,2-dicyclohexyl-2-[5,6-difluoro-2-[(4-methoxyphenoxy)methyl]benzimidazol-1-yl]acetamide Chemical compound C1=CC(OC)=CC=C1OCC1=NC2=CC(F)=C(F)C=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 JZPCOFXXXRSHSC-UHFFFAOYSA-N 0.000 claims description 3
- UMYJVIUGTFPHIA-UHFFFAOYSA-N n,2-dicyclohexyl-2-[5,6-difluoro-2-[[4-(hydroxymethyl)-3-methoxyphenoxy]methyl]benzimidazol-1-yl]acetamide Chemical compound C1=C(CO)C(OC)=CC(OCC=2N(C3=CC(F)=C(F)C=C3N=2)C(C2CCCCC2)C(=O)NC2CCCCC2)=C1 UMYJVIUGTFPHIA-UHFFFAOYSA-N 0.000 claims description 3
- AYKUJNTWFRPDNH-UHFFFAOYSA-N n,2-dicyclohexyl-2-[5-fluoro-2-[(2-methoxyphenoxy)methyl]benzimidazol-1-yl]acetamide Chemical compound COC1=CC=CC=C1OCC1=NC2=CC(F)=CC=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 AYKUJNTWFRPDNH-UHFFFAOYSA-N 0.000 claims description 3
- RIGJMUVTAGUXTQ-UHFFFAOYSA-N n,2-dicyclohexyl-2-[5-fluoro-2-[(2-methylphenoxy)methyl]benzimidazol-1-yl]acetamide Chemical compound CC1=CC=CC=C1OCC1=NC2=CC(F)=CC=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 RIGJMUVTAGUXTQ-UHFFFAOYSA-N 0.000 claims description 3
- WXHNPWYQUIDSBH-UHFFFAOYSA-N n,2-dicyclohexyl-2-[5-fluoro-2-[(3-methylphenoxy)methyl]benzimidazol-1-yl]acetamide Chemical compound CC1=CC=CC(OCC=2N(C3=CC=C(F)C=C3N=2)C(C2CCCCC2)C(=O)NC2CCCCC2)=C1 WXHNPWYQUIDSBH-UHFFFAOYSA-N 0.000 claims description 3
- LSPXQPGMYRFNJH-UHFFFAOYSA-N n,2-dicyclohexyl-2-[5-fluoro-2-[(4-fluorophenoxy)methyl]benzimidazol-1-yl]acetamide Chemical compound C1=CC(F)=CC=C1OCC1=NC2=CC(F)=CC=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 LSPXQPGMYRFNJH-UHFFFAOYSA-N 0.000 claims description 3
- JWLBKTDIMDOVFG-UHFFFAOYSA-N n,2-dicyclohexyl-2-[5-fluoro-2-[(4-methylphenoxy)methyl]benzimidazol-1-yl]acetamide Chemical compound C1=CC(C)=CC=C1OCC1=NC2=CC(F)=CC=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 JWLBKTDIMDOVFG-UHFFFAOYSA-N 0.000 claims description 3
- GOHXJHJARUQTOP-UHFFFAOYSA-N n,2-dicyclohexyl-2-[6-fluoro-2-(phenylmethoxymethyl)benzimidazol-1-yl]acetamide Chemical compound C1CCCCC1C(C(=O)NC1CCCCC1)N1C2=CC(F)=CC=C2N=C1COCC1=CC=CC=C1 GOHXJHJARUQTOP-UHFFFAOYSA-N 0.000 claims description 3
- JKKXRDZPXQEFMS-UHFFFAOYSA-N n,2-dicyclohexyl-2-[6-fluoro-2-[(2-methylphenoxy)methyl]benzimidazol-1-yl]acetamide Chemical compound CC1=CC=CC=C1OCC1=NC2=CC=C(F)C=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 JKKXRDZPXQEFMS-UHFFFAOYSA-N 0.000 claims description 3
- ZENMYKOPZJGBTG-UHFFFAOYSA-N n,2-dicyclohexyl-2-[6-fluoro-2-[2-(4-fluorophenyl)ethyl]benzimidazol-1-yl]acetamide Chemical compound C1=CC(F)=CC=C1CCC1=NC2=CC=C(F)C=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 ZENMYKOPZJGBTG-UHFFFAOYSA-N 0.000 claims description 3
- ORNRRCSSEFCLRW-UHFFFAOYSA-N n,2-dicyclohexyl-2-[6-fluoro-2-[2-(4-methoxyphenyl)ethyl]benzimidazol-1-yl]acetamide Chemical compound C1=CC(OC)=CC=C1CCC1=NC2=CC=C(F)C=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 ORNRRCSSEFCLRW-UHFFFAOYSA-N 0.000 claims description 3
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 2
- PTTFJVWBDDNNBV-UHFFFAOYSA-N 2-[2-(benzenesulfinylmethyl)-6-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound C1CCCCC1C(C(=O)NC1CCCCC1)N1C2=CC(F)=CC=C2N=C1CS(=O)C1=CC=CC=C1 PTTFJVWBDDNNBV-UHFFFAOYSA-N 0.000 claims description 2
- GFOHGNSOKMDZLS-UHFFFAOYSA-N 2-[2-(benzenesulfinylmethyl)benzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound C1CCCCC1C(N1C2=CC=CC=C2N=C1CS(=O)C=1C=CC=CC=1)C(=O)NC1CCCCC1 GFOHGNSOKMDZLS-UHFFFAOYSA-N 0.000 claims description 2
- WUSTWJXRVZLHCC-UHFFFAOYSA-N 2-[2-[(2-chlorophenoxy)methyl]-6-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound C1CCCCC1C(C(=O)NC1CCCCC1)N1C2=CC(F)=CC=C2N=C1COC1=CC=CC=C1Cl WUSTWJXRVZLHCC-UHFFFAOYSA-N 0.000 claims description 2
- QECISSLEMMGBSJ-UHFFFAOYSA-N 2-[2-[1-(4-chlorophenoxy)ethyl]-6-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound N=1C2=CC=C(F)C=C2N(C(C2CCCCC2)C(=O)NC2CCCCC2)C=1C(C)OC1=CC=C(Cl)C=C1 QECISSLEMMGBSJ-UHFFFAOYSA-N 0.000 claims description 2
- PVPDWDOLTUYFOJ-UHFFFAOYSA-N 2-[6-chloro-2-[(2,4-dichlorophenyl)sulfanylmethyl]-5-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound C1CCCCC1C(C(=O)NC1CCCCC1)N1C=2C=C(Cl)C(F)=CC=2N=C1CSC1=CC=C(Cl)C=C1Cl PVPDWDOLTUYFOJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- JUZZGJGXRBRZHJ-UHFFFAOYSA-N n,2-dicyclohexyl-2-[2-[(2,4-dimethylphenoxy)methyl]-6-fluorobenzimidazol-1-yl]acetamide Chemical compound CC1=CC(C)=CC=C1OCC1=NC2=CC=C(F)C=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 JUZZGJGXRBRZHJ-UHFFFAOYSA-N 0.000 claims description 2
- NXGXOSHMSUWYDW-UHFFFAOYSA-N n,2-dicyclohexyl-2-[2-[1-(2,4-dichlorophenoxy)ethyl]-6-fluorobenzimidazol-1-yl]acetamide Chemical compound N=1C2=CC=C(F)C=C2N(C(C2CCCCC2)C(=O)NC2CCCCC2)C=1C(C)OC1=CC=C(Cl)C=C1Cl NXGXOSHMSUWYDW-UHFFFAOYSA-N 0.000 claims description 2
- MEOOMFPOZBSORK-UHFFFAOYSA-N n,2-dicyclohexyl-2-[5-fluoro-2-(3-phenylpropyl)benzimidazol-1-yl]acetamide Chemical compound C=1C=CC=CC=1CCCC1=NC2=CC(F)=CC=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 MEOOMFPOZBSORK-UHFFFAOYSA-N 0.000 claims description 2
- VKULPVBJZPKCRC-UHFFFAOYSA-N n,2-dicyclohexyl-2-[6-fluoro-2-(1-phenoxypropyl)benzimidazol-1-yl]acetamide Chemical compound N=1C2=CC=C(F)C=C2N(C(C2CCCCC2)C(=O)NC2CCCCC2)C=1C(CC)OC1=CC=CC=C1 VKULPVBJZPKCRC-UHFFFAOYSA-N 0.000 claims description 2
- QTWMFFNVVMFGIP-UHFFFAOYSA-N n,2-dicyclohexyl-2-[6-fluoro-2-[(2-methoxyphenoxy)methyl]benzimidazol-1-yl]acetamide Chemical compound COC1=CC=CC=C1OCC1=NC2=CC=C(F)C=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 QTWMFFNVVMFGIP-UHFFFAOYSA-N 0.000 claims description 2
- DOIWFNVCGWXGPP-UHFFFAOYSA-N n,2-dicyclohexyl-2-[6-fluoro-2-[(3-methylphenoxy)methyl]benzimidazol-1-yl]acetamide Chemical compound CC1=CC=CC(OCC=2N(C3=CC(F)=CC=C3N=2)C(C2CCCCC2)C(=O)NC2CCCCC2)=C1 DOIWFNVCGWXGPP-UHFFFAOYSA-N 0.000 claims description 2
- VXWMVTREMJZIDN-UHFFFAOYSA-N n,2-dicyclohexyl-2-[6-fluoro-2-[1-[4-(trifluoromethoxy)phenoxy]ethyl]benzimidazol-1-yl]acetamide Chemical compound N=1C2=CC=C(F)C=C2N(C(C2CCCCC2)C(=O)NC2CCCCC2)C=1C(C)OC1=CC=C(OC(F)(F)F)C=C1 VXWMVTREMJZIDN-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- FPHRGNFLPIKHSH-UHFFFAOYSA-N 2,2-dicyclohexylacetamide Chemical compound C1CCCCC1C(C(=O)N)C1CCCCC1 FPHRGNFLPIKHSH-UHFFFAOYSA-N 0.000 claims 1
- QLVKSBLZJNEYCC-UHFFFAOYSA-N n,2-dicyclohexyl-2-[6-fluoro-2-[[4-(hydroxymethyl)phenoxy]methyl]benzimidazol-1-yl]acetamide Chemical compound C1=CC(CO)=CC=C1OCC1=NC2=CC=C(F)C=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 QLVKSBLZJNEYCC-UHFFFAOYSA-N 0.000 claims 1
- OPQYFNRLWBWCST-UHFFFAOYSA-N 2-(2-chlorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=CC=C1Cl OPQYFNRLWBWCST-UHFFFAOYSA-N 0.000 description 45
- WHKUVVPPKQRRBV-UHFFFAOYSA-N Trasan Chemical compound CC1=CC(Cl)=CC=C1OCC(O)=O WHKUVVPPKQRRBV-UHFFFAOYSA-N 0.000 description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 102100038495 Bile acid receptor Human genes 0.000 description 25
- KVFDZFBHBWTVID-UHFFFAOYSA-N cyclohexanecarbaldehyde Chemical compound O=CC1CCCCC1 KVFDZFBHBWTVID-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 19
- 239000000203 mixture Substances 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- SODPIMGUZLOIPE-UHFFFAOYSA-N (4-chlorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1 SODPIMGUZLOIPE-UHFFFAOYSA-N 0.000 description 14
- 239000003613 bile acid Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- XYZMOVWWVXBHDP-UHFFFAOYSA-N cyclohexyl isocyanide Chemical compound [C-]#[N+]C1CCCCC1 XYZMOVWWVXBHDP-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 150000001299 aldehydes Chemical class 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 239000012876 carrier material Substances 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- UGBFRCHGZFHSBC-UHFFFAOYSA-N cycloheptanecarbaldehyde Chemical compound O=CC1CCCCCC1 UGBFRCHGZFHSBC-UHFFFAOYSA-N 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- XTLSDEJNOQVCHL-UHFFFAOYSA-N isocyanocyclopentane Chemical compound [C-]#[N+]C1CCCC1 XTLSDEJNOQVCHL-UHFFFAOYSA-N 0.000 description 8
- 238000002953 preparative HPLC Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 6
- MZHCENGPTKEIGP-UHFFFAOYSA-N 2-(2,4-dichlorophenoxy)propanoic acid Chemical compound OC(=O)C(C)OC1=CC=C(Cl)C=C1Cl MZHCENGPTKEIGP-UHFFFAOYSA-N 0.000 description 6
- XRTZHWXWLUGOAT-UHFFFAOYSA-N 2-(2,4-dimethylphenoxy)acetic acid Chemical compound CC1=CC=C(OCC(O)=O)C(C)=C1 XRTZHWXWLUGOAT-UHFFFAOYSA-N 0.000 description 6
- QJVXBRUGKLCUMY-UHFFFAOYSA-N 2-(2-methylphenoxy)acetic acid Chemical compound CC1=CC=CC=C1OCC(O)=O QJVXBRUGKLCUMY-UHFFFAOYSA-N 0.000 description 6
- VZECTCSEONQIPP-UHFFFAOYSA-N 2-(3-methylphenoxy)acetic acid Chemical compound CC1=CC=CC(OCC(O)=O)=C1 VZECTCSEONQIPP-UHFFFAOYSA-N 0.000 description 6
- PPAUMJSTRVZNNE-UHFFFAOYSA-N 2-(benzenesulfinyl)acetic acid Chemical compound OC(=O)CS(=O)C1=CC=CC=C1 PPAUMJSTRVZNNE-UHFFFAOYSA-N 0.000 description 6
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 6
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 6
- YZGQDNOIGFBYKF-UHFFFAOYSA-N Ethoxyacetic acid Chemical compound CCOCC(O)=O YZGQDNOIGFBYKF-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 6
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 6
- 102100023172 Nuclear receptor subfamily 0 group B member 2 Human genes 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 108020001756 ligand binding domains Proteins 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 108010003814 member 2 group B nuclear receptor subfamily 0 Proteins 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 5
- 239000001828 Gelatine Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- AVDBMBYECMTQJQ-UHFFFAOYSA-N 2-(2,3-dimethylphenoxy)acetic acid Chemical compound CC1=CC=CC(OCC(O)=O)=C1C AVDBMBYECMTQJQ-UHFFFAOYSA-N 0.000 description 4
- MDQZIQPTGRZCOQ-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)sulfanylacetic acid Chemical compound OC(=O)CSC1=CC=C(Cl)C=C1Cl MDQZIQPTGRZCOQ-UHFFFAOYSA-N 0.000 description 4
- RSJMMLSDGNQOEO-UHFFFAOYSA-N 2-(2,5-dimethylphenoxy)acetic acid Chemical compound CC1=CC=C(C)C(OCC(O)=O)=C1 RSJMMLSDGNQOEO-UHFFFAOYSA-N 0.000 description 4
- WHLKFTSLSDHFMU-UHFFFAOYSA-N 2-(2-chloro-6-methylphenoxy)acetic acid Chemical compound CC1=CC=CC(Cl)=C1OCC(O)=O WHLKFTSLSDHFMU-UHFFFAOYSA-N 0.000 description 4
- IHONYPFTXGQWAX-UHFFFAOYSA-N 2-(2-methoxyphenoxy)acetic acid Chemical compound COC1=CC=CC=C1OCC(O)=O IHONYPFTXGQWAX-UHFFFAOYSA-N 0.000 description 4
- YNTJKQDWYXUTLZ-UHFFFAOYSA-N 2-(3-chlorophenoxy)propanoic acid Chemical compound OC(=O)C(C)OC1=CC=CC(Cl)=C1 YNTJKQDWYXUTLZ-UHFFFAOYSA-N 0.000 description 4
- WVELHLIHMYYZAT-UHFFFAOYSA-N 2-(4-ethylphenoxy)acetic acid Chemical compound CCC1=CC=C(OCC(O)=O)C=C1 WVELHLIHMYYZAT-UHFFFAOYSA-N 0.000 description 4
- ZBIULCVFFJJYTN-UHFFFAOYSA-N 2-(4-fluorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(F)C=C1 ZBIULCVFFJJYTN-UHFFFAOYSA-N 0.000 description 4
- BHFSBJHPPFJCOS-UHFFFAOYSA-N 2-(4-methoxyphenoxy)acetic acid Chemical compound COC1=CC=C(OCC(O)=O)C=C1 BHFSBJHPPFJCOS-UHFFFAOYSA-N 0.000 description 4
- TVSPPYGAFOVROT-UHFFFAOYSA-N 2-phenoxybutanoic acid Chemical compound CCC(C(O)=O)OC1=CC=CC=C1 TVSPPYGAFOVROT-UHFFFAOYSA-N 0.000 description 4
- 102100028161 ATP-binding cassette sub-family C member 2 Human genes 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 108010066419 Multidrug Resistance-Associated Protein 2 Proteins 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000001913 cellulose Chemical class 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 108020004017 nuclear receptors Proteins 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 239000011877 solvent mixture Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- IBKSOWUYKOORFF-UHFFFAOYSA-N tert-butyl n-(2-amino-4-fluorophenyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(F)C=C1N IBKSOWUYKOORFF-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- AZWCUHKWACRUGS-UHFFFAOYSA-N 2-(2,3-dihydro-1,4-benzodioxin-6-yloxy)propanoic acid Chemical compound O1CCOC2=CC(OC(C)C(O)=O)=CC=C21 AZWCUHKWACRUGS-UHFFFAOYSA-N 0.000 description 3
- ZGWNXHRVUJVMCP-UHFFFAOYSA-N 2-(2-chlorophenoxy)propanoic acid Chemical compound OC(=O)C(C)OC1=CC=CC=C1Cl ZGWNXHRVUJVMCP-UHFFFAOYSA-N 0.000 description 3
- LHHKQWQTBCTDQM-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)propanoic acid Chemical compound COC1=CC=C(CCC(O)=O)C=C1OC LHHKQWQTBCTDQM-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- AJQOASGWDCBKCJ-UHFFFAOYSA-N Butoxyacetic acid Chemical compound CCCCOCC(O)=O AJQOASGWDCBKCJ-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 150000001556 benzimidazoles Chemical class 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 229920002678 cellulose Chemical class 0.000 description 3
- 230000031154 cholesterol homeostasis Effects 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000005595 deprotonation Effects 0.000 description 3
- 238000010537 deprotonation reaction Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 150000002527 isonitriles Chemical class 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229940057948 magnesium stearate Drugs 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000011976 maleic acid Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- MGCQZNBCJBRZDT-UHFFFAOYSA-N midodrine hydrochloride Chemical compound [H+].[Cl-].COC1=CC=C(OC)C(C(O)CNC(=O)CN)=C1 MGCQZNBCJBRZDT-UHFFFAOYSA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 3
- 235000011007 phosphoric acid Nutrition 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000002821 scintillation proximity assay Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- WEZYFYMYMKUAHY-UHFFFAOYSA-N tert-butyl 2,4-dibenzylpiperazine-1-carboxylate Chemical compound C1C(CC=2C=CC=CC=2)N(C(=O)OC(C)(C)C)CCN1CC1=CC=CC=C1 WEZYFYMYMKUAHY-UHFFFAOYSA-N 0.000 description 3
- ZDTBMFFIPXTZEB-UHFFFAOYSA-N tert-butyl n-(2-amino-4-chloro-5-fluorophenyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC(F)=C(Cl)C=C1N ZDTBMFFIPXTZEB-UHFFFAOYSA-N 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- GRZHHTYDZVRPIC-UHFFFAOYSA-N (benzyloxy)acetic acid Chemical compound OC(=O)COCC1=CC=CC=C1 GRZHHTYDZVRPIC-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 2
- URNRRSJGOOTQBO-UHFFFAOYSA-N 2-(2,6-dichlorophenyl)sulfanylacetic acid Chemical compound OC(=O)CSC1=C(Cl)C=CC=C1Cl URNRRSJGOOTQBO-UHFFFAOYSA-N 0.000 description 2
- ANVXBTSSFGHHBD-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)sulfanylacetic acid Chemical compound COC1=CC=C(SCC(O)=O)C=C1OC ANVXBTSSFGHHBD-UHFFFAOYSA-N 0.000 description 2
- GIEQJKZWTIFEJM-UHFFFAOYSA-N 2-(3,4-dimethylphenoxy)acetic acid Chemical compound CC1=CC=C(OCC(O)=O)C=C1C GIEQJKZWTIFEJM-UHFFFAOYSA-N 0.000 description 2
- AHDPQRIYMMZJTF-UHFFFAOYSA-N 2-(3-methoxyphenoxy)acetic acid Chemical compound COC1=CC=CC(OCC(O)=O)=C1 AHDPQRIYMMZJTF-UHFFFAOYSA-N 0.000 description 2
- KMXZEXUYXUMHEQ-UHFFFAOYSA-N 2-(4-acetylphenoxy)acetic acid Chemical compound CC(=O)C1=CC=C(OCC(O)=O)C=C1 KMXZEXUYXUMHEQ-UHFFFAOYSA-N 0.000 description 2
- WNTGYJSOUMFZEP-UHFFFAOYSA-N 2-(4-chloro-2-methylphenoxy)propanoic acid Chemical compound OC(=O)C(C)OC1=CC=C(Cl)C=C1C WNTGYJSOUMFZEP-UHFFFAOYSA-N 0.000 description 2
- HQEROVXUKINLPI-UHFFFAOYSA-N 2-(4-fluorophenyl)sulfanylacetic acid Chemical compound OC(=O)CSC1=CC=C(F)C=C1 HQEROVXUKINLPI-UHFFFAOYSA-N 0.000 description 2
- SFTDDFBJWUWKMN-UHFFFAOYSA-N 2-(4-methylphenoxy)acetic acid Chemical compound CC1=CC=C(OCC(O)=O)C=C1 SFTDDFBJWUWKMN-UHFFFAOYSA-N 0.000 description 2
- WPNAGQJVWAFQJV-UHFFFAOYSA-N 2-(8-chloronaphthalen-1-yl)sulfanylacetic acid Chemical compound C1=CC(Cl)=C2C(SCC(=O)O)=CC=CC2=C1 WPNAGQJVWAFQJV-UHFFFAOYSA-N 0.000 description 2
- YHBWXWLDOKIVCJ-UHFFFAOYSA-N 2-[2-(2-methoxyethoxy)ethoxy]acetic acid Chemical compound COCCOCCOCC(O)=O YHBWXWLDOKIVCJ-UHFFFAOYSA-N 0.000 description 2
- HOJFKIABRYHUMX-UHFFFAOYSA-N 2-[2-[(2-chloro-6-methylphenoxy)methyl]-5-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound CC1=CC=CC(Cl)=C1OCC1=NC2=CC(F)=CC=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 HOJFKIABRYHUMX-UHFFFAOYSA-N 0.000 description 2
- SLXYMMJCHHHFME-UHFFFAOYSA-N 2-[2-[(4-chloro-2-methylphenoxy)methyl]-6-fluorobenzimidazol-1-yl]-n-cyclopentyl-2-(oxan-3-yl)acetamide Chemical compound CC1=CC(Cl)=CC=C1OCC1=NC2=CC=C(F)C=C2N1C(C(=O)NC1CCCC1)C1COCCC1 SLXYMMJCHHHFME-UHFFFAOYSA-N 0.000 description 2
- OYFQZHSKLFPZFR-UHFFFAOYSA-N 2-[2-[(4-chlorophenoxy)methyl]-6-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound C1CCCCC1C(C(=O)NC1CCCCC1)N1C2=CC(F)=CC=C2N=C1COC1=CC=C(Cl)C=C1 OYFQZHSKLFPZFR-UHFFFAOYSA-N 0.000 description 2
- VUCNQOPCYRJCGQ-UHFFFAOYSA-N 2-[4-(hydroxymethyl)phenoxy]acetic acid Chemical compound OCC1=CC=C(OCC(O)=O)C=C1 VUCNQOPCYRJCGQ-UHFFFAOYSA-N 0.000 description 2
- NVWNMNYBXVGBEN-UHFFFAOYSA-N 2-[4-(trifluoromethoxy)phenoxy]propanoic acid Chemical compound OC(=O)C(C)OC1=CC=C(OC(F)(F)F)C=C1 NVWNMNYBXVGBEN-UHFFFAOYSA-N 0.000 description 2
- MBVVWIKWEHKYGF-UHFFFAOYSA-N 2-[4-(trifluoromethyl)phenyl]sulfanylacetic acid Chemical compound OC(=O)CSC1=CC=C(C(F)(F)F)C=C1 MBVVWIKWEHKYGF-UHFFFAOYSA-N 0.000 description 2
- DXRFAIFCCKPUPB-UHFFFAOYSA-N 2-[6-chloro-2-[1-(4-chlorophenoxy)ethyl]-5-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound N=1C2=CC(F)=C(Cl)C=C2N(C(C2CCCCC2)C(=O)NC2CCCCC2)C=1C(C)OC1=CC=C(Cl)C=C1 DXRFAIFCCKPUPB-UHFFFAOYSA-N 0.000 description 2
- PIQCZHHPDSYZPP-UHFFFAOYSA-N 2-naphthalen-1-ylsulfanylacetic acid Chemical compound C1=CC=C2C(SCC(=O)O)=CC=CC2=C1 PIQCZHHPDSYZPP-UHFFFAOYSA-N 0.000 description 2
- NLVYFXLILFDECX-UHFFFAOYSA-N 2-pyridin-2-yloxyacetic acid Chemical compound OC(=O)COC1=CC=CC=N1 NLVYFXLILFDECX-UHFFFAOYSA-N 0.000 description 2
- UIYJGLLTSVRSBM-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yl)propanoic acid Chemical compound OC(=O)CCC1=CC=C2OCOC2=C1 UIYJGLLTSVRSBM-UHFFFAOYSA-N 0.000 description 2
- DNEJAQNUBWVFHS-UHFFFAOYSA-N 3-(3-propan-2-yloxy-1,2-oxazol-5-yl)propanoic acid Chemical compound CC(C)OC=1C=C(CCC(O)=O)ON=1 DNEJAQNUBWVFHS-UHFFFAOYSA-N 0.000 description 2
- BBSLOKZINKEUCR-UHFFFAOYSA-N 3-(4-chlorophenyl)propanoic acid Chemical compound OC(=O)CCC1=CC=C(Cl)C=C1 BBSLOKZINKEUCR-UHFFFAOYSA-N 0.000 description 2
- ZMKXWDPUXLPHCA-UHFFFAOYSA-N 3-(4-fluorophenyl)propanoic acid Chemical compound OC(=O)CCC1=CC=C(F)C=C1 ZMKXWDPUXLPHCA-UHFFFAOYSA-N 0.000 description 2
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 2
- JWNBCQQQLMTPLP-UHFFFAOYSA-N 3-propoxypyrrolidine Chemical compound CCCOC1CCNC1 JWNBCQQQLMTPLP-UHFFFAOYSA-N 0.000 description 2
- WDMCABATCGQAKK-UHFFFAOYSA-N 4,5-difluoro-2-nitroaniline Chemical compound NC1=CC(F)=C(F)C=C1[N+]([O-])=O WDMCABATCGQAKK-UHFFFAOYSA-N 0.000 description 2
- ZKDXHLFLKKWCBY-UHFFFAOYSA-N 4-Hydroxymethyl-3-methoxyphenoxyacetic acid Chemical compound COC1=CC(OCC(O)=O)=CC=C1CO ZKDXHLFLKKWCBY-UHFFFAOYSA-N 0.000 description 2
- UGUBQKZSNQWWEV-UHFFFAOYSA-N 4-oxo-4-phenylmethoxybutanoic acid Chemical compound OC(=O)CCC(=O)OCC1=CC=CC=C1 UGUBQKZSNQWWEV-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical group [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108070000005 Bile acid receptors Proteins 0.000 description 2
- 102100028282 Bile salt export pump Human genes 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 0 CCO*(C)c1c(*(C(*)C(*(C)*)=O)C2OC2N)c(*)c(*)c([Cn])c1* Chemical compound CCO*(C)c1c(*(C(*)C(*(C)*)=O)C2OC2N)c(*)c(*)c([Cn])c1* 0.000 description 2
- DKHJWWRYTONYHB-UHFFFAOYSA-N CPP Chemical compound OC(=O)C(C)OC1=CC=C(Cl)C=C1 DKHJWWRYTONYHB-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 239000004129 EU approved improving agent Substances 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 229910010084 LiAlH4 Inorganic materials 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108010093662 Member 11 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 102100022669 Nuclear receptor subfamily 5 group A member 2 Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000000923 atherogenic effect Effects 0.000 description 2
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 2
- QCSLCGJVQLZPHL-UHFFFAOYSA-N benzyl 3-[1-[1-cyclohexyl-2-(cyclohexylamino)-2-oxoethyl]-5-fluorobenzimidazol-2-yl]propanoate Chemical compound C=1C=CC=CC=1COC(=O)CCC1=NC2=CC(F)=CC=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 QCSLCGJVQLZPHL-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 2
- 229960000815 ezetimibe Drugs 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 102000004311 liver X receptors Human genes 0.000 description 2
- 108090000865 liver X receptors Proteins 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000006452 multicomponent reaction Methods 0.000 description 2
- HLAPWXSABMXJMP-UHFFFAOYSA-N n,2-dicyclohexyl-2-[2-[(2,3-dimethylphenoxy)methyl]-6-fluorobenzimidazol-1-yl]acetamide Chemical compound CC1=CC=CC(OCC=2N(C3=CC(F)=CC=C3N=2)C(C2CCCCC2)C(=O)NC2CCCCC2)=C1C HLAPWXSABMXJMP-UHFFFAOYSA-N 0.000 description 2
- KUASAWUVRBYPHB-UHFFFAOYSA-N n,2-dicyclohexyl-2-[2-[(2,5-dimethylphenoxy)methyl]-5-fluorobenzimidazol-1-yl]acetamide Chemical compound CC1=CC=C(C)C(OCC=2N(C3=CC=C(F)C=C3N=2)C(C2CCCCC2)C(=O)NC2CCCCC2)=C1 KUASAWUVRBYPHB-UHFFFAOYSA-N 0.000 description 2
- BYJQTTPUHFAJQK-UHFFFAOYSA-N n,2-dicyclohexyl-2-[2-[2-(3,4-dimethoxyphenyl)ethyl]-6-fluorobenzimidazol-1-yl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CCC1=NC2=CC=C(F)C=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 BYJQTTPUHFAJQK-UHFFFAOYSA-N 0.000 description 2
- PNXRZIHVOCQMLR-UHFFFAOYSA-N n,2-dicyclohexyl-2-[5,6-difluoro-2-(2-phenylethyl)benzimidazol-1-yl]acetamide Chemical compound C1CCCCC1C(C(=O)NC1CCCCC1)N1C=2C=C(F)C(F)=CC=2N=C1CCC1=CC=CC=C1 PNXRZIHVOCQMLR-UHFFFAOYSA-N 0.000 description 2
- AUGZTMUJOQBMEB-UHFFFAOYSA-N n,2-dicyclohexyl-2-[5,6-difluoro-2-[(3-methoxyphenoxy)methyl]benzimidazol-1-yl]acetamide Chemical compound COC1=CC=CC(OCC=2N(C3=CC(F)=C(F)C=C3N=2)C(C2CCCCC2)C(=O)NC2CCCCC2)=C1 AUGZTMUJOQBMEB-UHFFFAOYSA-N 0.000 description 2
- RAGJXPKXUKFFKB-UHFFFAOYSA-N n,2-dicyclohexyl-2-[6-fluoro-2-(naphthalen-1-ylsulfanylmethyl)benzimidazol-1-yl]acetamide Chemical compound C12=CC(F)=CC=C2N=C(CSC=2C3=CC=CC=C3C=CC=2)N1C(C(=O)NC1CCCCC1)C1CCCCC1 RAGJXPKXUKFFKB-UHFFFAOYSA-N 0.000 description 2
- FTQWRYSLUYAIRQ-UHFFFAOYSA-N n-[(octadecanoylamino)methyl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCNC(=O)CCCCCCCCCCCCCCCCC FTQWRYSLUYAIRQ-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- XEZQLSOFXLPSJR-UHFFFAOYSA-N oxane-2-carbaldehyde Chemical compound O=CC1CCCCO1 XEZQLSOFXLPSJR-UHFFFAOYSA-N 0.000 description 2
- KYHPVAHPKYNKOR-UHFFFAOYSA-N oxane-3-carbaldehyde Chemical compound O=CC1CCCOC1 KYHPVAHPKYNKOR-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229950009215 phenylbutanoic acid Drugs 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000754 repressing effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- NYKTXVPUGXBLOK-UHFFFAOYSA-N tert-butyl n-(2-amino-4,5-difluorophenyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC(F)=C(F)C=C1N NYKTXVPUGXBLOK-UHFFFAOYSA-N 0.000 description 2
- KCZFBLNQOSFGSH-UHFFFAOYSA-N tert-butyl n-(2-aminophenyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC=C1N KCZFBLNQOSFGSH-UHFFFAOYSA-N 0.000 description 2
- 125000001302 tertiary amino group Chemical group 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- COLOHWPRNRVWPI-UHFFFAOYSA-N 1,1,1-trifluoroethane Chemical compound [CH2]C(F)(F)F COLOHWPRNRVWPI-UHFFFAOYSA-N 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
- WGUXTQDCAZNJIF-UHFFFAOYSA-N 1-methyl-3,5-bis(trifluoromethyl)benzene Chemical compound CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WGUXTQDCAZNJIF-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 239000005631 2,4-Dichlorophenoxyacetic acid Substances 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 1
- AQJTUYIAEJKDKT-UHFFFAOYSA-N 2-[6-chloro-2-[(2,4-dichlorophenyl)sulfinylmethyl]-5-fluorobenzimidazol-1-yl]-n,2-dicyclohexylacetamide Chemical compound C1CCCCC1C(C(=O)NC1CCCCC1)N1C=2C=C(Cl)C(F)=CC=2N=C1CS(=O)C1=CC=C(Cl)C=C1Cl AQJTUYIAEJKDKT-UHFFFAOYSA-N 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- FIUFLISGGHNPSM-UHFFFAOYSA-N 3-(4-methoxyphenyl)propanoic acid Chemical compound COC1=CC=C(CCC(O)=O)C=C1 FIUFLISGGHNPSM-UHFFFAOYSA-N 0.000 description 1
- GNPISAHACGIXLZ-UHFFFAOYSA-N 3-(4-methylphenoxy)propanoic acid Chemical compound CC1=CC=C(OCCC(O)=O)C=C1 GNPISAHACGIXLZ-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010029704 Constitutive Androstane Receptor Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 238000006969 Curtius rearrangement reaction Methods 0.000 description 1
- 102100038637 Cytochrome P450 7A1 Human genes 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 108010001515 Galectin 4 Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 238000007167 Hofmann rearrangement reaction Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000724352 Homo sapiens Bile salt export pump Proteins 0.000 description 1
- 101000957672 Homo sapiens Cytochrome P450 7A1 Proteins 0.000 description 1
- 101001109685 Homo sapiens Nuclear receptor subfamily 5 group A member 2 Proteins 0.000 description 1
- 101100273566 Humulus lupulus CCL10 gene Proteins 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100038494 Nuclear receptor subfamily 1 group I member 2 Human genes 0.000 description 1
- 102100038512 Nuclear receptor subfamily 1 group I member 3 Human genes 0.000 description 1
- 101710105538 Nuclear receptor subfamily 5 group A member 2 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 108010001511 Pregnane X Receptor Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Chemical class 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 238000006058 Ugi-reaction Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000006790 cellular biosynthetic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- TXCGAZHTZHNUAI-UHFFFAOYSA-N clofibric acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 TXCGAZHTZHNUAI-UHFFFAOYSA-N 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000010235 enterohepatic circulation Effects 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 208000009866 extrahepatic cholestasis Diseases 0.000 description 1
- 108010015722 farnesoid X-activated receptor Proteins 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000009123 feedback regulation Effects 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000005454 flavour additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 102000053357 human ABCB11 Human genes 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000001024 intrahepatic cholestasis Diseases 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000004322 lipid homeostasis Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical class O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- VLEYYMSDWNFSEN-UHFFFAOYSA-N n,2-dicyclohexyl-2-[2-(2,4-dimethoxyphenyl)benzimidazol-1-yl]acetamide Chemical compound COC1=CC(OC)=CC=C1C1=NC2=CC=CC=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 VLEYYMSDWNFSEN-UHFFFAOYSA-N 0.000 description 1
- YROODNPTFZHYNN-UHFFFAOYSA-N n,2-dicyclohexyl-2-[2-[(2,3-dimethylphenoxy)methyl]-5-fluorobenzimidazol-1-yl]acetamide Chemical compound CC1=CC=CC(OCC=2N(C3=CC=C(F)C=C3N=2)C(C2CCCCC2)C(=O)NC2CCCCC2)=C1C YROODNPTFZHYNN-UHFFFAOYSA-N 0.000 description 1
- AKQKCHCMFJIQIG-UHFFFAOYSA-N n,2-dicyclohexyl-2-[2-[(2,4-dimethylphenoxy)methyl]-5,6-difluorobenzimidazol-1-yl]acetamide Chemical compound CC1=CC(C)=CC=C1OCC1=NC2=CC(F)=C(F)C=C2N1C(C(=O)NC1CCCCC1)C1CCCCC1 AKQKCHCMFJIQIG-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000012026 peptide coupling reagents Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001223 polyethylene glycol Chemical class 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000012762 regulation of cholesterol biosynthetic process Effects 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- CRWJEUDFKNYSBX-UHFFFAOYSA-N sodium;hypobromite Chemical compound [Na+].Br[O-] CRWJEUDFKNYSBX-UHFFFAOYSA-N 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- FELBQUPQCJZQQX-UHFFFAOYSA-N tert-butyl n-(2-amino-5-fluorophenyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC(F)=CC=C1N FELBQUPQCJZQQX-UHFFFAOYSA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the invention is concerned with novel substituted benzimidazole derivatives of the formula (I) wherein
- the invention is concerned with a process for the manufacture of the above compounds, pharmaceutical preparations which contain such compounds as well as the use of these compounds for the production of pharmaceutical preparations.
- FXR Farnesoid-X-receptor
- a bile acid receptor [ Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J. and Shan, B. (1999) Identification of a nuclear receptor for bile acids. Science 284, 1362-5 ].
- PXR is expressed in liver, intestine, kidney, and the adrenal gland. Four splice isoforms have been cloned in humans.
- chenodeoxycholic acid is the most potent FXR agonist. Binding of bile acids or synthetic ligands to FXR induces the transcriptional expression of small heterodimer partner (SHP), an atypical nuclear receptor family member that binds to several other nuclear hormone receptors, including LRH-1 and LXRalpha and blocks their transcriptional functions [ Lu, T. T., Makishima, M., Repa, J. J., Schoonjans, K., Kerr, T. A., Auwerx, J. and Mangelsdorf, D. J. (2000) Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 6,507-15 ].
- SHP small heterodimer partner
- CYP7A1 and CYP8B are enzymes involved in hepatic bile acid synthesis. FXR represses their expression via activation of the SHP pathway. FXR directly induces the expression of bile acid-exporting transporters for the ABC family in hepatocytes, including the bile salt export pump (ABCB11) and the multidrug resistance associated protein 2 (ABCC2) [ Kast, H. R., Goodwin, B., Tarr, P. T., Jones, S. A., Anisfeld, A. M., Stoltz, C. M., Tontonoz, P., Kliewer, S., Willson, T. M. and Edwards, P. A.
- FXR knockout mice have impaired resistance to bile acid-induced hepatotoxicity and synthetic FXR agonists have been shown to be hepatoprotective in animal models of cholestasis [ Liu, Y., Binz, J., Numerick, M. J., Dennis, S., Luo, G., Desai, B., MacKenzie, K. I., Mansfield, T. A., Kliewer, S. A., Goodwin, B. and Jones, S. A. (2003) Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra-and extrahepatic cholestasis. J. Clin. Invest.
- the process of enterohepatic circulation of bile acids is also a major regulator of serum cholesterol homeostasis.
- bile acids After biosynthesis from cholesterol in the liver, bile acids are secreted with bile into the lumen of the small intestine to aid in the digestion and absorption of fat and fat-soluble vitamins.
- the ratio of different bile acids determines their ability to solubilize cholesterol.
- FXR activation decreases the size and changes the composition of the bile acid pool, decreasing the intestinal solubilization of cholesterol, effectively blocking its absorption. Decreased absorption would be expected to result in lower plasma cholesterol levels. Indeed direct inhibitors of cholesterol absorption such as ezetimibe decrease plasma cholesterol, providing some evidence to support this hypothesis.
- FXR also decreases hepatic synthesis of triglycerides by repressing SREBP1-c expression by an alternate pathway involving SHP and LXRalpha.
- compounds that activate FXR may show superior therapeutic efficacy on plasma cholesterol and triglyceride lowering than current therapies.
- HMGCoA reductase inhibitors are effective at normalizing LDL-C levels but reduce the risk for cardiovascular events such as stroke and myocardial infarction by only about 30%. Additional therapies targeting further lowering of atherogenic LDL as well as other lipid risk factors such as high plasma triglyceride levels and low HDL-C levels are needed.
- T2D Type II diabetes
- NIDDM non-insulin dependent diabetes mellitus
- T2D is a cardiovascular-metabolic syndrome associated with multiple comorbidities including dyslipidemia and insulin resistance, as well as hypertension, endothelial dysfunction and inflammatory atherosclerosis.
- the first line treatment for dyslipidemia and diabetes is a low-fat and low-glucose diet, exercise and weight loss. Compliance can be moderate and treatment of the various metabolic deficiencies that develop becomes necessary with, for example, lipid-modulating agents such as statins and fibrates, hypoglycemic drugs such as sulfonylureas and metformin, or insulin sensitizers of the thiazolidinedione (TZD) class of PPARgamma-agonists.
- lipid-modulating agents such as statins and fibrates, hypoglycemic drugs such as sulfonylureas and metformin, or insulin sensitizers of the thiazolidinedione (TZD) class of PPARgamma-agonists.
- TGD thiazolidinedione
- modulators of FXR may have enhanced therapeutic potential by providing superior normalization of both LDL-C and triglyceride levels, currently achieved only with combinations of existing drugs and, in addition, may avoid feedback effects
- novel compounds of the present invention exceed the compounds known in the art, inasmuch as they bind to and selectively modulate FXR very efficiently. Consequently, cholesterol absorption is reduced, LDL cholesterol and triglycerides are lowered, and inflammatory atherosclerosis is reduced. Since multiple facets of combined dyslipidemia and cholesterol homeostasis are addressed by FXR modulators, they are expected to have an enhanced therapeutic potential compared to the compounds already known in the art.
- WO 2008/000643 mentions benzimidazole derivatives which are FXR agonists. Tempest et al. Tetrahedron Lett. (2001), 42, 4959-4962 mentions the synthesis of some benzimidazoles using a Ugi/de-Boc/cyclize strategy. WO 03/066629 mentions some interesting GSK-3 inhibitors.
- lower is used to mean a group consisting of one to seven, preferably of one to four carbon atom(s).
- halogen refers to fluorine, chlorine, bromine and iodine, with fluorine, chlorine and bromine being preferred.
- alkyl refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of one to twenty carbon atoms, preferably one to sixteen carbon atoms, more preferably one to ten carbon atoms. Lower-alkyl groups as described below also are preferred alkyl groups.
- lower-alkyl refers to a branched or straight-chain monovalent alkyl radical of one to seven carbon atoms, preferably one to four carbon atoms. This term is further exemplified by such radicals as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, t-butyl and the like.
- Lower-alkyl groups can optionally be substituted, e.g. by hydroxy. Such substituted lower-alkyl-groups are referred to as "hydroxy-lower-alkyl".
- Unsubstituted lower-alkyl groups are preferred
- fluoro-lower-alkyl refers to lower-alkyl groups which are mono- or multiply substituted with fluorine.
- fluoro-lower-alkyl groups are e.g. CFH 2 , CF 2 H, CF 3 , CF 3 CH 2 , CF 3 (CH 2 ) 2 , (CF 3 ) 2 CH and CF 2 H-CF 2 .
- amino signifies a primary, secondary or tertiary amino group bonded via the nitrogen atom, with the secondary amino group carrying an alkyl or cycloalkyl substituent and the tertiary amino group carrying two similar or different alkyl or cycloalkyl substituents or the two nitrogen substitutents together forming a ring, such as, for example, -NH 2 , methylamino, ethylamino, dimethylamino, diethylamino, methyl-ethylamino, pyrrolidin-1-yl or piperidino etc., preferably primary amino, dimethylamino and diethylamino and particularly dimethylamino.
- formylamino refers to the group HC(O)-N(H)-.
- cycloalkyl refers to a monovalent carbocyclic radical of 3 to 10 carbon atoms, preferably 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
- a cycloalkyl group can optionally be substituted as described in the description and claims.
- alkoxy refers to the group R'-O-, wherein R' is an alkyl.
- lower-alkoxy refers to the group R'-O-, wherein R' is a lower-alkyl.
- fluoro-lower-alkoxy refers to the group R"-O-, wherein R" is fluoro-lower-alkyl.
- fluoro-lower-alkoxy groups are e.g. CFH 2 -O, CF 2 H-O, CF 3 -O, CF 3 CH 2 -O, CF 3 (CH 2 ) 2 -O, (CF 3 ) 2 CH-O, and CF 2 H-CF 2 -O.
- alkylene refers to a straight chain or branched divalent saturated aliphatic hydrocarbon group of 1 to 20 carbon atoms, preferably 1 to 16 carbon atoms, more preferably up to 10 carbon atoms. Lower-alkylene groups as described below also are preferred alkylene groups.
- lower-alkylene refers to a straight chain or branched divalent saturated aliphatic hydrocarbon group of 1 to 7, preferably 1 to 6 or 3 to 6 carbon atoms. Straight chain alkylene or lower-alkylene groups are preferred.
- dioxo-lower-alkylene refers to a group -O-lower-alkylene-O-.
- aryl alone or in combination, relates to the phenyl or naphthyl group, preferably the phenyl group.
- heteroaryl refers to an aromatic 5 to 6 membered monocyclic ring or 9 to 10 membered bicyclic ring which can comprise 1, 2 or 3 atoms selected from nitrogen, oxygen and/or sulphur, such as furyl, pyridinyl, 2-oxo-1,2-dihydro-pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiophenyl, isoxazolyl, oxazolyl, oxadiazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, benzodioxolyl, benzoimidazolyl, indolyl, isoindolyl, 1,3-dioxo-isoindolyl, quinolinyl, indazolyl,
- heterocyclyl refers to 5 to 6 membered monocyclic ring or 8 to 10 membered bi- or tricyclic ring which can comprise 1, 2 or 3 atoms selected from nitrogen, oxygen and/or sulphur, such as morpholinyl, thiomorpholinyl, tetrahydropyranyl, 1,1-dioxo-thiomorpholinyl, piperidinyl, 2-oxo-piperidinyl, pyrrolidinyl, 2-oxo-pyrrolidinyl, piperazin-2-one, 8-oxa-3-aza-bicyclo[3.2.1]octyl and piperazinyl.
- a preferred heterocyclyl is tetrahydropyranyl.
- protecting group refers to groups which are used to protect functional groups, particularly hydroxy groups, temporarily.
- protecting groups are benzyl, p-methoxybenzyl, t-butyl-dimethylsilyl, t-butyl-diphenylsilyl and (for protection of amino groups) Boc and benzyloxycarbonyl.
- Compounds of formula (I) can form pharmaceutically acceptable acid addition salts.
- pharmaceutically acceptable salts are salts of compounds of formula (I) with physiologically compatible mineral acids, such as hydrochloric acid, sulphuric acid, sulphurous acid or phosphoric acid; or with organic acids, such as methanesulphonic acid, p-toluenesulphonic acid, acetic acid, lactic acid, trifluoroacetic acid, citric acid, fumaric acid, maleic acid, tartaric acid, succinic acid or salicylic acid.
- physiologically compatible mineral acids such as hydrochloric acid, sulphuric acid, sulphurous acid or phosphoric acid
- organic acids such as methanesulphonic acid, p-toluenesulphonic acid, acetic acid, lactic acid, trifluoroacetic acid, citric acid, fumaric acid, maleic acid, tartaric acid, succinic acid or salicylic acid.
- pharmaceutically acceptable salts
- salts examples include alkaline, earth-alkaline and ammonium salts such as e.g. Na-, K-, Ca- and trimethylammoniumsalt.
- pharmaceutically acceptable salts also refers to such salts. Salts obtained by the addition of an acid are preferred.
- esters embraces derivatives of the compounds of formula (I), in which a carboxy group has been converted to an ester.
- esters are preferred esters.
- the methyl and ethyl esters are especially preferred.
- pharmaceutically acceptable esters furthermore embraces compounds of formula (I) in which hydroxy groups have been converted to the corresponding esters with inorganic or organic acids such as, nitric acid, sulphuric acid, phosphoric acid, citric acid, formic acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulphonic acid, p-toluenesulphonic acid and the like, which are non toxic to living organisms.
- the compounds of formula (I) have one or more asymmetric C atoms and can therefore exist as an enantiomeric mixture, diastereomeric mixture or as optically pure compounds.
- Preferred compounds of formula (I) as described above are those, wherein X is -O-, -S-, -S(O)-, -C(R 11 R 12 )- or -C(R 11 R 12 )-C(O)O-, wherein R 11 and R 12 are as defined above. More preferably, X is -O-, -S- or -C(R 11 R 12 )-, wherein R 11 and R 12 are as defined above. Even more preferably, X is -CH 2 -O-, -CH(CH 3 )-O-, -CH 2 -S- or -CH 2 -CH 2 -. Each of the possibilites for X individually constitutes a separate preferred embodiment.
- R 1 is cycloalkyl, particularly wherein R 1 is cyclohexyl.
- R 2 is hydrogen.
- R 3 is cycloalkyl or heterocyclyl. If R 3 is heterocyclyl, tetrahydropyranyl is preferred. Preferably, R 3 is cycloalkyl. More preferably, R 3 is cyclohexyl.
- R 4 is lower-alkyl, lower-alkyl-O-lower-alkyl-O-lower-alkyl, aryl, aryl-lower-alkyl or a heteroaryl selected from the group consisting of pyridinyl and isoxazolyl, wherein an aryl or heteroaryl can optionally be substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxy, lower-alkyl, hydroxy-lower-alkyl, fluoro-lower-alkyl, lower-alkyl-carbonyl, lower-alkoxy, fluoro-lower-alkoxy and dioxo-lower-alkylene.
- R 4 is preferably an aryl, particularly phenyl.
- aryl which are substituted with dioxo-lower-alkylene are e.g. 2,3-dihydro-benzo[1,4]dioxinyl or benzo[1,3]dioxolyl.
- R 4 is phenyl or pyridinyl, which phenyl can optionally be substituted with 1 to 2 substituents independently selected from the group consisting of halogen, lower-alkyl and lower-alkoxy. More preferably, R 4 is 4-chloro-2-methyl-phenyl, 2-chloro-phenyl, 4-ethyl-phenyl, 2,4-dichloro-phenyl, phenyl, 4-methoxy-phenyl, 4-fluoro-phenyl or pyridine-2-yl.
- R 5 , R 6 , R 7 and R 8 independently from each other are hydrogen or halogen.
- R 5 is hydrogen.
- R 6 is hydrogen or fluoro.
- R 7 is hydrogen, fluoro or chloro.
- R 8 is hydrogen.
- R 9 and R 10 independently from each other are hydrogen or lower-alkyl, particularly those, wherein R 9 and R 10 independently from each other are hydrogen or methyl. Furthermore, it is preferred that R 11 and R 12 are hydrogen.
- preferred compounds are the compounds of formula (I) described in the examples as individual compounds as well as pharmaceutically acceptable salts as well as pharmaceutically acceptable esters thereof.
- Preferred compounds of formula (I) are those selected from the group consisting of:
- Particularly preferred compounds of formula (I) are those selected from the group consisting of
- the compounds of general formula (I) in this invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.
- the invention further relates to a process for the manufacture of compounds of formula (I) as defined above, which process comprises
- cyclisation of a compound of formula (II) or formula (III) can be performed under reaction conditions well known to the person skilled in the art, e.g. by the methods described below and in analogy to the examples described below.
- Suitable protecting groups in compounds of formula (III) are e.g. t-BOC and benzyloxycarbonyl.
- the present invention also relates to compounds of formula (I) as defined above, when prepared by a process as described above.
- a 2-azidoarylamine 1 a carboxylic acid 2, an isonitrile 3 and an aldehyde 4 are condensed to 5 in a multi-component reaction (MCR), a so called Ugi -type reaction (Scheme 1, step a; typical procedures may e.g. be found in " The Peptides” by Gross & Meienhofer Vol. 2, Academic Press, N.Y., 1980, pp 365-381 ).
- MCR multi-component reaction
- the azido bisamide 5 is converted to the benzimidazole I (Scheme 1, step b), which can be optionally N -alkylated by deprotonation with a strong base (e.g. NaH or LiHMDA) and subsequent treatment with an alkylating agent R 2 -X with X being a typical leaving group such as e.g. Cl, Br, I, SO 2 alkyl, SO 2 fluoroalkyl, SO 2 aryl (Scheme 1, step c).
- a strong base e.g. NaH or LiHMDA
- R 2 -X with X being a typical leaving group such as e.g. Cl, Br, I, SO 2 alkyl, SO 2 fluoroalkyl, SO 2 aryl
- Many of the building blocks 2-4, particularly the carboxylic acids 2 are commercially available. If not, they may be prepared from commercially available starting materials using procedures described in literature and typically known to those skilled in the art (e.g.
- Aldehydes 4 are either commercially available or can be prepared by numerous methods known to the person skilled in the art. Appropriate synthesis methods include e.g . reduction of the corresponding carboxylic acid esters by a suitable reducing agent (e.g. diisobutylaluminium hydride at low temperature or with LiAlH 4 at elevated or ambient temperature) in a solvent followed by oxidation of the primary alcohol (e.g . with tetrapropylammonium perruthenate (VII), activated MnO 2 or Dess-Martin periodinane) to yield aldehydes 4.
- a suitable reducing agent e.g. diisobutylaluminium hydride at low temperature or with LiAlH 4 at elevated or ambient temperature
- oxidation of the primary alcohol e.g . with tetrapropylammonium perruthenate (VII), activated MnO 2 or Dess-Martin periodinane
- the 2-azidoarylamine 1 is usually prepared in three steps from the corresponding 2-aminoarylcarboxylic acid, which is converted into a 2-azidoarylcarboxylic acid by diazotation with NaNO 2 in a suitable solvent (e.g . methanol) and subsequent treatment with a suitable azide salt such as NaN 3 or TMSN 3 .
- a suitable solvent e.g . methanol
- a suitable azide salt such as NaN 3 or TMSN 3
- the resulting 2-azidoarylcarboxylic acid is then converteted into 1 via Curtius rearrangement of the 2-azidoarylcarboxylic azide obtained from the 2-azidoarylcarboxylic acid by its activation with a suitable reagent (e.g .
- the 2-azidoaryl amine 1 can alternatively be prepared via the 2-azidoarylcarboxamide obtained by activation of the 2-azidoarylcarboxylic acid with a suitable reagent (e.g . chloroethylformiate in the presence of a base such as triethylamine) and subsequent treatment with ammonia.
- a suitable reagent e.g . chloroethylformiate in the presence of a base such as triethylamine
- This amide is converted into 1 in a so called Hofmann -rearrangement by treatment with a suitable reagent such as NaOBr.
- one of the starting materials or compounds of formula (I) contain one or more functional groups which are not stable or are reactive under the reaction conditions of one or more reaction steps
- appropriate protecting groups as described e.g . in " Protective Groups in Organic Chemistry” by T.W. Greene and P.G.M. Wutts, 2nd Ed., 1991, Wiley N.Y .
- Such protecting groups can be removed at a later stage of the synthesis using standard methods described in the literature.
- compounds (I) can be obtained as mixtures of diastereomers or enantiomers, which can be separated by methods well known in the art, e.g . (chiral) HPLC or crystallization. Racemic compounds can e.g . be separated into their antipodes via diastereomeric salts by crystallization with optically pure acids or by separation of the antipodes by specific chromatographic methods using either a chiral adsorbens or a chiral eluent.
- Mono boc-protected ortho arylene diamines 6 are commerically available or may be prepared from the corresponding unprotected diamine by treatment with di- tert -butyl dicarbonate in an organic solvent such as e.g. THF in the presence of a base such as e.g. diisopropylethylamine.
- ⁇ may be derivatized to other functional groups using typical standard procedures known to those skilled in the art (e.g . reduction of -CO 2 alkyl to -CH 2 OH with LiAlH 4 , hydrolysis of -CO 2 alkyl to CO 2 H and subsequent optional conversion to an amide, acylation of amino groups).
- one of the starting materials or compounds of formula (I) contain one or more functional groups which are not stable or are reactive under the reaction conditions of one or more reaction steps
- appropriate protecting groups as described e.g . in " Protective Groups in Organic Chemistry” by T.W. Greene and P.G.M. Wutts, 2nd Ed., 1991, Wiley N.Y .
- Such protecting groups can be removed at a later stage of the synthesis using standard methods described in the literature.
- compounds (I) can be obtained as mixtures of diastereomers or enantiomers, which can be separated by methods well known in the art, e.g . (chiral) HPLC or crystallization. Racemic compounds can e.g . be separated into their antipodes via diastereomeric salts by crystallization with optically pure acids or by separation of the antipodes by specific chromatographic methods using either a chiral adsorbens or a chiral eluent.
- R 1 as present in (I) after steps a and b or steps a, b and c in above shown schemes may be transformed into or replaced by other R 1 using one or a sequence of reaction steps. Two possible examples are given below:
- the conversion of a compound of formula (I) into a pharmaceutically acceptable salt can be carried out by treatment of such a compound with an inorganic acid, for example a hydrohalic acid, such as, for example, hydrochloric acid or hydrobromic acid, or other inorganic acids such as sulfuric acid, nitric acid, phosphoric acid etc., or with an organic acid, such as, for example, acetic acid, citric acid, maleic acid, fumaric acid, tartaric acid, methanesulfonic acid or p -toluenesulfonic acid.
- an inorganic acid for example a hydrohalic acid, such as, for example, hydrochloric acid or hydrobromic acid, or other inorganic acids such as sulfuric acid, nitric acid, phosphoric acid etc.
- an organic acid such as, for example, acetic acid, citric acid, maleic acid, fumaric acid, tartaric acid, methanesulfonic acid or p -toluen
- the corresponding carboxylate salts can be prepared from the compounds of formula (I) by treatment with physiologically compatible bases.
- a suitable solvent e.g. dioxane or THF
- a suitable solvent e.g ethanol, ethanol-water mixture, tetrahydrofuran-water mixture
- the conversion of compounds of formula (I) into pharmaceutically acceptable esters can be carried out e.g . by treatment of hydroxy groups present in the molecules with a carboxylic acid such as acetic acid, with a condensating reagent such as benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP), N , N -dicylohexylcarbodiimide (DCC), N-(3-dimethylaminopropyl)- N '-ethylcarbodiimide hydrochloride (EDCI) or O -(1,2-dihydro-2-oxo-1-pyridyl)- N , N , N , N- tetra-methyluronium-tetrafluorborate (TPTU) to produce the carboxylic ester.
- carboxy groups present in the compounds of formula (I) can be reacted with suitable alcohols under analogous conditions as described above.
- the novel compounds of the present invention have been found to bind to and selectively activate FXR. They can therefore be used in the treatment and prophylaxis of diseases which are modulated by FXR agonists.
- diseases include increased lipid and cholesterol levels, particularly high LDL-cholesterol, high triglycerides, low HDL-cholesterol, dyslipidemia, atherosclerotic disease, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, cholesterol gallstone disease, cholestasis/fibrosis of the liver, diseases of cholesterol absorption, cancer, particularly gastrointestinal cancer, osteoporosis, peripheral occlusive disease, ischemic stroke, Parkinson's disease and/or Alzheimer's disease.
- the invention therefore also relates to pharmaceutical compositions comprising a compound as defined above and a pharmaceutically acceptable carrier and/or adjuvant.
- the invention likewise embraces compounds as described above for use as therapeutically active substances, especially as therapeutically active substances for the treatment and/or prophylaxis of diseases which are modulated by FXR agonists, particularly as therapeutically active substances for the treatment and/or prophylaxis of increased lipid and cholesterol levels, high LDL-cholesterol, high triglycerides, low HDL-cholesterol, dyslipidemia, atherosclerotic disease, diabetes, non-insulin dependent diabetes mellitus, metabolic syndrome, cholesterol gallstone disease, cholestasis/fibrosis of the liver, diseases of cholesterol absorption, cancer, gastrointestinal cancer, osteoporosis, peripheral occlusive disease, ischemic stroke, Parkinson's disease and/or Alzheimer's disease.
- the invention also relates to the use of compounds as described above for the preparation of medicaments for the therapeutic and/or prophylactic treatment of diseases which are modulated by FXR agonists, particularly for the therapeutic and/or prophylactic treatment of increased lipid and cholesterol levels, high LDL-cholesterol, high triglycerides, low HDL-cholesterol, dyslipidemia, atherosclerotic disease, diabetes, non-insulin dependent diabetes mellitus, metabolic syndrome, cholesterol gallstone disease, cholestasis/fibrosis of the liver, diseases of cholesterol absorption, cancer, gastrointestinal cancer, osteoporosis, peripheral occlusive disease, ischemic stroke, Parkinson's disease and/or Alzheimer's disease.
- Such medicaments comprise a compound as described above.
- GST glutathione-s-transferase
- GAL Gal4 DNA binding domain
- LBD ligand binding domain
- GST-LBD fusion protein was performed in E. coli strain BL21(pLysS) cells by standard methods ( Current Protocols in Molecular Biology, Wiley Press, ed. Ausubel et al.).
- Binding of test substances to the FXR ligand binding domain was assessed in a radioligand displacement assay.
- the assay was performed in a buffer consisting of 50 mM Hepes, pH 7.4, 10 mM NaCl, 5 mM MgCl 2 , 0.01% CHAPS.
- 40nM of GST-FXR LBD fusion protein was bound to 10 ⁇ g glutathione ytrium silicate SPA beads (PharmaciaAmersham) in a final volume of 50 ⁇ l by shaking.
- a radioligand e.g.
- Baby hamster kidney cells (BHK21 ATCC CCL10) were grown in DMEM medium containing 10% FBS at 37 °C in a 95% 02/5% CO 2 atmosphere. Cells were seeded in 6-well plates at a density of 10 5 cells/well and then transfected with the pFA-FXR-LBD or expression plasmid plus a reporter plasmid. Transfection was accomplished with the Fugene 6 reagent (Roche Molecular Biochemicals) according to the suggested protocol. Six hours following transfection, the cells were harvested by trypsinization and seeded in 96-well plates at a density of 2 x 10 5 cells/well.
- Luminescence as a measure of luciferase activity, was detected in a Packard TopCount. Transcriptional activation in the presence of a test substance was expressed as fold-change in luminescence compared to that of cells incubated in the absence of the substance. EC 50 values were calculated using the XLfit program (ID Business Solutions Ltd. UK).
- the compounds according to formula (I) have an activity in at least one of the above assays (EC 50 or IC 50 ), preferably of 0.5 nM to 10 ⁇ M, more preferably 0.5 nM to 100 nM.
- the compounds of formula I and/or their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical preparations for enteral, parenteral or topical administration. They can be administered, for example, perorally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions or suspensions or infusion solutions, or topically, e.g. in the form of ointments, creams or oils. Oral administration is preferred.
- the production of the pharmaceutical preparations can be effected in a manner which will be familiar to any person skilled in the art by bringing the described compounds of formula I and/or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
- Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials.
- lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragées and hard gelatine capsules.
- Suitable carrier materials for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers might, however, be required in the case of soft gelatine capsules).
- Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and the like.
- Suitable carrier materials for injection solutions are, for example, water, alcohols, polyols, glycerol and vegetable oils.
- Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols.
- Suitable carrier materials for topical preparations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.
- Usual stabilizers preservatives, wetting and emulsifying agents, consistency-improving agents, flavour-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants.
- the dosage of the compounds of formula I can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case. For adult patients a daily dosage of about 1 to 1000 mg, especially about 1 to 300 mg, comes into consideration. Depending on severity of the disease and the precise pharmacokinetic profile the compound could be administered with one or several daily dosage units, e.g. in 1 to 3 dosage units.
- the pharmaceutical preparations conveniently contain about 1-500 mg, preferably 1-100 mg, of a compound of formula I.
- the purified product (4.28 g, 15.6 mmol, 1.0 equiv) was dissolved in DMF (50 mL) and a sat. solution of NH 4 Cl (13 mL) was added.
- Zinc powder (5.10 g, 78.0 mmol, 5.0 equiv) was added and the suspension stirred for 30 min at 80 °C and for an additional time period of 2 h at rt. The remaining solid was filtered off and the organic layer evaporated.
- the product was extracted from a sat. solution of NaHCO 3 with ethyl actetate, the organic layer dried over Na 2 SO 4 and the crude reaction product purified via Kieselgel chromatography.
- Film coated tablets containing the following ingredients can be manufactured in a conventional manner: Ingredients Per tablet Kernel: Compound of formula (I) 10.0 mg 200.0 mg Microcrystalline cellulose 23.5 mg 43.5 mg Lactose hydrous 60.0 mg 70.0 mg Povidone K30 12.5 mg 15.0 mg Sodium starch glycolate 12.5 mg 17.0 mg Magnesium stearate 1.5 mg 4.5 mg (Kernel Weight) 120.0 mg 350.0 mg Film Coat: Hydroxypropyl methyl cellulose 3.5 mg 7.0 mg Polyethylene glycol 6000 0.8 mg 1.6 mg Talc 1.3 mg 2.6 mg Iron oxyde (yellow) 0.8 mg 1.6 mg Titan dioxide 0.8 mg 1.6 mg
- the active ingredient is sieved and mixed with microcristalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidon in water.
- the granulate is mixed with sodium starch glycolate and magesiumstearate and compressed to yield kernels of 120 or 350 mg respectively.
- the kernels are lacquered with an aqueous solution / suspension of the above mentioned film coat.
- Capsules containing the following ingredients can be manufactured in a conventional manner: Ingredients Per capsule Compound of formula (1) 25.0 mg Lactose 150.0 mg Maize starch 20.0 mg Talc 5.0 mg The components are sieved and mixed and filled into capsules of size 2.
- Injection solutions can have the following composition: Compound of formula (I) 3.0 mg Polyethylene Glycol 400 150.0 mg Acetic Acid q.s. ad pH 5.0 Water for injection solutions ad 1.0 ml
- the active ingredient is dissolved in a mixture of Polyethylene Glycol 400 and water for injection (part).
- the pH is adjusted to 5.0 by Acetic Acid.
- the volume is adjusted to 1.0 ml by addition of the residual amount of water.
- the solution is filtered, filled into vials using an appropriate overage and sterilized.
- Soft gelatine capsules containing the following ingredients can be manufactured in a conventional manner:
- the active ingredient is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size.
- the filled soft gelatin capsules are treated according to the usual procedures.
- Sachets containing the following ingredients can be manufactured in a conventional manner: Compound of formula (I) 50.0 mg Lactose, fine powder 1015.0 mg Microcristalline cellulose (AVICEL PH 102) 1400.0 mg Sodium carboxymethyl cellulose 14.0 mg Potyvinylpyrrolidon K 30 10.0 mg Magnesiumstearate 10.0 mg Flavoring additives 1.0 mg
- the active ingredient is mixed with lactose, microcristalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidon in water.
- the granulate is mixed with magnesiumstearate and the flavouring additives and filled into sachets.
Abstract
Description
-
- X
- is -O-, -S-, -S(O)-, -S(O2)-, -C(R11R12)- or -C(R11R12)-C(O)O-;
- R1
- is lower-alkyl, cycloalkyl, cycloalkyl-lower-alkyl, heterocyclyl or heterocyclyl-lower-alkyl, wherein a lower-alkyl, cycloalkyl or heterocyclyl can optionally be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, lower-alkyl, lower-alkoxy, fluoro-lower-alkyl and fluoro-lower-alkoxy;
- R2
- is hydrogen or lower-alkyl; R3 is cycloalkyl, cycloalkyl-lower-alkyl, heterocyclyl or heterocyclyl-lower-alkyl, wherein a cycloalkyl or heterocyclyl can optionally be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, lower-alkyl, lower-alkoxy, fluoro-lower-alkyl and fluoro-lower-alkoxy;
- R4
- is lower-alkyl, cycloalkyl, cycloalkyl-lower-alkyl, aryl, aryl-lower-alkyl, heteroaryl, heteroaryl-lower-alkyl, heterocyclyl or heterocyclyl-lower-alkyl, wherein a lower-alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl can optionally be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, hydroxy, lower-alkyl, hydroxy-lower-alkyl, lower-alkyl-O-lower-alkyl-O-lower-alkyl, fluoro-lower-alkyl, lower-alkyl-carbonyl, lower-alkoxy, fluoro-lower-alkoxy and dioxo-lower-alkylene;
- R5, R6, R7 and R8
- independently from each other are hydrogen, halogen, lower-alkyl, lower-alkoxy, fluoro-lower-alkyl, fluoro-lower-alkoxy, cycloalkyl-oxy or heterocyclyl-oxy;
- R9 and R10
- independently from each other are hydrogen or lower-alkyl, or R9 and R10 are bound together to form a cycloalkyl or heterocyclyl together with the carbon atom to which they are attached;
- R11 and R12
- independently from each other are hydrogen or lower-alkyl, or R11 and R12 are bound together, to form a cycloalkyl or heterocyclyl together with the carbon atom to which they are attached;
- Further, the invention is concerned with a process for the manufacture of the above compounds, pharmaceutical preparations which contain such compounds as well as the use of these compounds for the production of pharmaceutical preparations.
- The Farnesoid-X-receptor (FXR) is a member of the nuclear hormone receptor superfamily of transcription factors. FXR was originally identified as a receptor activated by farnesol, and subsequent studies revealed a major role of FXR as a bile acid receptor [Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J. and Shan, B. (1999) Identification of a nuclear receptor for bile acids. Science 284, 1362-5]. PXR is expressed in liver, intestine, kidney, and the adrenal gland. Four splice isoforms have been cloned in humans.
- Among the major bile acids, chenodeoxycholic acid is the most potent FXR agonist. Binding of bile acids or synthetic ligands to FXR induces the transcriptional expression of small heterodimer partner (SHP), an atypical nuclear receptor family member that binds to several other nuclear hormone receptors, including LRH-1 and LXRalpha and blocks their transcriptional functions [Lu, T. T., Makishima, M., Repa, J. J., Schoonjans, K., Kerr, T. A., Auwerx, J. and Mangelsdorf, D. J. (2000) Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 6,507-15]. CYP7A1 and CYP8B are enzymes involved in hepatic bile acid synthesis. FXR represses their expression via activation of the SHP pathway. FXR directly induces the expression of bile acid-exporting transporters for the ABC family in hepatocytes, including the bile salt export pump (ABCB11) and the multidrug resistance associated protein 2 (ABCC2) [Kast, H. R., Goodwin, B., Tarr, P. T., Jones, S. A., Anisfeld, A. M., Stoltz, C. M., Tontonoz, P., Kliewer, S., Willson, T. M. and Edwards, P. A. (2002) Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem. 277, 2908-15; Ananthanarayanan, M., Balasubramanian, N., Makishima, M., Mangelsdorf, D. J. and Suchy, F. J. (2001) Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem. 276, 28857-65]. FXR knockout mice have impaired resistance to bile acid-induced hepatotoxicity and synthetic FXR agonists have been shown to be hepatoprotective in animal models of cholestasis [Liu, Y., Binz, J., Numerick, M. J., Dennis, S., Luo, G., Desai, B., MacKenzie, K. I., Mansfield, T. A., Kliewer, S. A., Goodwin, B. and Jones, S. A. (2003) Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra-and extrahepatic cholestasis. J. Clin. Invest. 112, 1678-87; Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G. and Gonzalez, F. J. (2000) Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102, 731-44]. These data show that FXR protects hepatocytes from bile acid toxicity by suppressing both cellular synthesis and import of bile acids and stimulating their biliary excretion.
- The process of enterohepatic circulation of bile acids is also a major regulator of serum cholesterol homeostasis. After biosynthesis from cholesterol in the liver, bile acids are secreted with bile into the lumen of the small intestine to aid in the digestion and absorption of fat and fat-soluble vitamins. The ratio of different bile acids determines their ability to solubilize cholesterol. FXR activation decreases the size and changes the composition of the bile acid pool, decreasing the intestinal solubilization of cholesterol, effectively blocking its absorption. Decreased absorption would be expected to result in lower plasma cholesterol levels. Indeed direct inhibitors of cholesterol absorption such as ezetimibe decrease plasma cholesterol, providing some evidence to support this hypothesis. However ezetimibe has limited efficacy which appears due to feedback upregulation of cholesterol synthesis in cells attempting to compensate for depletion of cholesterol. Recent data have shown that FXR opposes this effect in part by directly repressing the expression of HMGCoA reductase via a pathway involving SHP and LRH1 [Datta, S., Wang, L., Moore, D. D. and Osborne, T. F. (2006) Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase promoter by nuclear receptors liver receptor homologue-1 and small heterodimer partner: a mechanism for differential regulation of cholesterol synthesis and uptake. J. Biol. Chem. 281, 807-12]. FXR also decreases hepatic synthesis of triglycerides by repressing SREBP1-c expression by an alternate pathway involving SHP and LXRalpha. Thus compounds that activate FXR may show superior therapeutic efficacy on plasma cholesterol and triglyceride lowering than current therapies.
- Most patients with coronary artery disease have high plasma levels of atherogenic LDL. The HMGCoA reductase inhibitors (statins) are effective at normalizing LDL-C levels but reduce the risk for cardiovascular events such as stroke and myocardial infarction by only about 30%. Additional therapies targeting further lowering of atherogenic LDL as well as other lipid risk factors such as high plasma triglyceride levels and low HDL-C levels are needed.
- A high proportion of type 2 diabetic patients in the United States have abnormal concentrations of plasma lipoproteins. The prevalence of total cholesterol > 240 mg/dl is 37% in diabetic men and 44% in diabetic women and the prevalence for LDL-C > 160 mg/dl are 31% and 44%, respectively in these populations. Diabetes is a disease in which a patient's ability to control glucose levels in blood is decreased because of partial impairment in the response to insulin. Type II diabetes (T2D), also called non-insulin dependent diabetes mellitus (NIDDM), accounts for 80-90% of all diabetes cases in developed countries. In T2D, the pancreatic Islets of Langerhans produce insulin but the primary target tissues (muscle, liver and adipose tissue) develop a profound resistance to its effects. The body compensates by producing more insulin ultimately resulting in failure of pancreatic insulin-producing capacity. Thus T2D is a cardiovascular-metabolic syndrome associated with multiple comorbidities including dyslipidemia and insulin resistance, as well as hypertension, endothelial dysfunction and inflammatory atherosclerosis.
- The first line treatment for dyslipidemia and diabetes is a low-fat and low-glucose diet, exercise and weight loss. Compliance can be moderate and treatment of the various metabolic deficiencies that develop becomes necessary with, for example, lipid-modulating agents such as statins and fibrates, hypoglycemic drugs such as sulfonylureas and metformin, or insulin sensitizers of the thiazolidinedione (TZD) class of PPARgamma-agonists. Recent studies provide evidence that modulators of FXR may have enhanced therapeutic potential by providing superior normalization of both LDL-C and triglyceride levels, currently achieved only with combinations of existing drugs and, in addition, may avoid feedback effects on cellular cholesterol homeostasis.
- The novel compounds of the present invention exceed the compounds known in the art, inasmuch as they bind to and selectively modulate FXR very efficiently. Consequently, cholesterol absorption is reduced, LDL cholesterol and triglycerides are lowered, and inflammatory atherosclerosis is reduced. Since multiple facets of combined dyslipidemia and cholesterol homeostasis are addressed by FXR modulators, they are expected to have an enhanced therapeutic potential compared to the compounds already known in the art.
-
WO 2008/000643 mentions benzimidazole derivatives which are FXR agonists. Tempest et al. Tetrahedron Lett. (2001), 42, 4959-4962 mentions the synthesis of some benzimidazoles using a Ugi/de-Boc/cyclize strategy.WO 03/066629 - Unless otherwise indicated, the following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention herein.
- In this specification the term "lower" is used to mean a group consisting of one to seven, preferably of one to four carbon atom(s).
- The term "halogen" refers to fluorine, chlorine, bromine and iodine, with fluorine, chlorine and bromine being preferred.
- The term "alkyl", alone or in combination with other groups, refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of one to twenty carbon atoms, preferably one to sixteen carbon atoms, more preferably one to ten carbon atoms. Lower-alkyl groups as described below also are preferred alkyl groups.
- The term "lower-alkyl", alone or in combination with other groups, refers to a branched or straight-chain monovalent alkyl radical of one to seven carbon atoms, preferably one to four carbon atoms. This term is further exemplified by such radicals as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, t-butyl and the like. Lower-alkyl groups can optionally be substituted, e.g. by hydroxy. Such substituted lower-alkyl-groups are referred to as "hydroxy-lower-alkyl". Unsubstituted lower-alkyl groups are preferred
- The term "fluoro-lower-alkyl" refers to lower-alkyl groups which are mono- or multiply substituted with fluorine. Examples of fluoro-lower-alkyl groups are e.g. CFH2, CF2H, CF3, CF3CH2, CF3(CH2)2, (CF3)2CH and CF2H-CF2.
- The term "amino", alone or in combination, signifies a primary, secondary or tertiary amino group bonded via the nitrogen atom, with the secondary amino group carrying an alkyl or cycloalkyl substituent and the tertiary amino group carrying two similar or different alkyl or cycloalkyl substituents or the two nitrogen substitutents together forming a ring, such as, for example, -NH2, methylamino, ethylamino, dimethylamino, diethylamino, methyl-ethylamino, pyrrolidin-1-yl or piperidino etc., preferably primary amino, dimethylamino and diethylamino and particularly dimethylamino. The term "formylamino" refers to the group HC(O)-N(H)-.
- The term "cycloalkyl" refers to a monovalent carbocyclic radical of 3 to 10 carbon atoms, preferably 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. A cycloalkyl group can optionally be substituted as described in the description and claims.
- The term "alkoxy" refers to the group R'-O-, wherein R' is an alkyl. The term "lower-alkoxy" refers to the group R'-O-, wherein R' is a lower-alkyl.
- The term "fluoro-lower-alkoxy" refers to the group R"-O-, wherein R" is fluoro-lower-alkyl. Examples of fluoro-lower-alkoxy groups are e.g. CFH2-O, CF2H-O, CF3-O, CF3CH2-O, CF3(CH2)2-O, (CF3)2CH-O, and CF2H-CF2-O.
- The term "alkylene" refers to a straight chain or branched divalent saturated aliphatic hydrocarbon group of 1 to 20 carbon atoms, preferably 1 to 16 carbon atoms, more preferably up to 10 carbon atoms. Lower-alkylene groups as described below also are preferred alkylene groups. The term "lower-alkylene" refers to a straight chain or branched divalent saturated aliphatic hydrocarbon group of 1 to 7, preferably 1 to 6 or 3 to 6 carbon atoms. Straight chain alkylene or lower-alkylene groups are preferred. The term "dioxo-lower-alkylene" refers to a group -O-lower-alkylene-O-.
- The term "aryl", alone or in combination, relates to the phenyl or naphthyl group, preferably the phenyl group.
- The term "heteroaryl" refers to an aromatic 5 to 6 membered monocyclic ring or 9 to 10 membered bicyclic ring which can comprise 1, 2 or 3 atoms selected from nitrogen, oxygen and/or sulphur, such as furyl, pyridinyl, 2-oxo-1,2-dihydro-pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiophenyl, isoxazolyl, oxazolyl, oxadiazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, benzodioxolyl, benzoimidazolyl, indolyl, isoindolyl, 1,3-dioxo-isoindolyl, quinolinyl, indazolyl, benzoisothiazolyl, benzoxazolyl and benzoisoxazolyl. Preferred heteroaryl groups are pyridinyl and isoxazolyl.
- The term "heterocyclyl" refers to 5 to 6 membered monocyclic ring or 8 to 10 membered bi- or tricyclic ring which can comprise 1, 2 or 3 atoms selected from nitrogen, oxygen and/or sulphur, such as morpholinyl, thiomorpholinyl, tetrahydropyranyl, 1,1-dioxo-thiomorpholinyl, piperidinyl, 2-oxo-piperidinyl, pyrrolidinyl, 2-oxo-pyrrolidinyl, piperazin-2-one, 8-oxa-3-aza-bicyclo[3.2.1]octyl and piperazinyl. A preferred heterocyclyl is tetrahydropyranyl.
- The term "protecting group" refers to groups which are used to protect functional groups, particularly hydroxy groups, temporarily. Examples of protecting groups are benzyl, p-methoxybenzyl, t-butyl-dimethylsilyl, t-butyl-diphenylsilyl and (for protection of amino groups) Boc and benzyloxycarbonyl.
- Compounds of formula (I) can form pharmaceutically acceptable acid addition salts. Examples of such pharmaceutically acceptable salts are salts of compounds of formula (I) with physiologically compatible mineral acids, such as hydrochloric acid, sulphuric acid, sulphurous acid or phosphoric acid; or with organic acids, such as methanesulphonic acid, p-toluenesulphonic acid, acetic acid, lactic acid, trifluoroacetic acid, citric acid, fumaric acid, maleic acid, tartaric acid, succinic acid or salicylic acid. The term "pharmaceutically acceptable salts" refers to such salts. Compounds of formula (I) in which a COOH group is present can further form salts with bases. Examples of such salts are alkaline, earth-alkaline and ammonium salts such as e.g. Na-, K-, Ca- and trimethylammoniumsalt. The term "pharmaceutically acceptable salts" also refers to such salts. Salts obtained by the addition of an acid are preferred.
- The term "pharmaceutically acceptable esters" embraces derivatives of the compounds of formula (I), in which a carboxy group has been converted to an ester. Lower-alkyl, hydroxy-lower-alkyl, lower-alkoxy-lower-alkyl, amino-lower-alkyl, mono-or di-lower-alkyl-amino-lower-alkyl, morpholino-lower-alkyl, pyrrolidino-lower-alkyl, piperidino-lower-alkyl, piperazino-lower-alkyl, lower-alkyl-piperazino-lower-alkyl and aralkyl esters are examples of suitable esters. The methyl, ethyl, propyl, butyl and benzyl esters are preferred esters. The methyl and ethyl esters are especially preferred. The term "pharmaceutically acceptable esters" furthermore embraces compounds of formula (I) in which hydroxy groups have been converted to the corresponding esters with inorganic or organic acids such as, nitric acid, sulphuric acid, phosphoric acid, citric acid, formic acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulphonic acid, p-toluenesulphonic acid and the like, which are non toxic to living organisms.
-
- X
- is -O-, -S-, -S(O)-, -S(O2)-, -C(R11R12)- or -C(R11R12)-C(O)O-;
- R1
- is lower-alkyl, cycloalkyl, cycloalkyl-lower-alkyl, heterocyclyl or heterocyclyl-lower-alkyl, wherein a lower-alkyl, cycloalkyl or heterocyclyl can optionally be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, lower-alkyl, lower-alkoxy, fluoro-lower-alkyl and fluoro-lower-alkoxy;
- R2
- is hydrogen or lower-alkyl;
- R3
- is cycloalkyl, cycloalkyl-lower-alkyl, heterocyclyl or heterocyclyl-lower-alkyl, wherein a cycloalkyl or heterocyclyl can optionally be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, lower-alkyl, lower-alkoxy, fluoro-lower-alkyl and fluoro-lower-alkoxy;
- R4
- is lower-alkyl, cycloalkyl, cycloalkyl-lower-alkyl, aryl, aryl-lower-alkyl, heteroaryl, heteroaryl-lower-alkyl, heterocyclyl or heterocyclyl-lower-alkyl, wherein a lower-alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl can optionally be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, hydroxy, lower-alkyl, hydroxy-lower-alkyl, lower-alkyl-O-lower-alkyl-O-lower-alkyl, fluoro-lower-alkyl, lower-alkyl-carbonyl, lower-alkoxy, fluoro-lower-alkoxy and dioxo-lower-alkylene;
- R5, R6, R7 and R8
- independently from each other are hydrogen, halogen, lower-alkyl, lower-alkoxy, fluoro-lower-alkyl, fluoro-lower-alkoxy, cycloalkyl-oxy or heterocyclyl-oxy;
- R9 and R10
- independently from each other are hydrogen or lower-alkyl, or R9 and R10 are bound together to form a cycloalkyl or heterocyclyl together with the carbon atom to which they are attached;
- R11 and R12
- independently from each other are hydrogen or lower-alkyl, or R11 and R12 are bound together, to form a cycloalkyl or heterocyclyl together with the carbon atom to which they are attached;
- Compounds of formula (I) are individually preferred and physiologically acceptable salts thereof are individually preferred and pharmaceutically acceptable esters thereof are individually preferred, with the compounds of formula (I) being particularly preferred.
- The compounds of formula (I) have one or more asymmetric C atoms and can therefore exist as an enantiomeric mixture, diastereomeric mixture or as optically pure compounds.
- Preferred compounds of formula (I) as described above are those,
wherein X is -O-, -S-, -S(O)-, -C(R11R12)- or -C(R11R12)-C(O)O-, wherein R11 and R12 are as defined above. More preferably, X is -O-, -S- or -C(R11R12)-, wherein R11 and R12 are as defined above. Even more preferably, X is -CH2-O-, -CH(CH3)-O-, -CH2-S- or -CH2-CH2-. Each of the possibilites for X individually constitutes a separate preferred embodiment. - Other preferred compounds are those, wherein R1 is cycloalkyl, particularly wherein R1 is cyclohexyl. Furthermore, it is preferred that R2 is hydrogen.
- Another preferred embodiment of the present invention relates to compounds of formula (I) as defined above, wherein R3 is cycloalkyl or heterocyclyl. If R3 is heterocyclyl, tetrahydropyranyl is preferred. Preferably, R3 is cycloalkyl. More preferably, R3 is cyclohexyl.
- Another preferred embodiment of the present invention relates to compounds of formula (I) as described above, wherein R4 is lower-alkyl, lower-alkyl-O-lower-alkyl-O-lower-alkyl, aryl, aryl-lower-alkyl or a heteroaryl selected from the group consisting of pyridinyl and isoxazolyl, wherein an aryl or heteroaryl can optionally be substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxy, lower-alkyl, hydroxy-lower-alkyl, fluoro-lower-alkyl, lower-alkyl-carbonyl, lower-alkoxy, fluoro-lower-alkoxy and dioxo-lower-alkylene. If such substituent on a R4 group is dioxo-lower-alkylene, the R4 is preferably an aryl, particularly phenyl. Examples of aryl which are substituted with dioxo-lower-alkylene are e.g. 2,3-dihydro-benzo[1,4]dioxinyl or benzo[1,3]dioxolyl.
- Preferably, R4 is phenyl or pyridinyl, which phenyl can optionally be substituted with 1 to 2 substituents independently selected from the group consisting of halogen, lower-alkyl and lower-alkoxy. More preferably, R4 is 4-chloro-2-methyl-phenyl, 2-chloro-phenyl, 4-ethyl-phenyl, 2,4-dichloro-phenyl, phenyl, 4-methoxy-phenyl, 4-fluoro-phenyl or pyridine-2-yl.
- Other preferred compounds of formula (I) as described above are those, wherein R5, R6, R7 and R8 independently from each other are hydrogen or halogen. Preferably, R5 is hydrogen. Furthermore, it is preferred that R6 is hydrogen or fluoro. Furthermore, it is preferred that R7 is hydrogen, fluoro or chloro. Furthermore, it is preferred that R8 is hydrogen.
- Other preferred compounds are those, wherein R9 and R10 independently from each other are hydrogen or lower-alkyl, particularly those, wherein R9 and R10 independently from each other are hydrogen or methyl. Furthermore, it is preferred that R11 and R12 are hydrogen.
- In particular, preferred compounds are the compounds of formula (I) described in the examples as individual compounds as well as pharmaceutically acceptable salts as well as pharmaceutically acceptable esters thereof.
- Preferred compounds of formula (I) are those selected from the group consisting of:
- 2-[2-(4-Chloro-2-methyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,
- 2,N-Dicydohexyl-2-[6-fluoro-2-(4-hydroxymethyl-phenoxymethyl)-benzoimidazol-1-yl]-acetamide,
- 2-[2-(4-Chloro-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,
- 2- [2-(2-Chloro-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl] -2,N-dicyclohexyl-acetamide,
- 2,N-Dicyclohexyl-2-(6-fluoro-2-m-tolyloxymethyl-benzoimidazol-1-yl)-acetamide,
- 2,N-Dicyclohexyl-2- [6-fluoro-2-(2-methoxy-phenoxymethyl)-benzoimidazol-1-yl]-acetamide,
- 2,N-Dicyclohexyl-2-(6-fluoro-2-o-tolyloxymethyl-benzoimidazol-1-yl)-acetamide,
- 2,N-Dicyclohexyl-2-[2-(2,4-dimethyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-acetamide,
- 2,N-Dicyclohexyl-2-[2-(2,5-dimethyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-acetamide,
- 2-[2-(4-Chloro-2-methyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,
- 2-[2-(4-Acetyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,
- 2,N-Dicyclohexyl-2-[2-(4-ethyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-acetamide,
- 2,N-Dicyclohexyl-2-[2-(2,3-dimethyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-acetamide,
- 2-[2-(2-Chloro-6-methyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,
- 2,N-Dicyclohexyl-2-[2-(2,4-dichloro-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-acetamide,
- 2-[2-(4-Chloro-2-methyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-2-cycloheptyl-N-cyclohexyl-acetamide,
- 2-[2-(4-Chloro-2-methyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-2-cycloheptyl-N-cyclopentyl-acetamide,
- 2-[2-(4-Chloro-2-methyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-N-cyclopentyl-2-(tetrahydro-pyran-3-yl)-acetamide,
- (S)-2-[2-(4-Chloro-2-methyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,
- (R)-2-[2-(4-Chloro-2-methyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,
- 2-(2-Benzyloxymethyl-6-fluoro-benzoimidazol-1-yl)-2,N-dicyclohexyl-acetamide, 2-(2-Butoxymethyl-6-fluoro-benzoimidazol-1-yl)-2,N-dicyclohexyl-acetamide, 2,N-Dicyclohexyl-2-{6-fluoro-2-[1-(4-trifluoromethoxy-phenoxy)-ethyl]-benzoimidazol-1-yl}-acetamide,
- 2-{2-[1-(2-Chloro-phenoxy)-ethyl]-6-fluoro-benzoimidazol-1-yl}-2,N-dicyclohexyl-acetamide,
- 2,N-Dicyclohexyl-2-{2-[1-(2,4-dichloro-phenoxy)-ethyl]-6-fluoro-benzoimidazol-1-yl}-acetamide,
- 2,N-Dicyclohexyl-2-{2-[1-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-ethyl]-6-fluoro-benzoimidazol-1-yl}-acetamide,
- 2-{2-[1-(3-Chloro-phenoxy)-ethyl]-6-fluoro-benzoimidazol-1-yl}-2,N-dicyclohexyl-acetamide,
- 2-{2-[1-(4-Chloro-phenoxy)-ethyl]-6-fluoro-benzoimidazol-1-yl}-2,N-dicyclohehyl-acetamide,
- 2-{2-[1-(4-Chloro-2-methyl-phenoxy)-ethyl]-6-fluoro-benzoimidazol-1-yl}-2,N-dicyclohexyl-acetamide,
- (S)-2-{2-[(S)-1-(4-Chloro-2-methyl-phenoxy)-ethyl]-6-fluoro-benzoimidazol-1-yl} -2,N-dicyclohexyl-acetamide,
- (S)-2-{2-[ (R)-1-(4-Chloro-2-methyl-phenoxy)-ethyl]-6-fluoro-benzoimidazol-1-yl}-2,N-dicyclohexyl-acetamide,
- 2,N-Dicyclohexyl-2-[6-fluoro-2-(1-phenoxy-propyl)-benzoimidazol-1-yl]-acetamide,
- 2-{2-[1-(4-Chloro-phenoxy)-1-methyl-ethyl]-6-fluoro-benzoimidazol-1-yl}-2,N-dicyclohexyl-acetamide,
- 2,N-Dicyclohexyl-2-[2-(2,4-dichloro-phenylsulfanylmethyl)-6-fluoro-benzoimidazol-1-yl]-acetamide,
- 2,N-Dicyclohexyl-2-[2-(2,6-dichloro-phenylsulfanylmethyl)-6-fluoro-benzoimidazol-1-yl]-acetamide,
- 2,N-Dicyclohexyl-2-[6-fluoro-2-(naphthalen-1-ylsulfanylmethyl)-benzoimidazol-1-yl]-acetamide,
- 2-(2-Benzenesulfinylmethyl-6-fluoro-benzoimidazol-1-yl) -2,N-dicyclohexyl-acetamide,
- 2-(2-Benzenesulfinylmethyl-benzoimidazol-1-yl)-2,N-dicyclohexyl-acetamide,
- 2,N-Dicyclohexyl-2-{2-[2-(3,4-dimethoxy-phenyl)-ethyl]-6-fluoro-benzoimidazol-1-yl}-acetamide,
- 2,N-Dicyclohexyl-2-{6-fluoro-2-[2-(4-methoxy-phenyl)-ethyl]-benzoimidazol-1-yl}-acetamide,
- 2-{2-[2-(4-Chloro-phenyl)-ethyl]-6-fluoro-benzoimidazol-1-yl}-2,N-dicyclohexyl-acetamide,
- 2,N-Dicyclohexyl-2-{6-fluoro-2- [2-(4-fluoro-phenyl)-ethyl] -benzoimidazol-1-yl}-acetamide,
- 2-[2-(2-Benzo[1,3]dioxol-5-yl-ethyl)-6-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,
- 2-[2-(2-Chloro-phenoxymethyl)-5-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,
- 2,N-Dicyclohexyl-2-(5-fluoro-2-o-tolyloxymethyl-benzoimidazol-1-yl)-acetamide,
- 2,N-Dicyclohexyl-2-(5-fluoro-2-m-tolyloxymethyl-benzoimidazol-1-yl)-acetamide,
- 2,N-Dicyclohexyl-2-(5-fluoro-2-p-tolyloxymethyl-benzoimidazol-1-yl)-acetamide,
- 2,N-Dicyclohexyl-2-[5-fluoro-2-(4-fluoro-phenoxymethyl)-benzoimidazol-1-yl]-acetamide,
- 2,N-Dicyclohexyl-2-[2-(2,3-dimethyl-phenoxymethyl)-5-fluoro-benzoimidazol-1-yl]-acetamide,
- 2,N-Dicyclohexyl-2-[2-(3,4-dimethyl-phenoxymethyl)-5-fluoro-benzoimidazol-1-yl]-acetamide,
- 2,N-Dicyclohexyl-2-[2-(2,4-dimethyl-phenoxymethyl)-5-fluoro-benzoimidazol-1-yl]-acetamide,
- 2,N-Dicyclohexyl-2-[2-(2,5-dimethyl-phenoxymethyl)-5-fluoro-benzoimidazol-1-yl]-acetamide,
- 2-[2-(2-Chloro-6-methyl-phenoxymethyl)-5-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,
- 2,N-Dicyclohexyl-2- [5-fluoro-2-(2-methoxy-phenoxymethyl)-benzoimidazol-1-yl]-acetamide,
- 2,N-Dicyclohexyl-2- [5-fluoro-2-(4-methoxy-phenoxymethyl)-benzoimidazol-1-yl]-acetamide,
- 2,N-Dicyclohexyl-2- [5-fluoro-2-(pyridin-2-yloxymethyl)-benzoimidazol-1-yl]-acetamide,
- 2-[2-(4-Chloro-2-methyl-phenoxymethyl)-5-fluoro-benzoimidazol-1-yl]-2-cycloheptyl-N-cyclohexyl-acetamide,
- 2-[2-(4-Chloro-2-methyl-phenoxymethyl)-5-fluoro-benzoimidazol-1-yl]-2-cycloheptyl-N-cyclopentyl-acetamide,
- 2,N-Dicyclohexyl-2-(2-ethoxymethyl-5-fluoro-benzoimidazol-1-yl)-acetamide,
- 2,N-Dicyclohexyl-2-{5-fluoro-2- [2-(2-methoxy-ethoxy)-ethoxymethyl]-benzoimidazol-1-yl}-acetamide,
- 2,N-Dicyclohexyl-2-{5-fluoro-2-[2-(2-methoxy-ethoxy)-ethoxymethyl]-benzoimidazol-1-yl}-acetamide,
- 2-{2-[1-(2-Chloro-phenoxy)-ethyl]-5-fluoro-benzoimidazol-1-yl}-2,N-dicyclohexyl-acetamide,
- 2,N-Dicyclohexyl-2-{2-[1-(2,4-dichloro-phenoxy)-ethyl]-5-fluoro-benzoimidazol-1-yl}-acetamide,
- 2,N-Dicyclohexyl-2-{2-[1-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-ethyl]-5-fluoro-benzoimidazol-1-yl}-acetamide,
- 2,N-Dicyclohexyl-2-(5-fluoro-2-phenethyl-benzoimidazol-1-yl)-acetamide,
- 2,N-Dicyclohexyl-2-[5-fluoro-2-(3-phenyl-propyl)-benzoimidazol-1-yl] -acetamide,
- 3-[1-(Cyclohexyl-cyclohexylcarbamoyl-methyl)-5-fluoro-1H-benzoimidazol-2-yl]-propionic acid benzyl ester,
- 2-[2-(2-Chloro-phenoxymethyl)-5,6-difluoro-benzoimidazol-1-yl] -2,N-dicyclohexyl-acetamide,
- 2,N-Dicyclohexyl-2-[5,6-difluoro-2-(4-fluoro-phenoxymethyl)-benzoimidazol-1-yl]-acetamide,
- 2,N-Dicyclohexyl-2-(5,6-difluoro-2-phenoxymethyl-benzoimidazol-1-yl)-acetamide,
- 2,N-Dicyclohexyl-2-(5,6-difluoro-2-m-tolyloxymethyl-benzoimidazol-1-yl)-acetamide,
- 2,N-Dicyclohexyl-2-(5,6-difluoro-2-o-tolyloxymethyl-benzoimidazol-1-yl)-acetamide,
- 2,N-Dicyclohexyl-2-[2-(2,4-dimethyl-phenoxymethyl)-5,6-difluoro-benzoimidazol-1-yl]-acetamide,
- 2,N-Dicyclohexyl-2-[2-(4-ethyl-phenoxymethyl)-5,6-difluoro-benzoimidazol-1-yl]-acetamide,
- 2,N-Dicyclohexyl-2-[5,6-difluoro-2-(4-methoxy-phenoxymethyl)-benzoimidazol-1-yl]-acetamide,
- 2,N-Dicyclohexyl-2-[5,6-difluoro-2-(3-methoxy-phenoxymethyl)-benzoimidazol-1-yl]-acetamide,
- 2,N-Dicyclohexyl-2-[5,6-difluoro-2-(4-hydroxymethyl-3-methoxy-phenoxymethyl)-benzoimidazol-1-yl]-acetamide,
- 2-[2-(4-Chloro-2-methyl-phenoxymethyl)-5,6-difluoro-benzoimidazol-1-yl]-N-cyclopentyl-2-(tetrahydro-pyran-2-yl)-acetamide,
- 2,N-Dicyclohexyl-2-(2-ethoxymethyl-5,6-difluoro-benzoimidazol-1-yl)-acetamide,
- 2-(2-Butoxymethyl-5,6-difluoro-benzoimidazol-1-yl)-2,N-dicyclohexyl-acetamide,
- 2-{2-[1-(2-Chloro-phenoxy)-ethyl]-5,6-difluoro-benzoimidazol-1-yl}-2,N-dicyclohexyl-acetamide,
- 2,N-Dicyclohexyl-2-{2-[1-(2,4-dichloro-phenoxy)-ethyl]-5,6-difluoro-benzoimidazol-1-yl}-acetamide,
- 2,N-Dicyclohexyl-2-{2-[1-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-ethyl]-5,6-difluoro-benzoimidazol-1-yl}-acetamide,
- 2,N-Dicyclohexyl-2-(5,6-difluoro-2-phenethyl-benzoimidazol-1-yl)-acetamide,
- 2,N-Dicyclohexyl-2-[5,6-difluoro-2-(3-phenyl-propyl)-benzoimidazol-1-yl]-acetamide,
- 2-[6-Chloro-2-(4-chloro-phenoxymethyl)-5-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,
- 2-{6-Chloro-2-[1-(4-chloro-phenoxy)-ethyl]-5-fluoro-benzoimidazol-1-yl}-2,N-dicyclohexyl-acetamide,
- 2-{6-Chloro-2-[1-(3-chloro-phenoxy)-ethyl]-5-fluoro-benzoimidazol-1-yl}-2,N-dicyclohexyl-acetamide,
- 2-[6-Chloro-5-fluoro-2-(1-phenoxy-propyl)-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,
- 2-[6-Chloro-2-(3,4-dimethoxy-phenylsulfanylmethyl)-5-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,
- 2-[6-Chloro-5-fluoro-2-(4-fluoro-phenylsulfanylmethyl)-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,
- 2-[6-Chloro-2-(2,4-dichloro-phenylsulfinylmethyl)-5-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,
- 2-[6-Chloro-5-fluoro-2-(4-trifluoromethyl-phenylsulfanylmethyl)-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,
- 2-[6-Chloro-2-(8-chloro-naphthalen-1-ylsulfanylmethyl)-5-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,
- 2-(2-Benzenesulfinylmethyl-6-chloro-5-fluoro-benzoimidazol-1-yl)-2,N-dicyclohexyl-acetamide, and
- 2-{6-Chloro-5-fluoro-2-[2-(3-isopropoxy-isoxazol-5-yl)-ethyl]-benzoimidazol-1-yl}-2,N-dicyclohexyl-acetamide,
- Particularly preferred compounds of formula (I) are those selected from the group consisting of
- (S)-2-[2-(4-Chloro-2-methyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,
- 2-{2-[1-(4-Chloro-2-methyl-phenoxy)-ethyl]-6-fluoro-benzoimidazol-1-yl}-2,N-dicyclohexyl-acetamide,
- 2-[2-(2-Chloro-phenoxymethyl)-5-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,
- 2,N-Dicyclohexyl-2-[5-fluoro-2-(4-methoxy-phenoxymethyl)-benzoimidazol-1-yl]-acetamide,
- 2,N-Dicyclohexyl-2-[5-fluoro-2-(pyridin-2-yloxymethyl)-benzoimidazol-1-yl]-acetamide,
- 2,N-Dicyclohexyl-2-(5-fluoro-2-phenethyl-benzoimidazol-1-yl)-acetamide,
- 2,N-Dicyclohexyl-2-(5,6-difluoro-2-phenoxymethyl-benzoimidazol-1-yl)-acetamide,
- 2,N-Dicyclohexyl-2-[2-(4-ethyl-phenoxymethyl)-5,6-difluoro-benzoimidazol-1-yl]-acetamide,
- 2,N-Dicyclohexyl-2-{2-[1-(2,4-dichloro-phenoxy)-ethyl]-5,6-difluoro-benzoimidazol-1-yl}-acetamide, and
- 2-[6-Chloro-5-fluoro-2-(4-fluoro-phenylsulfanylmethyl)-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,
- It will be appreciated that the compounds of general formula (I) in this invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.
- The invention further relates to a process for the manufacture of compounds of formula (I) as defined above, which process comprises
- a) cyclisation of a compound of formula (II)
- b) cyclisation of a compound of formula (III)
- The cyclisation of a compound of formula (II) or formula (III) can be performed under reaction conditions well known to the person skilled in the art, e.g. by the methods described below and in analogy to the examples described below. Suitable protecting groups in compounds of formula (III) are e.g. t-BOC and benzyloxycarbonyl.
- The present invention also relates to compounds of formula (I) as defined above, when prepared by a process as described above.
- The compounds of formula (I) as well as the starting materials of formula (II) and (III) can be prepared by methods known in the art or as described below. Unless otherwise indicated, the substituents R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and X are as described above.
-
- In a suitable organic solvent such as e.g. MeOH a 2-azidoarylamine 1, a carboxylic acid 2, an isonitrile 3 and an aldehyde 4 are condensed to 5 in a multi-component reaction (MCR), a so called Ugi-type reaction (Scheme 1, step a; typical procedures may e.g. be found in "The Peptides" by Gross & Meienhofer Vol. 2, Academic Press, N.Y., 1980, pp 365-381). In a subsequent intramolecular Staudinger-type reaction with a suitable reagent such as e.g. PPh3, the azido bisamide 5 is converted to the benzimidazole I (Scheme 1, step b), which can be optionally N-alkylated by deprotonation with a strong base (e.g. NaH or LiHMDA) and subsequent treatment with an alkylating agent R2-X with X being a typical leaving group such as e.g. Cl, Br, I, SO2alkyl, SO2fluoroalkyl, SO2aryl (Scheme 1, step c). Many of the building blocks 2-4, particularly the carboxylic acids 2, are commercially available. If not, they may be prepared from commercially available starting materials using procedures described in literature and typically known to those skilled in the art (e.g. by alkylation of the corresponding phenols/alcohols with chloro-acetic acid ethyl ester and subsequent ester hydrolysis under aqueous basic conditions using e.g. LiOH or NaOH in a mixture of water and THF) . The isonitriles 3 can e.g. be obtained by dehydration of the corresponding formamide R1-NH-CHO with a suitable reagent such as e.g. phosgene, POCl3 or Me2N=CH+Cl Cl- or by reaction of the corresponding amine R1-NH2 with CHCl3 and NaOH in a suitable solvent such as methanol. Aldehydes 4 are either commercially available or can be prepared by numerous methods known to the person skilled in the art. Appropriate synthesis methods include e.g. reduction of the corresponding carboxylic acid esters by a suitable reducing agent (e.g. diisobutylaluminium hydride at low temperature or with LiAlH4 at elevated or ambient temperature) in a solvent followed by oxidation of the primary alcohol (e.g. with tetrapropylammonium perruthenate (VII), activated MnO2 or Dess-Martin periodinane) to yield aldehydes 4. The 2-azidoarylamine 1 is usually prepared in three steps from the corresponding 2-aminoarylcarboxylic acid, which is converted into a 2-azidoarylcarboxylic acid by diazotation with NaNO2 in a suitable solvent (e.g. methanol) and subsequent treatment with a suitable azide salt such as NaN3 or TMSN3. The resulting 2-azidoarylcarboxylic acid is then converteted into 1 via Curtius rearrangement of the 2-azidoarylcarboxylic azide obtained from the 2-azidoarylcarboxylic acid by its activation with a suitable reagent (e.g. chloroethylformiate in the presence of a base such as triethylamine) and subsequent treatment with a suitable source of azide anions (e.g. NaN3). The 2-azidoaryl amine 1 can alternatively be prepared via the 2-azidoarylcarboxamide obtained by activation of the 2-azidoarylcarboxylic acid with a suitable reagent (e.g. chloroethylformiate in the presence of a base such as triethylamine) and subsequent treatment with ammonia. This amide is converted into 1 in a so called Hofmann-rearrangement by treatment with a suitable reagent such as NaOBr.
- If one of the starting materials or compounds of formula (I) contain one or more functional groups which are not stable or are reactive under the reaction conditions of one or more reaction steps, appropriate protecting groups (as described e.g. in "Protective Groups in Organic Chemistry" by T.W. Greene and P.G.M. Wutts, 2nd Ed., 1991, Wiley N.Y.) can be introduced before the critical step applying methods well known in the art. Such protecting groups can be removed at a later stage of the synthesis using standard methods described in the literature.
- If compounds 1, 2, 3 or 4 contain stereogenic centers, compounds (I) can be obtained as mixtures of diastereomers or enantiomers, which can be separated by methods well known in the art, e.g. (chiral) HPLC or crystallization. Racemic compounds can e.g. be separated into their antipodes via diastereomeric salts by crystallization with optically pure acids or by separation of the antipodes by specific chromatographic methods using either a chiral adsorbens or a chiral eluent.
-
- In this approach a mono boc-protected ortho arylene diamine 6, a carboxylic acid 2, an isonitrile 3, and an aldehyde 4 are condensed in an organic solvent such as e.g. methanol to provide the bis-amide 7 again in an Ugi-type condensation (Scheme 2, step a). Bisamide 7 is then deprotected with TFA or HCl and spontaneously undergoes cyclization to the desired benzimidazole I (Scheme 2, step b), which can be optionally N-alkylated by deprotonation with a strong base (e.g. NaH or LiHMDA) and subsequent treatment with an alkylating agent R2-X with X being a typical leaving group such as e.g. Cl, Br, I, SO2alkyl, SO2fluoroalkyl, SO2aryl (Scheme 2, step c). Typical procedures applicable to this approach were described e.g. by P. Tempest, V. Ma, S. Thomas, Z. Hua, M. G. Kelly, C. Hulme Tetrahedron Lett. 2001, 42, 4959-4962 and P. Tempest, V. Ma, M. G. Kelly, W. Jones, C. Hulme Tetrahedron Lett. 2001, 42, 4963-4968, or by W. Zhang, P. Tempest Tetrahedron Lett. 2004, 45, 6757-6760. Mono boc-protected ortho arylene diamines 6 are commerically available or may be prepared from the corresponding unprotected diamine by treatment with di-tert-butyl dicarbonate in an organic solvent such as e.g. THF in the presence of a base such as e.g. diisopropylethylamine.
- If desired or required functional groups present in I (such as -CO2alkyl, amino groups, cyano groups and others) may be derivatized to other functional groups using typical standard procedures known to those skilled in the art (e.g. reduction of -CO2alkyl to -CH2OH with LiAlH4, hydrolysis of -CO2alkyl to CO2H and subsequent optional conversion to an amide, acylation of amino groups).
- If one of the starting materials or compounds of formula (I) contain one or more functional groups which are not stable or are reactive under the reaction conditions of one or more reaction steps, appropriate protecting groups (as described e.g. in "Protective Groups in Organic Chemistry" by T.W. Greene and P.G.M. Wutts, 2nd Ed., 1991, Wiley N.Y.) can be introduced before the critical step applying methods well known in the art. Such protecting groups can be removed at a later stage of the synthesis using standard methods described in the literature.
- If compounds 2, 3, 4 or 6 contain stereogenic centers, compounds (I) can be obtained as mixtures of diastereomers or enantiomers, which can be separated by methods well known in the art, e.g. (chiral) HPLC or crystallization. Racemic compounds can e.g. be separated into their antipodes via diastereomeric salts by crystallization with optically pure acids or by separation of the antipodes by specific chromatographic methods using either a chiral adsorbens or a chiral eluent.
- R1 as present in (I) after steps a and b or steps a, b and c in above shown schemes may be transformed into or replaced by other R1 using one or a sequence of reaction steps. Two possible examples are given below:
- a) R1 = CH2Ph may for instance be removed using debenzylation conditions (e.g. hydrogenolysis in a solvent such as methanol in presence of a catalyst such as Pd(0) on charcoal powder) and a new R1 can be introduced e.g. by deprotonation of the resulting CONHR2 with a strong base (e.g. LiHMDA) and treatment with an alkylating agent R1-X (X being a typical leaving group such as e.g. Cl, Br, I, SO2alkyl, SO2fluoroalkyl, SO2aryl, and R1 being C1-10-alkyl, lower-alkoxy-lower-alkyl, lower-alkoxy-carbonyl-lower-alkyl, cycloalkyl, cycloalkyl-lower-alkyl, aryl-lower-alkyl, di-aryl-lower-alkyl, heteroaryl-lower-alkyl or heterocyclyl-lower-alkyl) or alternatively by a Pd(II)-promoted coupling with R1-X (R1 being aryl or heteroaryl and X being Cl, Br, I or OSO2CF3)
- b) Amidolysis of the -CR3CONR1R2-moiety of (I) to -CR3COOH may be carried out using suitable conditions such as heating in isopropanol in presence of NaOH or LiOH. A new amide bond can then be formed using an amine HNR1R2 and a typical peptide coupling reagent such as e.g. EDCI, DCC or TPTU.
- Functional groups present in (I) which are not stable or are reactive under the reaction conditions of one or more of the reaction steps, can be protected with appropriate protecting groups (as described e.g. in "Protective Groups in Organic Chemistry" by T.W. Greene and P.G.M. Wutts, 2nd Ed., 1991, Wiley N.Y.) before the critical step applying methods well known in the art. Such protecting groups can be removed at a later stage of the synthesis using standard methods described in the literature.
- The conversion of a compound of formula (I) into a pharmaceutically acceptable salt can be carried out by treatment of such a compound with an inorganic acid, for example a hydrohalic acid, such as, for example, hydrochloric acid or hydrobromic acid, or other inorganic acids such as sulfuric acid, nitric acid, phosphoric acid etc., or with an organic acid, such as, for example, acetic acid, citric acid, maleic acid, fumaric acid, tartaric acid, methanesulfonic acid or p-toluenesulfonic acid. The salts with an inorganic or organic acid can be obtained by standard methods known to the person skilled in the art, e.g. by dissolving the compound of formula (I) in a suitable solvent such as e.g. dioxane or THF and adding an appropriate amount of the corresponding acid. The products can conveniently be isolated by filtration or by chromatography. If a carboxy group is present, the corresponding carboxylate salts can be prepared from the compounds of formula (I) by treatment with physiologically compatible bases. One possible method to form such a salt is e.g. by addition of 1/n equivalents of a basic salt such as e.g. M(OH)n, wherein M = metal or ammonium cation and n = number of hydroxide anions, to a solution of the compound in a suitable solvent (e.g. ethanol, ethanol-water mixture, tetrahydrofuran-water mixture) and to remove the solvent by evaporation or lyophilisation.
- The conversion of compounds of formula (I) into pharmaceutically acceptable esters can be carried out e.g. by treatment of hydroxy groups present in the molecules with a carboxylic acid such as acetic acid, with a condensating reagent such as benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP), N,N-dicylohexylcarbodiimide (DCC), N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDCI) or O-(1,2-dihydro-2-oxo-1-pyridyl)-N,N,N,N-tetra-methyluronium-tetrafluorborate (TPTU) to produce the carboxylic ester. Furthermore, carboxy groups present in the compounds of formula (I) can be reacted with suitable alcohols under analogous conditions as described above.
- Insofar as their preparation is not described in the examples, the compounds of formula (I) as well as all intermediate products can be prepared according to analogous methods or according to the methods set forth above. Starting materials are commercially available, are known in the art, or can be prepared by methods analogous to those described herein.
- As described above, the novel compounds of the present invention have been found to bind to and selectively activate FXR. They can therefore be used in the treatment and prophylaxis of diseases which are modulated by FXR agonists. Such diseases include increased lipid and cholesterol levels, particularly high LDL-cholesterol, high triglycerides, low HDL-cholesterol, dyslipidemia, atherosclerotic disease, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, cholesterol gallstone disease, cholestasis/fibrosis of the liver, diseases of cholesterol absorption, cancer, particularly gastrointestinal cancer, osteoporosis, peripheral occlusive disease, ischemic stroke, Parkinson's disease and/or Alzheimer's disease.
- The invention therefore also relates to pharmaceutical compositions comprising a compound as defined above and a pharmaceutically acceptable carrier and/or adjuvant.
- The invention likewise embraces compounds as described above for use as therapeutically active substances, especially as therapeutically active substances for the treatment and/or prophylaxis of diseases which are modulated by FXR agonists, particularly as therapeutically active substances for the treatment and/or prophylaxis of increased lipid and cholesterol levels, high LDL-cholesterol, high triglycerides, low HDL-cholesterol, dyslipidemia, atherosclerotic disease, diabetes, non-insulin dependent diabetes mellitus, metabolic syndrome, cholesterol gallstone disease, cholestasis/fibrosis of the liver, diseases of cholesterol absorption, cancer, gastrointestinal cancer, osteoporosis, peripheral occlusive disease, ischemic stroke, Parkinson's disease and/or Alzheimer's disease.
- The invention also relates to the use of compounds as described above for the preparation of medicaments for the therapeutic and/or prophylactic treatment of diseases which are modulated by FXR agonists, particularly for the therapeutic and/or prophylactic treatment of increased lipid and cholesterol levels, high LDL-cholesterol, high triglycerides, low HDL-cholesterol, dyslipidemia, atherosclerotic disease, diabetes, non-insulin dependent diabetes mellitus, metabolic syndrome, cholesterol gallstone disease, cholestasis/fibrosis of the liver, diseases of cholesterol absorption, cancer, gastrointestinal cancer, osteoporosis, peripheral occlusive disease, ischemic stroke, Parkinson's disease and/or Alzheimer's disease. Such medicaments comprise a compound as described above.
- Prevention and/or treatment of high LDL cholesterol levels, high triglycerides, dyslipidemia, cholesterol gallstone disease, cancer, non-insulin dependent diabetes mellitus and metabolic syndrome is preferred, particularly high LDL cholesterol, high triglyceride levels and dyslipidemia.
- The following tests were carried out in order to determine the activity of the compounds of formula (I). Background information on the binding assay can be found in: Nichols J S et al. "Development of a scintillation proximity assay for peroxisome proliferator-activated receptor gamma ligand binding domain", (1998) Anal. Biochem. 257: 112-119.
- Bacterial and mammalian expression vectors were constructed to produce glutathione-s-transferase (GST) and Gal4 DNA binding domain (GAL) proteins fused to the ligand binding domain (LBD) of human FXR (aa 193-473). To accomplish this, the portions of the sequences encoding the FXR LBD were amplified by polymerase chain reaction (PCR) from a full-length clone by PCR and then subcloned into the plasmid vectors. The final clone was verified by DNA sequence analysis.
- The induction, expression, and subsequent purification of GST-LBD fusion protein was performed in E. coli strain BL21(pLysS) cells by standard methods (Current Protocols in Molecular Biology, Wiley Press, ed. Ausubel et al.).
- Binding of test substances to the FXR ligand binding domain was assessed in a radioligand displacement assay. The assay was performed in a buffer consisting of 50 mM Hepes, pH 7.4, 10 mM NaCl, 5 mM MgCl2, 0.01% CHAPS. For each reaction well in a 96-well plate, 40nM of GST-FXR LBD fusion protein was bound to 10 µg glutathione ytrium silicate SPA beads (PharmaciaAmersham) in a final volume of 50 µl by shaking. A radioligand (e.g. 20nM of 2,N-dicyclohexyl-2-[2-(2,4 dimethoxy-phenyl)-benzoimidazol-1-yl]-acetamide) and test compounds were added, and scintillation proximity counting was performed. All binding assays were performed in 96-well plates and the amount of bound ligand was measured on a Packard TopCount using OptiPlates (Packard). Dose response curves were performed within a range of test compound concentrations from 6 x 10-9 M to 2.5 x 10-5 M and IC50s were calculated.
- Baby hamster kidney cells (BHK21 ATCC CCL10) were grown in DMEM medium containing 10% FBS at 37 °C in a 95% 02/5% CO2 atmosphere. Cells were seeded in 6-well plates at a density of 105 cells/well and then transfected with the pFA-FXR-LBD or expression plasmid plus a reporter plasmid. Transfection was accomplished with the Fugene 6 reagent (Roche Molecular Biochemicals) according to the suggested protocol. Six hours following transfection, the cells were harvested by trypsinization and seeded in 96-well plates at a density of 2 x 105 cells/well. After 24 hours to allow attachment of cells, the medium was removed and replaced with 100 µl of phenol red-free medium containing the test substances or control ligands (final DMSO concentration: 0.4%). Following incubation of the cells for 24 hours with substances, 50 µl of the supernatant was discarded and then 50 µl of Luciferase Constant-Light Reagent (Roche Molecular Biochemicals) was added to lyse the cells and initiate the luciferase reaction. Luminescence, as a measure of luciferase activity, was detected in a Packard TopCount. Transcriptional activation in the presence of a test substance was expressed as fold-change in luminescence compared to that of cells incubated in the absence of the substance. EC50 values were calculated using the XLfit program (ID Business Solutions Ltd. UK).
- The compounds according to formula (I) have an activity in at least one of the above assays (EC50 or IC50), preferably of 0.5 nM to 10 µM, more preferably 0.5 nM to 100 nM.
- For example, the following compounds showed the following EC50 and IC50 values in the assays described above:
Example Transactivation EC50 [µM] SPA binding IC50 [µM] 31 0.254 0.118 49 0.095 0.038 56 0.982 0.105 - The compounds of formula I and/or their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical preparations for enteral, parenteral or topical administration. They can be administered, for example, perorally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions or suspensions or infusion solutions, or topically, e.g. in the form of ointments, creams or oils. Oral administration is preferred.
- The production of the pharmaceutical preparations can be effected in a manner which will be familiar to any person skilled in the art by bringing the described compounds of formula I and/or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
- Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials. Thus, for example, lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carrier materials for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers might, however, be required in the case of soft gelatine capsules). Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and the like. Suitable carrier materials for injection solutions are, for example, water, alcohols, polyols, glycerol and vegetable oils. Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols. Suitable carrier materials for topical preparations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.
- Usual stabilizers, preservatives, wetting and emulsifying agents, consistency-improving agents, flavour-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants.
- The dosage of the compounds of formula I can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case. For adult patients a daily dosage of about 1 to 1000 mg, especially about 1 to 300 mg, comes into consideration. Depending on severity of the disease and the precise pharmacokinetic profile the compound could be administered with one or several daily dosage units, e.g. in 1 to 3 dosage units.
- The pharmaceutical preparations conveniently contain about 1-500 mg, preferably 1-100 mg, of a compound of formula I.
- The following Examples serve to illustrate the present invention in more detail.
- Ar = argon, DMF = N,N-dimethylformamide, DMSO = dimethyl sulfoxide, NaHCO3 = sodium hydrogen carbonate, Na2SO4 = sodium sulfate, h = hour, HCl = hydrogen chloride, HPLC = high performance liquid chromatography, ISP = ion spray positive (mode), ISN = ion spray negative (mode), min = minutes, NMR = nuclear magnetic resonance, MS = mass spectrum, P = protecting group, R = any group, rt = room temperature, SiO2 = silica gel, THF = tetrahydrofuran, X = halogen.
- Reactions were carried out under nitrogen or argon atmosphere, when appropriate.
- To a solution of (2-amino-4-fluoro-phenyl)-carbamic acid tert-butyl ester (22.63 mg, 0.10 mmol, 1.0 equiv; Intermediate A) in MeOH (1.0 mL) was added cyclohexanecarbaldehyde (16.83 mg, 18.05 µl, 0.15 mmol, 1.5 equiv; [2043-61-0]) and the mixture stirred at rt. After 30 min, (4-chloro-2-methyl-phenoxy)-acetic acid (20.06 mg, 0.10 mmol, 1.0 equiv; [CAS RN 94-74-6]) and cyclohexyl isocyanide (10.92 mg, 12.27 µl, 0.10 mmol, 1.0 equiv; [931-53-3]) were added and stirring continued at rt for 2 h. A solution of 4 M HCl in dioxane (0.2 mL) was added and the reaction mixture stirred at rt overnight. Removal of the solvent mixture under reduced pressure and purification by preparative HPLC on reversed phase eluting with a gradient of acetonitrile / water provided 38.7 mg (50%) of the title compound. MS (ISP): 512.3 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with (4-hydroxymethyl-phenoxy)-acetic acid ([CAS RN 68858-21-9]). MS (ISP): 494.5 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with (4-chloro-phenoxy)-acetic acid ([CAS RN 122-88-3]). MS (ISP): 498.3 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with (2-chloro-phenoxy)-acetic acid ([CAS RN 614-61-9]). MS (ISN): 497.6 [M-H]-.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with m-tolyloxy-acetic acid ([CAS RN 1643-15-8]). MS (ISP): 478.2 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with (2-methoxy-phenoxy)-acetic acid ([CAS RN 1878-85-9]). MS (ISP): 494.3 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with o-tolyloxy-acetic acid ([CAS RN 1878-49-5]). MS (ISP): 478.2 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with (2,4-dimethyl-phenoxy)-acetic acid ([CAS RN 13334-49-1]). MS (ISP): 492.3 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with (2,5-dimethyl-phenoxy)-acetic acid ([CAS RN 7356-41-4]). MS (ISP): 492.3 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with (4-chloro-2-methyl-phenoxy)-acetic acid ([CAS RN 94-74-6]). MS (ISP): 512.3 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with (4-acetyl-phenoxy)-acetic acid ([CAS RN 1878-81-5]). MS (ISP): 506.3[M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with (4-ethyl-phenoxy)-acetic acid ([CAS RN 24431-27-4]). MS (ISP): 492.3 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with (2,3-dimethyl-phenoxy)-acetic acid ([CAS RN 2935-63-9]). MS (ISP): 492.3 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with (2-chloro-6-methyl-phenoxy)-acetic acid ([CAS RN 19094-75-8]). MS (ISP): 512.2 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with (2,4-dichloro-phenoxy)-acetic acid ([CAS RN 94-75-7]). MS (ISP): 532.2 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing cyclohexanecarbaldehyde with cycloheptanecarbaldehyde ([CAS RN 4277-29-6]). MS (ISP): 526.5 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing cyclohexanecarbaldehyde with cycloheptanecarbaldehyde ([CAS RN 4277-29-6]) and cyclohexyl isocyanide with cyclopentyl isocyanide ([CAS RN 68498-54-4]). MS (ISP): 512.5 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing cyclohexanecarbaldehyde with tetrahydro-pyran-3-carbaldehyde ([CAS RN 77342-93-9]) and cyclohexyl isocyanide with cyclopentyl isocyanide ([CAS RN 68498-54-4]). MS (ISP): 500.5 [M+H]+.
- The title compound was prepared in analogy to Example 1, conducting purification by chiral preparative HPLC (Chiralpak AD) eluting with a gradient of isopropanol /heptane. MS (ISP): 512.5 [M+H]+.
- The title compound was prepared in analogy to Example 1, conducting purification by chiral preparative HPLC (Chiralpak AD) eluting with a gradient of isopropanol /heptane. MS (ISP): 512.5 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with benzyloxy-acetic acid ([CAS RN 30379-55-6]). MS (ISP): 478.2 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with butoxy-acetic acid ([CAS RN 2516-93-0]). MS (ISP): 444.3 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with 2-(4-trifluoromethoxy-phenoxy)-propionic acid ([CAS RN 175204-35-0]). MS (ISP): 562.3 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with 2-(2-chloro-phenoxy)-propionic acid ([CAS RN 25140-86-7]). MS (ISP): 512.2 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with 2-(2,4-dichloro-phenoxy)-propionic acid ([CAS RN 120-36-5]). MS (ISP): 546.3 |M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with 2-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-propionic acid (commercially available from Matrix Scientific, Inc., USA.). MS (ISP): 536.3 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with 2-(3-chloro-phenoxy)-propionic acid ([CAS RN 101-10-0]). MS (ISP): 512.3 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with 2-(4-chloro-phenoxy)-propionic acid ([CAS RN 3307-39-9]). MS (ISP): 512.5 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with 2-(4-chloro-2-methyl-phenoxy)-propionic acid ([CAS RN 93-65-2]). MS (ISP): 526.3 [M+H]+.
- The title compound was prepared in analogy to Example 29, conducting purification by chiral preparative HPLC (Chiralpak AD) eluting with a gradient of isopropanol / heptane. MS (ISP): 526.5 [M+H]+.
- The title compound was prepared in analogy to Example 29, conducting purification by chiral preparative HPLC (Chiralpak AD) eluting with a gradient of isopropanol / heptane. MS (ISP): 526.5 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with 2-phenoxy-butyric acid ([CAS RN 13794-14-4]). MS (ISP): 492.4 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with 2-(4-chloro-phenoxy)-2-methyl-propionic acid ([CAS RN 882-09-7]). MS (ISP): 526.3 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with (2,4-dichloro-phenylsulfanyl)-acetic acid ([CAS RN 7720-41-4]). MS (ISP): 548.5 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with (2,6-dichloro-phenylsulfanyl)-acetic acid ([CAS RN 21248-45-3]). MS (ISP): 548.5 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with (naphthalen-1-ylsulfanyl)-acetic acid ([CAS RN 10404-24-7]). MS (ISP): 530.3 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with benzenesulfinyl-acetic acid ([CAS RN 3959-08-8]). MS (ISP): 496.6 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (2-amino-4-fluoro-phenyl)-carbamic acid tert-butyl ester (Intermediate A) with (2-amino-phenyl)-carbamic acid tert-butyl ester ([CAS RN 146651-75-4]) and (4-chloro-2-methyl-phenoxy)-acetic acid with benzenesulfinyl-acetic acid ([CAS RN 3959-08-8]). MS (ISP): 478.1 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with 3-(3,4-dimethoxy-phenyl)-propionic acid ([CAS RN 2107-70-2]). MS (ISP): 522.3 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with 3-(4-methoxy-phenyl)-propionic acid ([CAS RN 1929-29-9]). MS (ISP): 492.3 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with 3-(4-chloro-phenyl)-propionic acid ([CAS RN 2019-34-3]). MS (ISP): 496.3 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with 3-(4-fluoro-phenyl)-propionic acid ([CAS RN 459-31-4]). MS (ISP): 480.3 [M+H]+.
- The title compound was prepared in analogy to Example 1, replacing (4-chloro-2-methyl-phenoxy)-acetic acid with 3-benzo[1,3]dioxol-5-yl-propionic acid ([CAS RN 2815-95-4]). MS (ISP): 506.3 [M+H]+.
- (2-Amino-5-fluoro-phenyl)-carbamic acid tert-butyl ester [CAS RN 362670-07-3] (Intermediate B) was prepared as described in M. J. Bamford, M. J. Alberti, N. Bailey, S. Davies, D. K. Dean, A. Gaiba, S. Garland, J. D. Harling, D. K. Jung, T. A. Panchal, C. A. Parr, J. G. Steadman, A. K. Takle, J. T. Townsend, D. M. Wilson, J. Witherington Bioorg. Med. Chem. Lett. 2005, 15, 3402-3406.
- To a solution of (2-amino-5-fluoro-phenyl)-carbamic acid tert-butyl ester (22.63 mg, 0.10 mmol, 1.0 equiv; Intermediate B) in MeOH (1.0 mL) was added cyclohexanecarbaldehyde (16.83 mg, 18.05 µl, 0.15 mmol, 1.5 equiv; [2043-61-0]) and the mixture stirred at rt. After 30 min, (2-chloro-phenoxy)-acetic acid (18.66 mg, 0.10 mmol, 1.0 equiv; [CAS RN 614-61-9]) and cyclohexyl isocyanide (10.92 mg, 12.27 µl, 0.10 mmol, 1.0 equiv; [931-53-3]) were added and stirring continued at rt for 2 h. A solution of 4 M HCl in dioxane (0.2 mL) was added and the reaction mixture stirred at rt overnight. Removal of the solvent mixture under reduced pressure and purification by preparative HPLC on reversed phase eluting with a gradient of acetonitrile / water provided 6.3 mg (13%) of the title compound. MS (ISP): 498.1 [M+H]+.
- The title compound was prepared in analogy to Example 44, replacing (2-chloro-phenoxy)-acetic acid with o-tolyloxy-acetic acid ([CAS RN 1878-49-5]). MS (ISP): 478.3 [M+H]+.
- The title compound was prepared in analogy to Example 44, replacing (2-chloro-phenoxy)-acetic acid with m-tolyloxy-acetic acid ([CAS RN 1643-15-8]). MS (ISP): 478.3 [M+H]+.
- The title compound was prepared in analogy to Example 44, replaying (2-chloro-phenoxy)-acetic acid with p-tolyloxy-acetic acid ([CAS RN 940-64-7]). MS (ISP): 478.3 [M+H]+.
- The title compound was prepared in analogy to Example 44, replacing (2-chloro-phenoxy)-acetic acid with (4-fluoro-phenoxy)-acetic acid ([CAS RN 405-79-8]). MS (ISP):482.3 [M+H]+.
- The title compound was prepared in analogy to Example 44, replacing (2-chloro-phenoxy)-acetic acid with (2,3-dimethyl-phenoxy)-acetic acid ([CAS RN 2935-63-9]). MS (ISP): 492.3 [M+H]+.
- The title compound was prepared in analogy to Example 44, replacing (2-chloro-phenoxy)-acetic acid with (3,4-dimethyl-phenoxy)-acetic acid ([CAS RN 13335-73-4]). MS (ISP): 492.3 [M+H]+.
- The title compound was prepared in analogy to Example 44, replacing (2-chloro-phenoxy)-acetic acid with (2,4-dimethyl-phenoxy)-acetic acid ([CAS RN 13334-49-1]). MS (ISP): 492.3 [M+H]+.
- The title compound was prepared in analogy to Example 44, replacing (2-chloro-phenoxy)-acetic acid with (2,5-dimethyl-phenoxy)-acetic acid ([CAS RN 7356-41-4]). MS (ISP): 492.3 [M+H]+.
- The title compound was prepared in analogy to Example 44, replacing (2-chloro-phenoxy)-acetic acid with (2-chloro-6-methyl-phenoxy)-acetic acid ([CAS RN 19094-75-8]). MS (ISP): 512.3 [M+H]+.
- The title compound was prepared in analogy to Example 44, replacing (2-chloro-phenoxy)-acetic acid with (2-methoxy-phenoxy)-acetic acid ([CAS RN 1878-85-9]). MS (ISP): 494.3 [M+H]+.
- The title compound was prepared in analogy to Example 44, replacing (2-chloro-phenoxy)-acetic acid with (4-methoxy-phenoxy)-acetic acid ([CAS RN 1877-75-4]). MS (ISP): 494.3 [M+H]+.
- The title compound was prepared in analogy to Example 44, replacing (2-chloro-phenoay)-acetic acid with (pyridin-2-yloxy)-acetic acid ([CAS RN 58530-50-0]). MS (ISP): 465.3 [M+H+].
- The title compound was prepared in analogy to Example 44, replacing (2-chloro-phenoxy)-acetic acid with (4-chloro-2-methyl-phenoxy)-acetic acid ([CAS RN 94-74-6]) and cyclohexanecarbaldehyde with cycloheptanecarbaldehyde ([CAS RN 4277-29-6]). MS (ISP): 526.5 [M+H]+.
- The title compound was prepared in analogy to Example 44, replacing (2-chloro-phenoxy)-acetic acid with (4-chloro-2-methyl-phenoxy)-acetic acid ([CAS RN 94-74-6]), cyclohexanecarbaldehyde with cycloheptanecarbaldehyde ([CAS RN 4277-29-6]) and cyclohexyl isocyanide with cyclopentyl isocyanide ([CAS RN 68498-54-4]). MS (ISP): 512.5 [M+H]+.
- The title compound was prepared in analogy to Example 44, replacing (2-chloro-phenoxy)-acetic acid with ethoxy-acetic acid ([CAS RN 627-03-2]). MS (ISP): 416.3 [M+H]+.
- The title compound was prepared in analogy to Example 44, replacing (2-chloro-phenoxy)-acetic acid with butoxy-acetic acid ([CAS RN 2516-93-0]). MS (ISP): 444.3 [M+H]+.
- The title compound was prepared in analogy to Example 44, replacing (2-chloro-phenoxy)-acetic acid with [2-(2-methoxy-ethoxy)-ethoxy]-acetic acid ([CAS RN 16024-58-1]). MS (ISP): 490.3 [M+H]+.
- The title compound was prepared in analogy to Example 44, replacing (2-chloro-phenoxy)-acetic acid with 2-(2-chloro-phenoxy)-propionic acid ([CAS RN 25140-86-7]). MS (ISP): 512.3 [M+H]+.
- The title compound was prepared in analogy to Example 44, replacing (2-chloro-phenoxy)-acetic acid with 2-(2,4-dichloro-phenoxy)-propionic acid ([CAS RN 120-36-5]). MS (ISP): 546.3 [M+H]+.
- The title compound was prepared in analogy to Example 44, replacing (2-chloro-phenoxy)-acetic acid with 2-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-propionic acid (commercially available from Matrix Scientific, Inc., USA.). MS (ISP): 536.4 [M+H]+.
- The title compound was prepared in analogy to Example 44, replacing (2-chloro-phenoxy)-acetic acid with 3-phenyl-propionic acid ([CAS RN 501-52-0]). MS (ISP): 462.3 [M+H]+.
- The title compound was prepared in analogy to Example 44, replacing (2-chloro-phenoxy)-acetic acid with 4-phenyl-butyric acid ([CAS RN 1821-12-1]). MS (ISP): 476.4 [M+H]+.
- The title compound was prepared in analogy to Example 44, replacing (2-chloro-phenoxy)-acetic acid with succinic acid monobenzyl ester ([CAS RN 103-40-2]). MS (ISP): 519.6 [M+H]+.
- To a solution of di-tert-butyl dicarbonate (14.8 g, 67.8 mmol, 2.0 equiv; [CAS RN 24424-99-5]) and 4-dimethylaminopyridine (0.21 g, 1.7 mmol, 0.05 equiv; DMAP; [CAS RN 1122-58-3]) in THF (100 mL) was added 4,5-difluoro-2-nitro-phenylamine (5.9 g, 33.9 mmol, 1.0 equiv; [CAS RN 78056-39-0]) and the mixture was stirred at rt for 72 h. The solvent was evaporated under reduced pressure and the crude reaction product extracted from a sat. solution of NaHCO3 with ethyl acetate. The organic phases were dried over Na2SO4, the residue taken up in dichloromethane and cooled to 0°C. Trifluoroacetic acid (7.73 g, 67.8 mmol, 2.0 equiv) was added slowly and the reaction mixture stirred at 0° C for 48 h. A solution of 2 N NaOH was added to adjust the pH of the solution to 7. The organic layer was separated and evaporated under reduced pressure. The residue was taken up in ethyl acetate and the product extracted from a sat. solution of NaHCO3, the organic phase dried over Na2SO4 and the intermediate isolated via Kieselgel chromatography. The purified product (4.28 g, 15.6 mmol, 1.0 equiv) was dissolved in DMF (50 mL) and a sat. solution of NH4Cl (13 mL) was added. Zinc powder (5.10 g, 78.0 mmol, 5.0 equiv) was added and the suspension stirred for 30 min at 80 °C and for an additional time period of 2 h at rt. The remaining solid was filtered off and the organic layer evaporated. The product was extracted from a sat. solution of NaHCO3 with ethyl actetate, the organic layer dried over Na2SO4 and the crude reaction product purified via Kieselgel chromatography. 1H NMR (300 MHz, DMSO): δ 1.46 ( s, 9H), 5.03 (br s, 2H), 6.65 (dd, J = 8.2 Hz, J = 12.9 Hz, 1H), 7.30 (dd, J = 8.9 Hz, J = 12.3 Hz, 1H), 8.38 (br s, 1H). MS (ISN): 243.4 [M-H]-.
- To a solution of (2-amino-4,5-difluoro-phenyl)-carbamic acid tert-butyl ester (24.42 mg, 0.10 mmol, 1.0 equiv; Intermediate C) in MeOH (1.0 mL) was added cyclohexanecarbaldehyde (16.83 mg, 18.05 µl, 0.15 mmol, 1.5 equiv; [2043-61-0]) and the mixture stirred at rt. After 30 min, (2-chloro-phenoxy)-acetic acid (18.66 mg, 0.10 mmol, 1.0 equiv; [CAS RN 614-61-9]) and cyclohexyl isocyanide (10.92 mg, 12.27 µl, 0.10 mmol, 1.0 equiv; [931-53-3]) were added and stirring continued at rt for 2 h. A solution of 4 M HCl in dioxane (0.2 mL) was added and the reaction mixture stirred at rt overnight. Removal of the solvent mixture under reduced pressure and purification by preparative HPLC on reversed phase eluting with a gradient of acetonitrile / water provided 17.5 mg (34%) of the title compound. MS (ISP): 516.2 [M+H]+.
- The title compound was prepared in analogy to Example 68, replacing (2-chloro-phenoxy)-acetic acid with (4-fluoro-phenoxy)-acetic acid ([CAS RN 405-79-8]). MS (ISP): 500.2 [M+H]+.
- The title compound was prepared in analogy to Example 68, replacing (2-chloro-phenoxy)-acetic acid with phenoxy-acetic acid ([CAS RN 122-59-8]). MS (ISP): 482.3 [M+H]+.
- The title compound was prepared in analogy to Example 68, replacing (2-chloro-phenoxy)-acetic acid with m-tolyloxy-acetic acid ([CAS RN 1643-15-8]). MS (ISP): 496.2 [M+H]+.
- The title compound was prepared in analogy to Example 68, replacing (2-chloro-phenoxy)-acetic acid with o-tolyloxy-acetic acid ([CAS RN 1878-49-5]). MS (ISP): 496.2 [M+H]+.
- The title compound was prepared in analogy to Example 68, replacing (2-chloro-phenoxy)-acetic acid with (2,4-dimethyl-phenoxy)-acetic acid ([CAS RN 13334-49-1]). MS (ISP): 510.3 [M+H]+.
- The title compound was prepared in analogy to Example 68, replacing (2-chloro-phenoxy)-acetic acid with (4-ethyl-phenoxy)-acetic acid ([CAS RN 24431-27-4]). MS (ISP): 510.3 [M+H]+.
- The title compound was prepared in analogy to Example 68, replacing (2-chloro-phenoxy)-acetic acid with (4-methoxy-phenoxy)-acetic acid ([CAS RN 1877-75-4]). MS (ISP): 512.3 [M+H]+.
- The title compound was prepared in analogy to Example 68, replacing (2-chloro-phenoxy)-acetic acid with (3-methoxy-phenoxy)-acetic acid ([CAS RN 2088-24-6]). MS (ISP): 512.2 [M+H]+.
- The title compound was prepared in analogy to Example 68, replacing (2-chloro-phenoxy)-acetic acid with (4-hydroxymethyl-3-methoxy-phenoxy)-acetic acid ([CAS RN 83590-77-6]). MS (ISP): 542.2 [M+H]+.
- The title compound was prepared in analogy to Example 68, replacing (2-chloro-phenoxy)-acetic acid with (4-chloro-2-methyl-phenoxy)-acetic acid ([CAS RN 94-74-6]), cyclohexanecarbaldehyde with tetrahydro-pyran-2-carbaldehyde ([CAS RN 19611-45-1]) and cyclohexyl isocyanide with cyclopentyl isocyanide ([CAS RN 68498-54-4]). MS (ISP): 518.3 [M+H]+.
- The title compound was prepared in analogy to Example 68, replacing (2-chloro-phenoxy)-acetic acid with ethoxy-acetic acid ([CAS RN 627-03-2]). MS (ISP): 434.4 [M+H]+.
- The title compound was prepared in analogy to Example 68, replacing (2-chloro-phenoxy)-acetic acid with butoxy-acetic acid ([CAS RN 2516-93-0]). MS (ISP): 462.3 [M+H]+.
- The title compound was prepared in analogy to Example 68, replacing (2-chloro-phenoxy)-acetic acid with 2-(2-chloro-phenoxy)-propionic acid ([CAS RN 25140-86-7]). MS (ISP): 530.1 [M+H]+.
- The title compound was prepared in analogy to Example 68, replacing (2-chloro-phenoxy)-acetic acid with 2-(2,4-dichloro-phenoxy)-propionic acid ([CAS RN 120-36-5]). MS (ISP): 564.3 [M+H]+.
- The title compound was prepared in analogy to Example 68, replacing (2-chloro-phenoxy)-acetic acid with 2-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-propionic acid (commercially available from Matrix Scientific, Inc., USA.). MS (ISP): 554.3 [M+H]+.
- The title compound was prepared in analogy to Example 68, replacing (2-chloro-phenoxy)-acetic acid with 3-phenyl-propionic acid ([CAS RN 501-52-0]). MS (ISP): 480.4 [M+H]+.
- The title compound was prepared in analogy to Example 68, replacing (2-chloro-phenoxy)-acetic acid with 4-phenyl-butyric acid ([CAS RN 1821-12-1]). MS (ISP): 494.4 [M+H]+.
- (2-Amino-4-chloro-5-fluoro-phenyl)-carbamic acid tert-butyl ester [CAS RN 579474-50-3] (Intermediate D) was prepared as described in
WO 03 / 066 623 A1 - To a solution of (2-amino-4-chloro-5-fluoro-phenyl)-carbamic acid tert-butyl ester (26.07 mg, 0.10 mmol, 1.0 equiv; Intermediate D) in MeOH (1.0 mL) was added cyclohexanecarbaldehyde (16.83 mg, 18.05 µl, 0.15 mmol, 1.5 equiv; [2043-61-0]) and the mixture stirred at rt. After 30 min, (4-chloro-phenoxy)-acetic acid (18.66 mg, 0.10 mmol, 1.0 equiv; [CAS RN 122-88-3]) and cyclohexyl isocyanide (10.92 mg, 12.27 µl, 0.10 mmol, 1.0 equiv; [931-53-3]) were added and stirring continued at rt for 2 h. A solution of 4 M HCl in dioxane (0.2 mL) was added and the reaction mixture stirred at rt overnight. Removal of the solvent mixture under reduced pressure and purification by preparative HPLC on reversed phase eluting with a gradient of acetonitrile / water provided 19.6 mg (37%) of the title compound. MS (ISP): 532.3 [M+H]+.
- The title compound was prepared in analogy to Example 86, replacing (4-chloro-phenoxy)-acetic acid with 2-(4-chloro-phenoxy)-propionic acid ([CAS RN 3307-39-9]). MS (ISP): 546.3 [M+H]+.
- The title compound was prepared in analogy to Example 86, replacing (4-chloro-phenoxy)-acetic acid with 2-(3-chloro-phenoxy)-propionic acid ([CAS RN 101-10-0]). MS (ISP): 546.3 [M+H]+.
- The title compound was prepared in analogy to Example 86, replacing (4-chloro-phenoxy)-acetic acid with 2-phenoxy-butyric acid ([CAS RN 13794-14-4]). MS (ISP): 526.3 [M+H]+.
- The title compound was prepared in analogy to Example 86, replacing (4-chloro-phenoxy)-acetic acid with (3,4-dimethoxy-phenylsulfanyl)-acetic acid ([CAS RN 95735-63-0]). MS (ISP): 574.3 [M+H]+.
- The title compound was prepared in analogy to Example 86, replacing (4-chloro-phenoxy)-acetic acid with (4-fluoro-phenylsulfanyl)-acetic acid ([CAS RN 332-51-4]). MS (ISP): 532.3 [M+H]+.
- The title compound was prepared in analogy to Example 86, replacing (4-chloro-phenoxy)-acetic acid with (2,4-dichloro-phenylsulfanyl)-acetic acid ([CAS RN 7720-41-4]). MS (ISP): 584.3 [M+H]+.
- The title compound was prepared in analogy to Example 86, replacing (4-chloro-phenoxy)-acetic acid with (4-trifluoromethyl-phenylsulfanyl)-acetic acid ([CAS RN 102582-93-4]). MS (ISP): 582.3 [M+H]+.
- The title compound was prepared in analogy to Example 86, replacing (4-chloro-phenoxy)-acetic acid with (8-chloro-naphthalen-1-ylsulfanyl)-acetic acid ([CAS RN 129-94-2]). MS (ISP): 598.5 [M+H]+.
- The title compound was prepared in analogy to Example 86, replacing (4-chloro-phenoxy)-acetic acid with benzenesulfinyl-acetic acid ([CAS RN 3959-08-8]). MS (ISP): 530.3 [M+H]+.
- The title compound was prepared in analogy to Example 86, replacing (4-chloro-phenoxy)-acetic acid with 3-(3-isopropoxy-isoxazol-5-yl)-propionic acid ([CAS RN 882624-61-5]). MS (ISP): 545.3 [M+H]+.
- Film coated tablets containing the following ingredients can be manufactured in a conventional manner:
Ingredients Per tablet Kernel: Compound of formula (I) 10.0 mg 200.0 mg Microcrystalline cellulose 23.5 mg 43.5 mg Lactose hydrous 60.0 mg 70.0 mg Povidone K30 12.5 mg 15.0 mg Sodium starch glycolate 12.5 mg 17.0 mg Magnesium stearate 1.5 mg 4.5 mg (Kernel Weight) 120.0 mg 350.0 mg Film Coat: Hydroxypropyl methyl cellulose 3.5 mg 7.0 mg Polyethylene glycol 6000 0.8 mg 1.6 mg Talc 1.3 mg 2.6 mg Iron oxyde (yellow) 0.8 mg 1.6 mg Titan dioxide 0.8 mg 1.6 mg - The active ingredient is sieved and mixed with microcristalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidon in water. The granulate is mixed with sodium starch glycolate and magesiumstearate and compressed to yield kernels of 120 or 350 mg respectively. The kernels are lacquered with an aqueous solution / suspension of the above mentioned film coat.
- Capsules containing the following ingredients can be manufactured in a conventional manner:
Ingredients Per capsule Compound of formula (1) 25.0 mg Lactose 150.0 mg Maize starch 20.0 mg Talc 5.0 mg - Injection solutions can have the following composition:
Compound of formula (I) 3.0 mg Polyethylene Glycol 400 150.0 mg Acetic Acid q.s. ad pH 5.0 Water for injection solutions ad 1.0 ml - The active ingredient is dissolved in a mixture of Polyethylene Glycol 400 and water for injection (part). The pH is adjusted to 5.0 by Acetic Acid. The volume is adjusted to 1.0 ml by addition of the residual amount of water. The solution is filtered, filled into vials using an appropriate overage and sterilized.
- Soft gelatine capsules containing the following ingredients can be manufactured in a conventional manner:
-
Compound of formula (I) 5.0 mg Yellow wax 8.0 mg Hydrogenated Soya bean oil 8.0 mg Partially hydrogenated plant oils 34.0 mg Soya bean oil 110.0 mg Weight of capsule contents 165.0 mg Gelatin capsule Gelatin 75.0 mg Glycerol 85 % 32.0 mg Karion 83 8.0 mg (dry matter) Titan dioxide 0.4 mg Iron oxide yellow 1.1 mg - The active ingredient is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size. The filled soft gelatin capsules are treated according to the usual procedures.
- Sachets containing the following ingredients can be manufactured in a conventional manner:
Compound of formula (I) 50.0 mg Lactose, fine powder 1015.0 mg Microcristalline cellulose (AVICEL PH 102) 1400.0 mg Sodium carboxymethyl cellulose 14.0 mg Potyvinylpyrrolidon K 30 10.0 mg Magnesiumstearate 10.0 mg Flavoring additives 1.0 mg - The active ingredient is mixed with lactose, microcristalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidon in water. The granulate is mixed with magnesiumstearate and the flavouring additives and filled into sachets.
wherein
the term "lower" refers to a group consisting of one to seven carbon atoms;
"cycloalkyl" is a monovalent carbocyclic radical of 3 to 10 carbon atoms;
"aryl is the phenyl or naphthyl group;
"heteroaryl" is an aromatic 5 to 6 membered monocyclic ring or 9 to 10 membered bicyclic ring which comprises 1, 2 or 3 atoms selected from nitrogen, oxygen and/or sulphur; and
"heterocyclyl" is a 5 to 6 membered monocyclic ring or 8 to 10 membered bi- or tricyclic ring which comprises 1, 2 or 3 atoms selected from nitrogen, oxygen and/or sulphur.
wherein
the term "lower" refers to a group consisting of one to seven carbon atoms;
"cycloalkyl" is a monovalent carbocyclic radical of 3 to 10 carbon atoms;
"aryl is the phenyl or naphthyl group;
"heteroaryl" is an aromatic 5 to 6 membered monocyclic ring or 9 to 10 membered bicyclic ring which comprises 1, 2 or 3 atoms selected from nitrogen, oxygen and/or sulphur; and
"heterocyclyl" is a 5 to 6 membered monocyclic ring or 8 to 10 membered bi- or tricyclic ring which comprises 1, 2 or 3 atoms selected from nitrogen, oxygen and/or sulphur.
Claims (27)
- Compounds of formula (I)X is -O-, -S-, -S(O)-, -S(O2)-, -C(R11R12)- or -C(R11R12)-C(O)O-;R1 is lower-alkyl, cycloalkyl, cycloalkyl-lower-alkyl, heterocyclyl or heterocyclyl-lower-alkyl, wherein a lower-alkyl, cycloalkyl or heterocyclyl can optionally be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, lower-alkyl, lower-alkoxy, fluoro-lower-alkyl and fluoro-lower-alkoxy;R2 is hydrogen or lower-alkyl;R3 is cycloalkyl, cycloalkyl-lower-alkyl, heterocyclyl or heterocyclyl-lower-alkyl, wherein a cycloalkyl or heterocyclyl can optionally be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, lower-alkyl, lower-alkoxy, fluoro-lower-alkyl and fluoro-lower-alkoxy;R4 is lower-alkyl, cycloalkyl, cycloalkyl-lower-alkyl, aryl, aryl-lower-alkyl, heteroaryl, heteroaryl-lower-alkyl, heterocyclyl or heterocyclyl-lower-alkyl, wherein a lower-alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl can optionally be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, hydroxy, lower-alkyl, hydroxy-lower-alkyl, lower-alkyl-O-lower-alkyl-O-lower-alkyl, fluoro-lower-alkyl, lower-alkyl-carbonyl, lower-alkoxy, fluoro-lower-alkoxy and dioxo-lower-alkylene;R5, R6, R7 and R8 independently from each other are hydrogen, halogen, lower-alkyl, lower-alkoxy, fluoro-lower-alkyl, fluoro-lower-alkoxy, cycloalkyl-oxy or heterocyclyl-oxy;R9 and R10 independently from each other are hydrogen or lower-alkyl, or R9 and R10 are bound together to form a cycloalkyl or heterocyclyl together with the carbon atom to which they are attached;R11 and R12 independently from each other are hydrogen or lower-alkyl, or R11 and R12 are bound together, to form a cycloalkyl or heterocyclyl together with the carbon atom to which they are attached;and pharmaceutically acceptable salts and esters thereof;
wherein
the term "lower" refers to a group consisting of one to seven carbon atoms; "cycloalkyl" is a monovalent carbocyclic radical of 3 to 10 carbon atoms;
"aryl is the phenyl or naphthyl group;
"heteroaryl" is an aromatic 5 to 6 membered monocyclic ring or 9 to 10 membered bicyclic ring which comprises 1, 2 or 3 atoms selected from nitrogen, oxygen and/or sulphur; and
"heterocyclyl" is a 5 to 6 membered monocyclic ring or 8 to 10 membered bi- or tricyclic ring which comprises 1,2 or 3 atoms selected from nitrogen, oxygen and/or sulphur. - Compounds according to claim 1, wherein X is -O-, -S-, -S(O)-, - C(R11R12)- or -C(R11R12)-C(O)O-, wherein R11 and R12 are as defined in claim 1.
- Compounds according to any of claims 1 - 2, wherein X is -O-, -S- or -C(R11R12)-, wherein R11 and R12 are as defined in claim 1.
- Compounds according to any of claims 1-3, wherein X is -CH2-O-, -CH(CH3)-O-, -CH2-S-or -CH2-CH2-.
- Compounds according to any of claims 1-4, wherein R1 is cycloalkyl.
- Compounds according to any of claims 1-5, wherein R1 is cyclohexyl.
- Compounds according to any of claims 1-6, wherein R2 is hydrogen.
- Compounds according to any of claims 1 - 7, wherein R3 is cycloalkyl or heterocyclyl.
- Compounds according to any of claims 1-8, wherein R3 is cycloalkyl.
- Compounds according to any of claims 1 - 9, wherein R3 is cyclohexyl.
- Compounds according to any of claims 1-10, wherein R4 is lower-alkyl, lower-alkyl-O-lower-alkyl-O-lower-alkyl, aryl, aryl-lower-alkyl or a heteroaryl selected from the group consisting of pyridinyl and isoxazolyl, wherein an aryl or heteroaryl can optionally be substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxy, lower-alkyl, hydroxy-lower-alkyl, fluoro-lower-alkyl, lower-alkyl-carbonyl, lower-alkoxy, fluoro-lower-alkoxy and dioxo-lower-alkylcne.
- Compounds according to any of claims 1-11, wherein R4 is phenyl or pyridinyl, which phenyl can optionally be substituted with 1 to 2 substituents independently selected from the group consisting of halogen, lower-alkyl and lower-alkoxy.
- Compounds according to any of claims 1 - 12, wherein R4 is 4-chloro-2-methyl-phenyl, 2-chloro-phenyl, 4-ethyl-phenyl, 2,4-dichloro-phenyl, phenyl, 4-methoxy-phenyl, 4-fluoro-phenyl or pyridine-2-yl.
- Compounds according to any of claims 1 - 13, wherein R5, R6, R7 and R8 independently from each other are hydrogen or halogen.
- Compounds according to any of claims 1 - 14, wherein R5 is hydrogen.
- Compounds according to any of claims 1-15, wherein R6 is hydrogen or fluoro.
- Compounds according to any of claims 1-16, wherein R7 is hydrogen, fluoro or chloro.
- Compounds according to any of claims 1-17, wherein R8 is hydrogen.
- Compounds according to any of claims 1 - 18, wherein R9 and R10 independently from each other are hydrogen or lower-alkyl.
- Compounds according to any of claims 1-19, wherein R9 and R10 independently from each other are hydrogen or methyl.
- Compounds according to any of claims 1 - 20, wherein R11 and R12 are hydrogen.
- Compounds according to any of claims 1-21, selected from the group consisting of2- [2-(4-Chloro-2-methyl-phenoacymethyl)-6-fluoro-benzoimidazol-1-yl] -2,N-dicyclohexyl-acetamide,2,N-Dicyclohexyl-2-[6-fluoro-2-(4-hydroxymethyl-phenoxymethyl)-benzoimidazol-1-yl]-acetamide,2-[2-(4-Chloro-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-2,N-dicyclohxyl-acetamide,2-[2-(2-Chloro-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,2,N-Dicyclohexyl-2-(6-fluoro-2-m-tolyloxymethyl-benzoimidazol-1-yl)-acetamide,2,N-Dicyclohexyl-2-[6-fluoro-2-(2-methoxy-phenoxymethyl)-benzoimidazol-1-yl]-acetamide,2,N-Dicyclohexyl-2-(6-fluoro-2-o-tolyloxymethyl-benzoimidazol-1-yl)-acetamide,2,N-Dicyclohexyl-2-[2-(2,4-dimethyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-acetamide,2,N-Dicyclohexyl-2-[2-(2,5-dimethyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-acetamide,2-[2-(4-Chloro-2-methyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,2-[2-(4-Acetyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,2,N-Dicyclohexyl-2-[2-(4-ethyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-acetamide,2,N-Dicydohexyl-2-[2-(2,3-dimethyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-acetamide,2-[2-(2-Chloro-6-methyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,2,N-Dicyclohexyl-2-[2-(2,4-dichloro-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-acetamide,2-[2-(4-Chloro-2-methyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-2-cycloheptyl-N-cyclohexyl-acetamide,2-[2-(4-Chloro-2-methyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-2-cycloheptyl-N-cyclopentyl-acetamide,2-[2-(4-Chloro-2-methyl-phenomethyl)-6-fluoro-benzoimidazol-1-yl]-N-cyclopentyl-2-(tetrahydro-pyran-3-yl)-acetamide,(S)-2-[2-(4-Chloro-2-methyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,(R)-2-[2-(4-Chloro-2-methyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,2-(2-Benzyloxymethyl-6-fluoro-benzoimidazol-1-yl)-2,N-dicyclohexyl-acetamide,2-(2-Butoxymethyl-6-fluoro-benzoimidazol-1-yl)-2,N-dicyclohexyl-acetamide,2,N-Dicyclohexyl-2-{6-fluoro-2-[1-(4-trifluoromethoxy-phenoxy)-ethyl]-benzoimidazol-1-yl}-acetamide,2-{2-[1-(2-Chloro-phenoxy)-ethyl]-6-fluoro-benzoimidazol-1-yl}-2,N-dicyclohexyl-acetamide,2,N-Dicyclohexyl-2-{2-[1-(2,4-dichloro-phenoxy)-ethyl]-6-fluoro-benzoimidazol-1-yl}-acetamide,2,N-Dicyclohexyl-2-{2-[1-(2,3-dihydro-benzo[1,4] dioxin-6-yloxy)-ethyl] -6-fluoro-benzoimidazol-1-yl}-acetamide,2-{2-[1-(3-Chloro-phenoxy)-ethyl]-6-fluoro-benzoimidazol-1-yl}-2,N-dicyclohexyl-acetamide,2-{2-[1-(4-Chloro-phenoxy)-ethyl]-6-fluoro-benzoimidazol-1-yl}-2,N-dicyclohexyl-acetamide,2-{2-[1-(4-Chloro-2-methyl-phenoxy)-ethyl]-6-fluoro-benzoimidazol-1-yl}-2,N-dicyclohexyl-acetamide,(S)-2-(2-[(S)-1-(4-Chloro-2-methyl-phenoxy)-ethyl]-6-fluoro-benzoimidazol-1-yl}-2,N-dicyclohexyl-acetamide,(S)-2-{2-[(R)-1-(4-Chloro-2-methyl-phenoxy)-ethyl]-6-fluoro-benzoimidazol-1-yl}-2,N-dicyclohexyl-acetamide,2,N-Dicyclohexyl-2- [6-fluoro-2-(1-phenoxy-propyl)-benzoimidazol-1-yl] -acetamide,2-{2-[1-(4-Chloro-phenoxy)-1-methyl-ethyl] -6-fluoro-benzoimidazol-1-yl}-2,N-dicyclohexyl-acetamide,2,N-Dicyclohexyl-2-[2-(2,4-dichloro-phenylsulfanylmethyl)-6-fluoro-benzoimidazol-1-yl]-acetamide,2,N-Dicyclohexyl-2-[2-(2,6-dichloro-phenylsulfanylmethyl)-6-fluoro-benzoimidazol-1-yl]-acetamide,2,N-Dicydohexyl-2-[6-fluoro-2-(naphthalen-1-ylsulfanylmethyl)-benzoimidazol-1-yl]-acetamide,2-(2-Benzenesulfinylmethyl-6-fluoro-benzoimidazol-1-yl)-2,N-dicyclohexyl-acetamide,2-(2-Benzenesulfinylmethyl-benzoimidazol-1-yl)-2,N-dicyclohexyl-acetamide,2,N-Dicycloheyl-2-{2-[2-(3,4-dimethoxy-phenyl)-ethyl]-6-fluoro-benzoimidazol-1-yl}-acetamide,2,N-Dicyclohexyl-2-{6-fluoro-2-[2-(4-methoxy-phenyl)-ethyl]-benzoimidazol-1-yl}-acetamide,2-{2-[2-(4-Chloro-phenyl)-ethyl]-6-fluoro-benzoimidazol-1-yl}-2,N-dicyclohexyl-acetamide,2,N-Dicyclohexyl-2-{6-fluoro-2- [2-(4-fluoro-phenyl)-ethyl]-benzoimidazol-1-yl}-acetamide,2-[2-(2-Benzo[1,3]dioxol-5-yl-ethyl)-6-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,2-[2-(2-Chloro-phenoxymethyl)-5-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,2,N-Dicyclohexyl-2-(5-fluoro-2-o-tolyloxymethyl-benzoimidazol-1-yl)-acetamide,2,N-Dicyclohexyl-2-(5-fluoro-2-m-tolyloxymethyl-benzoimidazol-1-yl)-acetamide,2,N-Dicyclohexyl-2-(5-fluoro-2-p-tolyloxymethyl-benzoimidazol-1-yl)-acetamide,2,N-Dicyclohexyl-2-[5-fluoro-2-(4-fluoro-phenoxymethyl)-benzoimidazol-1-yl]-acetamide,2,N-Dicydohexyl-2-[2-(2,3-dimethyl-phenoxymethyl)-5-fluoro-benzoimidazol-1-yl]-acetamide,2,N-Dicyclohexyl-2-[2-(3,4-dimethyl-phenoxymethyl)-5-fluoro-benzoimidazol-1-yl]-acetamide,2,N-Dicyclohexyl-2-[2-(2,4-dimethyl-phenoxymethyl)-5-fluoro-benzoimidazol-1-yl]-acetamide,2,N-Dicydohexyl-2-[2-(2,5-dimethyl-phenoxymethyl)-5-fluoro-benzoimidazol-1-yl]-acetamide,2-[2-(2-Chtoro-6-methyl-phenoxymethyl)-5-fluoro-benzoimidazol-l-yt]-2,N-dicyclohexyl-acetamide,2,N-Dicyclohexyl-2-[5-fluoro-2-(2-methoxy-phenoxymethyl)-benzoimidazol-1-yl]-acetamide,2,N-Dicyclohexyl-2-[S-fluoro-2-(4-methoxy-phenoxymethyl)-benzoimidazol-1-yl]-acetamide,2,N-Dicyclohexyl-2-[5-fluoro-2-(pyridin-2-yloxymethyl)-benzoimidazol-1-yl]-acetamide,2-[2-(4-Chloro-2-methyl-phenoxymethyl)-5-fluoro-benzoimidazol-1-yl]-2-cycloheptyl-N-cyclohexyl-acetamide,2-[2-(4-Chloro-2-methyl-phenoxymethyl)-5-fluoro-benzoimidazol-1-yl]-2-cycloheptyl-N-cyclopentyl-acetamide,2,N-Dicyclohexyl-2-(2-ethoxymethyl-5-fluoro-benzoimidazol-1-yl)-acetamide,2,N-Dicyclohexyl-2-{5-fluoro-2-[2-(2-methoxy-ethoxy)-ethoxymethyl]-benzoimidazol-1-yl}-acetamide,2,N-Dicyclohexyl-2-{5-fluoro-2-[2-(2-methoxy-ethoxy)-ethoxymethyl]-benzoimidazol-1-yl}-acetamide,2-{2-[1-(2-Chloro-phenoxy)-ethyl]-5-fluoro-benzoimidazol-1-yl}-2,N-dicyclohexyl-acetamide,2,N-Dicyclohexyl-2-{2-[1-(2,4-dichloro-phenoxy)-ethyl]-5-fluoro-benzoimidazol-1-yl}-acetamide,2,N-Dicyclohexyl-2-{2-[1-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-ethyl]-5-fluoro-benzoimidazol-1-yl}-acetamide,2,N-Dicyclohexyl-2-(5-fluoro-2-phenethyl-benzoimidazol-1-yl)-acetamide,2,N-Dicyclohexyl-2-[5-fluoro-2-(3-phenyl-propyl)-benzoimidazol-1-yl]-acetamide,3-[1-(Cydohexyl-cydohexylcarbamoyl-methyl)-5-fluoro-1H-benzoimidazol-2-yl]-propionic acid benzyl ester,2-[2-(2-Chloro-phenoxymethyl)-5,6-difluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,2,N-Dicyclohexyl-2-[5,6-difluoro-2-(4-fluoro-phenoxymethyl)-benzoimidazol-1-yl]-acetamide,2,N-Dicyclohexyl-2-(5,6-difluoro-2-phenoxymethyl-benzoimidazol-1-yl)-acetamide,2,N-Dicyclohexyl-2-(5,6-difluoro-2-m-tolyloxymethyl-benzoimidazol-1-yl)-acetamide,2,N-Dicyclohexyl-2-(5,6-difluoro-2-o-tolyloxymethyl-benzoimidazol-1-yl)-acetamide,2,N-Dicydohexyl-2-[2-(2,4-dimethyl-phenoxymethyl)-5,6-difluoro-benzoimidazol-1-yl]-acetamide,2,N-Dicyclohexyl-2-[2-(4-ethyl-phenoxymethyl)-5,6-difluoro-benzoimidazol-1-yl]-acetamide,2,N-Dicyclohexyl-2-[5,6-difluoro-2-(4-methoxy-phenoxymethyl)-benzoimidazol-1-yl]-acetamide,2,N-Dicydohexyl-2-[5,6-difluoro-2-(3-methoxy-phenoxymethyl)-benzoimidazol-1-yl]-acetamide,2,N-Dicyclohexyl-2-[5,6-difluoro-2-(4-hydroxymethyl-3-methoxy-phenoxymethyl)-benzoimidazol-1-yl] -acetamide,2-[2-(4-Chloro-2-methyl-phenoxymethyl)-5,6-difluoro-benzoimidazol-1-yl]-N-cyclopentyl-2-(tetrahydro-pyran-2-yl)-acetamide,2,N-Dicyclohexyl-2-(2-ethoxymethyl-5,6-difluoro-benzoimidazol-1-yl)-acetamide,2-(2-Butoxymethyl-5,6-difluoro-benzoimidazol-1-yl)-2,N-dicyclohexyl-acetamide,2-{2-[1-(2-Chloro-phenoxy)-ethyl]-5,6-difluoro-benzoimidazol-1-yl}-2,N-dicyclohexyl-acetamide,2,N-Dicyclohexyl-2-{2-[1-(2,4-dichloro-phenoxy)-ethyl]-5,6-difluoro-benzoimidazol-1-yl}-acetamide,2,N-Dicyclohexyl-2-{2-[1-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-ethyl] -5,6-difluoro-benzoimidazol-1-yl}-acetamide,2,N-Dicydohexyl-2-(5,6-difluoro-2-phenethyl-benzoimidazol-1-yl)-acetamide,2,N-Dicyclohexyl-2-[5,6-difluoro-2-(3-phenyl-propyl)-benzoimidazol-1-yl]-acetamide,2-[6-Chloro-2-(4-chloro-phenoxymethyl)-5-fluoro-benzoimidazol-1-yl]-2,N dicyclohexyl-acetamide,2-{6-Chloro-2-[1-(4-chloro-phenoxy)-ethyl]-5-fluoro-benzoimidazol-1-yl}-2,N dicyclohexyl-acetamide,2-{6-Chloro-2-[1-(3-chloro-phenoxy)-ethyl]-5-fluoro-benzoimidazol-1-yl}-2,N-dicyclohexyl-acetamide,2- [6-Chloro-5-fluoro-2-(1-phenoxy-propyl)-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,2-[6-Chloro-2-(3,4-dimethoxy-phenylsulfanylmethyl)-5-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,2-[6-Chloro-5-fluoro-2-(4-fluoro-phenylsulfanylmethyl)-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,2-[6-Chloro-2-(2,4-dichloro-phenylsulfanylmethyl)-5-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,2-[6-Chloro-5-fluoro-2-(4-trifluoromethyl-phenylsulfanylmethyl)-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,2- [6-Chloro-2-(8-chloro-naphthalen-1-ylsulfanylmethyl)-5-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,2-(2-Benzenesulfinylmethyl-6-chloro-5-fluoro-benzoimidazol-1-yl)-2,N-dicyclohexyl-acetamide, and2-{6-Chloro-5-fluoro-2-[2-(3-isopropoxy-isoxazol-5-yl)-ethyl]-benzoimidazol-1-yl}-2,N-dicyclohexyl-acetamide,and pharmaceutically acceptable salts and esters thereof.
- Compounds according to any of claims 1 - 22, selected from the group consisting of(S)-2-[2-(4-Chloro-2-methyl-phenoxymethyl)-6-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,2-{2-[1-(4-Chloro-2-methyl-phenoxy)-ethyl]-6-fluoro-benzoimidazol-1-yl}-2,N-dicyclohexyl-acetamide,2-[2-(2-Chloro-phenoxymethyl)-5-fluoro-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,2,N-Dicyclohexyl-2- [5-fluoro-2-(4-methoxy-phenoxymethyl)-benzoimidazol-1-yl]-acetamide,2,N-Dicyclohexyl-2-[5-fluoro-2-(pyridin-2-yloxymethyl)-benzoimidazol-1-yl]-acetamide,2,N-Dicyclohexyl-2-(5-fluoro-2-phenethyl-benzoimidazol-1-yl)-acetamide,2,N-Dicyclohexyl-2-(5,6-difluoro-2-phenoxymethyl-benzoimidazol-1-yl)-acetamide,2,N-Dicyclohexyl-2-[2-(4-ethyl-phenoxymethyl)-5,6-difluoro-benzoimidazol-1-yl]-acetamide,2,N-Dicyclohexyl-2-{2-[1-(2,4-dichloro-phenoxy)-ethyl]-5,6-difluoro-benzoimidazol-1-yl}-acetamide, and2-[6-Chloro-5-fluoro-2-(4-fluoro-phenylsulfanylmethyl)-benzoimidazol-1-yl]-2,N-dicyclohexyl-acetamide,and pharmaceutically acceptable salts and esters thereof.
- A process for the manufacture of compounds of formula (I) as defined in any of claims 1 - 23, which process comprises
- Pharmaceutical compositions comprising a compound according to any of claims 1 - 23 and a pharmaceutically acceptable carrier and/or adjuvant.
- Compounds according to any of claims 1 - 23 for use as therapeutic active substances.
- The use of compounds according to any of claims 1 - 23 for the preparation of medicaments for the therapeutic and/or prophylactic treatment of increased lipid and cholesterol levels, high LDL-cholesterol, high triglycerides, low HDL-cholesterol, dyslipidemia, atherosclerotic disease, diabetes, non-insulin dependent diabetes mellitus, metabolic syndrome, cholesterol gallstone disease, cholestasis/fibrosis of the liver, diseases of cholesterol absorption, cancer, gastrointestinal cancer, osteoporosis, peripheral occlusive disease, ischemic stroke, Parkinson's disease and/or Alzheimer's disease.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08787302A EP2188263B1 (en) | 2007-08-27 | 2008-08-19 | Benzimidazole derivatives used as fxr agonists |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07115005 | 2007-08-27 | ||
PCT/EP2008/060820 WO2009027264A1 (en) | 2007-08-27 | 2008-08-19 | Benzimidazole derivatives used as fxr agonists |
EP08787302A EP2188263B1 (en) | 2007-08-27 | 2008-08-19 | Benzimidazole derivatives used as fxr agonists |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2188263A1 EP2188263A1 (en) | 2010-05-26 |
EP2188263B1 true EP2188263B1 (en) | 2012-06-27 |
Family
ID=39967744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08787302A Not-in-force EP2188263B1 (en) | 2007-08-27 | 2008-08-19 | Benzimidazole derivatives used as fxr agonists |
Country Status (15)
Country | Link |
---|---|
US (1) | US7790904B2 (en) |
EP (1) | EP2188263B1 (en) |
JP (1) | JP5204232B2 (en) |
KR (1) | KR101237577B1 (en) |
CN (1) | CN102083799B (en) |
AR (1) | AR070648A1 (en) |
AU (1) | AU2008291148B2 (en) |
BR (1) | BRPI0815696A2 (en) |
CA (1) | CA2697167C (en) |
CL (1) | CL2008002506A1 (en) |
ES (1) | ES2387230T3 (en) |
MX (1) | MX2010002341A (en) |
PE (1) | PE20090622A1 (en) |
TW (1) | TW200916099A (en) |
WO (1) | WO2009027264A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2222645B1 (en) * | 2007-11-15 | 2013-03-20 | F. Hoffmann-La Roche AG | Benzimidazole derivatives and their use as fxr agonists |
CN102149688B (en) * | 2008-09-11 | 2014-11-19 | 霍夫曼-拉罗奇有限公司 | New benzimidazole derivatives |
US8309581B2 (en) * | 2009-09-29 | 2012-11-13 | Hoffmann-La Roche Inc. | Benzimidazole derivatives |
WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
LT3043865T (en) | 2013-09-11 | 2021-04-26 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection |
CN106632065B (en) * | 2016-12-06 | 2019-08-30 | 沈阳药科大学 | Benzimidazoles compound and its application |
CN106905241B (en) * | 2017-02-14 | 2020-03-17 | 沈阳药科大学 | 1, 2-disubstituted benzimidazole derivative and application thereof |
CA3051776A1 (en) | 2017-02-21 | 2018-08-30 | Genfit | Combination therapy |
CN110944635A (en) | 2017-03-30 | 2020-03-31 | 国家医疗保健研究所 | Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses |
MX2022000742A (en) | 2019-07-18 | 2022-02-14 | Enyo Pharma | Method for decreasing adverse-effects of interferon. |
KR20220128402A (en) | 2020-01-15 | 2022-09-20 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | Use of an FXR agonist to treat infection by hepatitis D virus |
CN111793034B (en) * | 2020-07-24 | 2021-11-19 | 华中科技大学 | Benzimidazole salt derivative and application thereof in preparing antitumor drugs |
JP2024502673A (en) | 2021-01-14 | 2024-01-22 | ウエヌイグレックオ・ファーマ | Synergistic effect of FXR agonist and IFN for treatment of HBV infection |
TW202308629A (en) | 2021-04-28 | 2023-03-01 | 法商Enyo製藥公司 | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2829765A1 (en) * | 2001-09-14 | 2003-03-21 | Lipha | Use of new and known benzimidazolyl alkoxyaryl alkanoic acid derivatives for treating pathologies associated with insulin resistance or hyperglycemia |
MXPA04007697A (en) * | 2002-02-06 | 2004-11-10 | Vertex Pharma | Heteroaryl compounds useful as inhibitors of gsk-3. |
US6949542B2 (en) | 2002-02-06 | 2005-09-27 | Hoffman-La Roche Inc. | Dihydro-benzo[b][1,4]diazepin-2-one derivatives |
CN1816530A (en) * | 2003-07-01 | 2006-08-09 | 麦克公司 | Opthalmic compositions for treating ocular hypertension |
BRPI0713946A2 (en) * | 2006-06-29 | 2012-12-04 | Hoffmann La Roche | compounds, pharmaceutical compositions comprising them, method for the therapeutic and / or prophylactic treatment of diseases that are modulated by fxr agonists, and use of the compounds |
-
2008
- 2008-08-19 MX MX2010002341A patent/MX2010002341A/en active IP Right Grant
- 2008-08-19 BR BRPI0815696A patent/BRPI0815696A2/en not_active IP Right Cessation
- 2008-08-19 CA CA2697167A patent/CA2697167C/en not_active Expired - Fee Related
- 2008-08-19 CN CN2008801044809A patent/CN102083799B/en not_active Expired - Fee Related
- 2008-08-19 EP EP08787302A patent/EP2188263B1/en not_active Not-in-force
- 2008-08-19 ES ES08787302T patent/ES2387230T3/en active Active
- 2008-08-19 AU AU2008291148A patent/AU2008291148B2/en not_active Ceased
- 2008-08-19 KR KR1020107006719A patent/KR101237577B1/en not_active IP Right Cessation
- 2008-08-19 WO PCT/EP2008/060820 patent/WO2009027264A1/en active Application Filing
- 2008-08-19 JP JP2010522312A patent/JP5204232B2/en not_active Expired - Fee Related
- 2008-08-22 US US12/196,355 patent/US7790904B2/en not_active Expired - Fee Related
- 2008-08-25 AR ARP080103690A patent/AR070648A1/en not_active Application Discontinuation
- 2008-08-26 CL CL2008002506A patent/CL2008002506A1/en unknown
- 2008-08-26 TW TW097132603A patent/TW200916099A/en unknown
- 2008-08-26 PE PE2008001443A patent/PE20090622A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2697167C (en) | 2013-07-16 |
AR070648A1 (en) | 2010-04-28 |
CL2008002506A1 (en) | 2009-06-12 |
CN102083799A (en) | 2011-06-01 |
US7790904B2 (en) | 2010-09-07 |
BRPI0815696A2 (en) | 2016-06-21 |
CN102083799B (en) | 2013-10-16 |
JP5204232B2 (en) | 2013-06-05 |
AU2008291148B2 (en) | 2011-03-17 |
US20090062356A1 (en) | 2009-03-05 |
MX2010002341A (en) | 2010-03-22 |
ES2387230T3 (en) | 2012-09-18 |
PE20090622A1 (en) | 2009-05-16 |
AU2008291148A1 (en) | 2009-03-05 |
CA2697167A1 (en) | 2009-03-05 |
KR101237577B1 (en) | 2013-02-26 |
JP2010536915A (en) | 2010-12-02 |
KR20100051734A (en) | 2010-05-17 |
EP2188263A1 (en) | 2010-05-26 |
TW200916099A (en) | 2009-04-16 |
WO2009027264A1 (en) | 2009-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2188263B1 (en) | Benzimidazole derivatives used as fxr agonists | |
US7816540B2 (en) | Carboxyl- or hydroxyl-substituted benzimidazole derivatives | |
US7645785B2 (en) | Benzimidazole derivatives | |
US8008503B2 (en) | Methyl-benzimidazole derivatives | |
KR20110069173A (en) | New benzimidazole derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100329 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: PLANCHER, JEAN-MARC Inventor name: MARTIN, RAINER E. Inventor name: GRETHER, UWE Inventor name: BENSON, GREGORY MARTIN Inventor name: YANG, MINMIN Inventor name: TAYLOR, SVEN Inventor name: BLEICHER, KONRAD Inventor name: RICHTER, HANS |
|
17Q | First examination report despatched |
Effective date: 20100924 |
|
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 564146 Country of ref document: AT Kind code of ref document: T Effective date: 20120715 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602008016821 Country of ref document: DE Effective date: 20120823 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2387230 Country of ref document: ES Kind code of ref document: T3 Effective date: 20120918 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120927 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20120627 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 564146 Country of ref document: AT Kind code of ref document: T Effective date: 20120627 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D Effective date: 20120627 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120928 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121027 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121029 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
26N | No opposition filed |
Effective date: 20130328 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602008016821 Country of ref document: DE Effective date: 20130328 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120819 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120927 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20130806 Year of fee payment: 6 Ref country code: DE Payment date: 20130902 Year of fee payment: 6 Ref country code: ES Payment date: 20130730 Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20130725 Year of fee payment: 6 Ref country code: TR Payment date: 20130801 Year of fee payment: 6 Ref country code: GB Payment date: 20130726 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20130819 Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120819 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120819 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080819 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602008016821 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20140819 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140831 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140831 Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140819 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602008016821 Country of ref document: DE Effective date: 20150303 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20150430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140819 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150303 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140901 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20150930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140820 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140819 |